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1.1
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In this thesis the use of recombinant human thyrotropin (rhTSH) as a possible
adjunct to radioiodine therapy for thyroid volume reduction in patients with
nontoxic, nodular goiter is explored. This first chapter reviews the clinical man-
ifestations, diagnostic evaluation and treatment (by thyroidectomy, L-thyrox-
ine or radioiodine) of nontoxic, nodular goiter. Next, an introduction to the
hormone thyrotropin (thyroid stimulating hormone, TSH) is given and there-
after we focus on the development of rhTSH for use in humans, particularly in
patients with differentiated thyroid cancer.
Nontoxic, Nodular Goiter
1.1.1 Introduction
Nontoxic, nodular goiter may be defined as a structurally and functionally hetero-
geneous thyroid enlargement in an euthyroid patient, which is not caused by an
autoimmune, inflammatory or neoplastic process. Worldwide, the most frequent
cause of goiter is iodine deficiency. In nonendemic areas the etiology of goiter is
multifactorial with a hereditary predisposition and a female preponderance. The
initially diffuse goiters tend to grow gradually and to become more nodular. This
can lead to compression of the trachea and esophagus and obstruction of venous
outflow. With time, thyroid function often becomes more autonomous (1), and
euthyroidism may gradually change into subclinical and eventually into overt
hyperthyroidism.
1.1.2 Clinical manifestations
A nontoxic goiter is often discovered incidentally in an asymptomatic patient. The
clinical manifestations of nontoxic, nodular goiter are caused by compression of
vital structures in the neck or upper thoracic cavity (trachea, esophagus, and neck
veins). Patients with mild tracheal compression are usually asymptomatic. When
tracheal narrowing becomes more severe, dyspnea and stridor develop, initially
only on exertion, but later also at rest. In patients with intrathoracic extension of
a goiter, dyspnea, and stridor may be nocturnal or positional, occurring especial-
ly during maneuvers that force the thyroid into the thoracic inlet, like reaching.
Esophageal compression is less common than tracheal compression because the
esophagus is positioned more posteriorly in the neck. Obstruction of the jugular
or subclavian veins or the superior vena cava results in facial plethora and dilated
neck and upper thoracic veins. Vocal cord paralysis, either transient or perma-
nent, can occur because of stretching or compression of a recurrent laryngeal
nerve and results in hoarseness and dyspnea.
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1.1.3 Diagnostic evaluation
The diagnostic evaluation of a patient with a nontoxic, nodular goiter starts with
a careful history and physical examination. Serum TSH and free thyroxine levels
should be measured to identify (subclinical) hyperthyroidism. Thyroid scintigra-
phy and ultrasonography are not routinely indicated. Patients who have symp-
toms and signs of tracheal compression (inspiratory stridor and dyspnea) should
have radiographs taken of the trachea or CT or MR imaging of the neck and upper
thorax. Iodinated contrast agents should be avoided because of the risk of induc-
ing hyperthyroidism. Pulmonary function tests, especially flow-volume loops, are
useful to evaluate airway obstruction. Fine-needle aspiration biopsy may be help-
ful when thyroid cancer is suspected. Cytology should be obtained from dominant
nodules and those with a firmer consistency within the thyroid gland (2).
1.1.4 Treatment
The main indications for treatment of patients with nontoxic, nodular goiter are
compression of the trachea or esophagus and venous outflow obstruction. Other
indications are goiter growth, neck discomfort, and cosmetic concerns. There are
three treatment options: thyroidectomy, suppression therapy with L-thyroxine
and administration of radioactive iodine. These will be discussed here.
1.1.4.1 Thyroidectomy
Surgery is standard therapy for patients with nontoxic, nodular goiter. Surgical
treatment, usually consisting of bilateral subtotal thyroidectomy, leads to fast
decompression of vital structures. A second advantage of surgical treatment is
the possibility of histopathological examination of the removed tissue.
Resection of goiters, even of substernal ones, can usually be accomplished
through a transcervical approach, either by digital mobilization or by using a
spoon technique (3). Therefore, thoracotomy is rarely needed. However, surgical
treatment is not without risk. Surgical morbidity (vocal cord paralysis,
hypoparathyroidism, tracheal obstruction caused by tracheomalacia, and hemor-
rhage) is higher in patients with large goiters and in case of subsequent opera-
tions. The rate of postoperative hypothyroidism depends on the extent of surgery.
The mortality for bilateral thyroid operations in nontoxic, nodular goiter is less
than 1 percent.
The rate of goiter recurrence increases with the duration of follow-up after sur-
gery. With adequate surgery, the recurrence rate should not be higher than
approximately 10% after 10 years. Postoperatively, L-thyroxine is frequently pre-
scribed to decrease the chance of goiter recurrence. However, several studies
have yielded no convincing evidence that this treatment is effective (4,5).
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1.1.4.2 L-Thyroxine
Thyroid hormone therapy is the second treatment option for patients with non-
toxic, nodular goiter. The hypothesis underlying L-thyroxine treatment is that
growth of a nontoxic, nodular goiter, like that of normal thyroid tissue, is depend-
ent on TSH secretion and therefore, that suppression of TSH secretion will cause
shrinkage of the goiter.
Only two randomized trials on the effect of L-thyroxine therapy in patients with
nontoxic goiter using objective thyroid volume measurements have been report-
ed. In a study by Berghout et al. (6) thyroid volume decreased significantly after 9
months of L-thyroxine treatment in TSH-suppressive doses in about half of the
patients (mean decrease 25% in the responders). Goiter size returned to baseline
after discontinuation of therapy. In a recent study by Wesche et al. (7) a significant
decrease in goiter size was observed in 43% of patients after 2 years of L-thyrox-
ine therapy (mean decrease 22% in the responders). In the nonresponders a mean
increase in thyroid volume of 16% was found.
The efficacy of L-thyroxine treatment in patients with large, nodular goiters is
probably even less than found in the above mentioned randomized studies in
which most patients had relatively small goiters. Many patients with large nodu-
lar goiters have a serum TSH level below the normal range, and no shrinkage of
the goiter can be expected when TSH secretion is already suppressed (8).
Furthermore, L-thyroxine therapy is inadvisable in patients with a suppressed
serum TSH level, because it may cause overt thyrotoxicosis. 
There is no evidence that L-thyroxine therapy alters the natural history of nodu-
lar goiter. Therefore, lifelong treatment is probably necessary. Long-term treat-
ment with L-thyroxine in doses sufficient to suppress serum TSH may have
adverse effects on bone mineral density and on the heart. A meta-analysis, com-
prising all controlled cross-sectional studies on the effects of L-thyroxine therapy
on bone mineral density published between 1982 and 1994, demonstrated signifi-
cant decreases in bone mineral density at the lumbar spine, the proximal femur,
and the radius in postmenopausal women receiving long-term thyroid hormone
suppression therapy (9). No negative effect of therapy on bone mineral density
was found in premenopausal women and in men. In contrast, a recent longitudi-
nal study showed also in premenopausal women a decrease in bone mineral den-
sity after only 2 years of suppression therapy with L-thyroxine (7).
A low serum TSH concentration in persons 60 years of age or older is associated
with a threefold increased risk of developing atrial fibrillation in the subsequent
decade (10). Therefore, it is not unreasonable to assume that thyroid hormone
suppression therapy might have cardiac adverse effects. This therapy does indeed
increase left ventricular mass. Whether it also causes cardiac dysfunction is not
clear. Studies on this subject have yielded discordant results (11-13).
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1.1.4.3 Radioiodine
In the first studies on radioiodine therapy for nontoxic goiter, which appeared in
the German literature, satisfactory clinical results with response rates ranging
from 65% to 99% were reported in large numbers of patients (14-16). Several years
later, two retrospective studies were published in the Anglo-Saxon literature,
comprising 14 and 15 patients, respectively (17,18). Response rates in these studies
were fairly high (79% and 100%, respectively). In these early studies the effects of
radioiodine therapy were evaluated by measurements of neck circumference and
by thyroid volume measurements using palpation and planar scintigraphy, meth-
ods that are known to be inaccurate. 
In later studies, comprising a total of 252 patients, accurate measurements of thy-
roid volume were performed by ultrasonography, CT and MRI (Table 1). Ultrasound
was used in the studies on relatively small nodular goiters (mean thyroid volumes
varying from 56 to 88 mL), whereas MRI and CT were used in the studies on large
nodular goiters (mean thyroid volumes varying from 194 to 311 mL).
Radioiodine treatment resulted in a mean reduction in thyroid volume of approx-
imately 40% after 1 year (7,19-24). A positive correlation between the reduction in
goiter volume and the dose of radioiodine per gram of thyroid tissue was found
(23,25), and a negative correlation between the decrease in goiter volume and pre-
treatment goiter volume (7,25). Furthermore, the degree of nodularity of the goi-
ter appeared to influence the result of radioiodine therapy. In a study by Hegedüs
et al. (26) on nontoxic, diffuse goiters thyroid volume reduction was 60% on aver-
age at one year after radioiodine therapy, which is considerably larger than the
above mentioned 40% found in studies on nontoxic, nodular goiters.
In most studies, iodine-131 doses were aimed at an absorbed dose of 3.7 to 4.4
MBq (100 to 120 µCi) iodine-131 per gram of thyroid tissue, corrected for the per-
centage uptake of radioiodine in the thyroid at 24 hours. Standard, fractionated
doses may also be effective (27). However, studies on this issue with accurate
measurements of thyroid volume are lacking. 
In most patients not only thyroid volume but also compressive symptoms
decreased. In one study, there was a significant tracheal widening as measured by
MRI (21) (Figure 1), and improvement in respiratory function was found in two
studies (21,28).
Long-term results of radioiodine treatment for nontoxic, nodular goiter are also
satisfying. Decreases in thyroid volume of 50% to 60% after 3 to 5 years have been
reported (20,25,29). In the study by Nygaard et al. (20) it was observed that thy-
roid volume decreased during the first 2 years after radioiodine treatment (Figure
2). Thereafter no significant further changes were observed.
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Early side effects (pain in the thyroid region, radiation thyroiditis, increase in
compression symptoms, esophagitis) were usually mild and transient (21,29,30). In
studies on the effects of radioiodine therapy on thyroid volume and thyroid hor-
mone levels in the first weeks after therapy only small increases in thyroid volume
and serum thyroid hormone levels were found (24,30). The development of
autoimmune (Graves’) hyperthyroidism is the most important late complication,
occurring several months after therapy. It is probably triggered by radiation-
induced release of thyroid antigens, and elevated serum levels of TSH receptor
antibodies have been found at the time of thyrotoxicosis (31,32). The incidence of
this complication is approximately 5%. The hyperthyroidism may be quite severe.
Therefore, informing patients to be alert on symptoms and signs of hyperthy-
roidism is important to promptly recognize this complication.
Reported incidences of posttreatment hypothyroidism after radioiodine therapy
for nontoxic, nodular goiter in literature vary from 8% to 100% (7,18-20,22-25).
Nygaard and coworkers (20), using the life table method, calculated a cumulative
risk of hypothyroidism of 22% at 5 years after radioiodine treatment for small non-
toxic goiters. However, in more recent studies higher incidences were found, e.g.,
22% after 1 year (24) and 45% after 2 years (7). Posttreatment hypothyroidism
appears to be more common in patients with small goiters and in those with high
pretreatment serum antithyroid peroxidase antibody concentrations (25).
An important issue is the risk of induction of cancer by radioiodine therapy for
volume reduction of nontoxic, nodular goiters, because large doses of radioiodine
are used, especially for large goiters with low radioiodine uptake. There are no fol-
low-up data on cancer incidence in patients with nontoxic, nodular goiter treated
with radioiodine. The risk for induction of thyroid cancer is not higher than that
after radioiodine therapy of patients with small, toxic nodular goiters, because
the absorbed doses in the thyroid are similar. The lifetime risk of radiation-
induced cancer in extrathyroidal tissues and organs strongly depends on the
administered dose of radioiodine and on the age of the patients. It has been esti-
mated that the lifetime risk of radiation-induced cancer in extrathyroidal tissues
in people of 65 years and older, treated with high doses of radioiodine, is similar
to the surgical mortality of subtotal thyroidectomy (33).
Until now, most clinicians have restricted radioiodine therapy for nontoxic goiter
to elderly patients, especially those who have a high operative risk or refuse sur-
gery. In these patients, the benefit of noninvasive radioiodine treatment out-
weighs the lifetime risk of radiation-induced cancer. However, radioiodine may
prove to be an attractive alternative to surgery in younger patients, provided that
the dose of radioiodine administered is relatively low (e.g., patients with small
goiters and sufficient radioiodine uptake). 
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In this respect, it is of interest to explore strategies to enhance radioiodine uptake
in patients with nontoxic, nodular goiter. One of the causes of a low uptake in
patients with nontoxic, nodular goiter is the fact that the serum TSH level is in the
low-normal range or even below normal in most of these patients. Therefore, the
administration of thyrotropin before radioiodine therapy for nontoxic goiter can
be expected to increase the uptake of radioiodine in the thyroid.
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Figure 1. Axial T1-weighted MR images before (top) and one year after (bottom) radioiodine therapy. Note the tracheal
compression by the intrathoracic part of the nodular goiter before and after radioiodine therapy (arrows). There is consid-
erable improvement of tracheal compression one year after radioiodine therapy. 
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Figure 2.  Median thyroid volume before and after radioiodine treatment in 39 patients with nontoxic multinodular goiter
who remained euthyroid after a single dose. Bars are quartiles. (From Nygaard B, Hegedüs L, Gervil M, et al.: Radioiodine
treatment of multinodular non-toxic goitre. BMJ 1993; 307: 828).
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Thyrotropin (TSH)
The function of the thyroid gland is regulated by TSH. This hormone is produced
by the anterior pituitary gland. The pituitary cells that secrete TSH (thyrotrophs)
are under control of neurons in the hypothalamus that secrete thyrotropin-releas-
ing hormone (TRH). TRH is a tripeptide produced in cells in the nucleus paraven-
tricularis of the hypothalamus. It is transported along their axons to nerve termi-
nals in the median eminence of the hypothalamus. Here TRH is released into the
hypophyseal portal blood and transported to the anterior pituitary gland. Other
important regulators of TSH secretion are the thyroid hormones thyroxine (T4)
and triiodothyronine (T3). They inhibit TSH secretion and to a lesser extent TRH
secretion. TRH and the thyroid hormones maintain TSH secretion and therefore
thyroid function remarkably constant. In this way the hypothalamic-pituitary-thy-
roid axis is a classic example of an endocrine feedback loop. Other regulators of
TSH secretion, although less important, are somatostatin and dopamine, which
inhibit TSH secretion, and α−adrenergic agonists which stimulate TSH secretion
(34).
Thyroid stimulating activity has been extracted from the pituitaries of almost all
mammalian species as well as from those of lower vertebrates. TSH preparations
purified from pituitary glands contain heterogeneous components with variable
biological activity. The molecular weights of these components are in the range of
28 to 30 kDa. The differences in molecular weight are caused by heterogeneity of
carbohydrate chains of the TSH molecule (35).
TSH is a glycoprotein and consists of a heterodimer containing two noncovalent-
ly linked subunits: an α−subunit, which is common to the other glycoprotein hor-
mones [luteinizing hormone (LH), follicle stimulating hormone (FSH) and human
chorionic gonadotropin (HCG)] and a β−subunit, which is hormone-specific. The
human α−subunit contains 92 amino acids and the human TSH β−subunit has an
apoprotein core of 112 amino acids (36). Human TSH contains three aspargine
linked oligosaccharide chains that, when fully processed, terminate either with
sialic acid linked to galactose, or with sulfate attached to N-acetylgalactosamine.
Two of these oligosaccharide chains are attached to the α−subunit and one is
attached to the β−subunit. These oligosaccharide chains play an important role in
biological activity and determine the metabolic clearance rate of TSH (37). The
structures of the oligosaccharide chains of TSH are altered in different physiolog-
ical and pathological states, resulting in alterations of the bioactivity of the hor-
mone (38-41). For example, in hypothalamic hypothyroidism, secreted thyrotropin
has impaired biologic activity because of impaired binding to its receptor. This
suggests that TRH regulates not only the secretion of TSH, but also its specific
molecular and conformational features required for hormone action (42-45). TRH
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influences the carbohydrate structure of TSH. The glycosylated forms of TSH
secreted after acute intravenous stimulation with TRH differ from the forms of
TSH circulating in the steady state condition (46). Basal TSH has a different
oligosaccharide composition from TSH in serum 30 min after TRH administration.
Basal TSH has fewer core fucose residues and more exposed galactose residues
than TSH released after acute TRH administration. The amounts of oligosaccha-
ride branching and the amounts of N-acetylglucosamine were similar, whereas the
degrees of sialylation for basal TSH and TRH-released TSH were highly variable.
The biochemical differences detected in basal TSH vs. TRH-released TSH may
reflect different post-translational processing and storage of these molecules in
thyrotrophs. The release of particular isoforms of human TSH depending on TRH
is an important principle in the physiological control of thyroid function by the
pituitary. 
Thyrotropin is released in a pulsatile manner and has a diurnal rhythm with the
highest levels at night. It has a plasma half-life of approximately 30 min. TSH reg-
ulates not only the function of the thyroid follicular cells including thyroid hor-
mone synthesis and secretion, but also the proliferation of thyroid cells. All
actions of TSH follow binding of the molecule to its receptor (47-51). The TSH
receptor, member of the G protein-coupled receptor family, is localized on the
basal surface of the follicular cells of the thyroid. Binding of TSH to the receptor
activates the adenylyl cyclase-cyclic AMP-protein kinase A pathway and the Ca-
protein kinase C pathway (47-50).
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Bovine and Human Cadaver Pituitary TSH
Bovine and human cadaver pituitary TSH have been administered to humans.
Despite the structural differences of TSH molecules between species, their thy-
rotropic activities are not species specific (35). Rationale for the use of bovine TSH
(bTSH) in humans was obtained when similar binding and activity was seen for
human and bovine TSH in the chick bioassay (52). Bovine TSH administration
stimulates increases in the serum levels of T4, T3 and thyroglobulin (Tg) in humans
(53,54). Also enhancement of thyroid radioiodine uptake in normal subjects fol-
lowing injection of either bovine or human pituitary TSH has been demonstrated
(55,56). Pharmacokinetic studies showed a peak serum TSH concentration 4 hours
after intramuscular (im) administration of bovine TSH. Ten hours after the admin-
istration of bovine TSH, serum TSH concentrations were half of the peak serum
TSH levels. Initial results in thyroid cancer patients suggested that administration
of bovine TSH was effective, although it did not stimulate radioiodine uptake as
good as thyroid hormone withdrawal (57,58).
Local and systemic adverse events, such as local induration, urticaria, nausea and
vomiting and anaphylactic shock, were associated with bovine TSH administra-
tion (40,59,60). These adverse effects were particularly evident in patients treat-
ed at multiple occasions. Because of these allergic reactions and the diminished
effectiveness of the agent with repeated doses, patients were studied for the
development of antibodies to bovine TSH (61-63). Indeed, anti-bovine TSH anti-
bodies were detected in the sera of patients with thyroid carcinoma, after repeat-
ed administration of bovine TSH. Due to antibody formation development of
resistance to bovine TSH appeared to be inevitable in patients who received
repeated injections of this hormone (64). Antibodies of the IgG class, which
bound both bovine TSH and human TSH, were detected using specific radioim-
munoassays and radioimmunoelectrophoretic techniques in patients with thyroid
carcinoma, who had received multiple injections of bovine TSH. Antibodies per-
sisted for more than one year and binding of bovine TSH was greater than that of
human TSH throughout this period. Characterization of these antibodies with
respect to their binding to human and bovine glycoprotein hormones and sub-
units revealed two populations of antibodies, one which binds both bovine and
human TSH, and one which binds only bovine TSH. Both antibodies appeared to
be directed towards antigenic sites on the β−subunit of TSH, as both the human
and the bovine TSH β−subunits displaced the binding of intact TSH from antibod-
ies whereas the α−subunits were virtually unreactive. The binding studies sug-
gested that the cross-reactivity of the antibody to human TSH occurred on the
basis of common antigenic determinants on the β−subunits of the two species
(65). 
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Neutralizing anti-bovine TSH antibodies developing in patients, who had received
multiple doses of bovine TSH, also interfered with measurement of endogenous
TSH levels. Less suppression of serum TSH levels was found in patients receiving
adequate replacement therapy after thyroidectomy for thyroid carcinoma. This
was due to interference of circulating anti-bovine TSH antibodies in the radioim-
munoassay (66,67). This was truly hindering the ability to monitor the efficacy of
thyroid hormone suppression therapy in thyroid cancer patients and may possi-
bly result in the development of secondary hypothyroidism in patients with an
intact thyroid gland. Because of the occurrence of allergic reactions and the rela-
tive ineffectiveness with multiple dosing due to the development of anti-TSH
antibodies, bovine TSH has been abandoned for use in humans and is currently no
longer available.
Preparations of purified human TSH extracted from human cadaver pituitary
glands have been used as an alternative for bovine TSH (55). Preparations of
human thyrotropin, prepared from human cadaver pituitary glands and highly
purified using a monoclonal antibody technique, stimulate thyroid function (68),
but disadvantages of human cadaver pituitary TSH are its limited availability and
contamination of the preparation by other pituitary hormones and their subunits.
Nowadays the administration of human pituitary cadaver TSH to patients is no
longer advised because of the potential transmission of the agent for Creutzfeldt-
Jacob disease and the risk of the development of this disease years later (69).
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Recombinant Human Thyrotropin (rhTSH) 
1.4.1 Development of and in vitro studies with rhTSH
The abovementioned problems with the use of bovine and human cadaver TSH
have stimulated the development of rhTSH. TSH generated by recombinant DNA
techniques would be far less likely to induce allergic reactions and TSH antibod-
ies or cause transmission of infectious agents.
The human thyrotropin β−subunit gene was isolated and characterized from two
genomic libraries (70,71). Chinese hamster ovary (CHO) cells co-transfected with
two plasmids, one carrying the human α−subunit cDNA with mouse dihydrofolate
reductase gene and the other carrying human TSH β−subunit cDNA have been
used to produce rhTSH. Each cDNA was driven to expression under the control of
a SV40 early promoter. rhTSH and its α−subunit were secreted into culture media,
and their secretion increased with exposure of the cells to increasing concentra-
tions of methotrexate (72).  In an adenovirus transformed human embryonal kid-
ney cell line, cotransfection of two virus vectors, each containing one subunit of
human TSH, together with a plasmid containing the adenovirus VA RNA genes
produced rhTSH as well as free human α− and TSH β−subunits (73). 
Studies on the structure of rhTSH followed because gel filtration analysis revealed
that the molecular size of the rhTSH was not the same as that of natural human
TSH. The rhTSH synthesized was larger in molecular weight than standard human
TSH preparation on gel chromatography suggesting an altered glycosylation pat-
tern. The structure and particularly the glycosylation pattern of recombinant gly-
coproteins are influenced by the specific subclone and culture conditions used to
produce the recombinant hormones. Since TSH and other recombinant proteins
are expressed in non-human cell lines, they are likely to have different glycosyla-
tion patterns (72,73). 
The investigators, who previously characterized rhTSH secreted by CHO cells
after stable transfection of the human TSH β−gene, studied structure-function
relationships of different isoforms of this glycoprotein (74). They produced rhTSH
and quantitated it by immunoassays, receptor binding assays, and amino acid
analysis and further characterized it by a variety of biochemical methods, includ-
ing chromatofocusing and carbohydrate analysis. The results indicated that
secreted rhTSH, similar to intrapituitary human TSH, was a mixture of isoforms,
caused at least in part by the degree of sialylation. The degree of sialylation, high-
ly dependent on the bioreactor production conditions, appears to be the major
factor affecting bioactivity of rhTSH.
The contribution of the individual monosaccharides to hormonal activity was
determined by sequential deglycosylation of rhTSH using exoglycosidases and by
1.41.4
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studying the effect of resialylation of desialylated rhTSH using sialyltransferases
(75). Sequential removal of sialic acid, galactose or N-acetylglucosamine resulted
in a more than 10-fold increase in the in vitro bioactivity of rhTSH. The metabolic
clearance of the derivatives was faster than that of intact hormone. Agalacto-
rhTSH was cleared slower than asialo-rhTSH. However, the in vivo bioactivity
decreased progressively with each monosaccharide removal. The increased in
vitro cyclic AMP-stimulating activity, increased metabolic clearance and the
decreased in vivo biologic activity were all reversed by resialylation of the termi-
nal galactose residues. These results indicate that the bioactivities of rhTSH are
modulated by terminal sialylation. The modification of the oligosaccharides by
glycosidases and glycosyltransferases could be used as a powerful tool to delin-
eate the function of carbohydrates in glycoproteins and to engineer more potent
hormone analogues with a longer half-life and/or higher bioactivity.
Huber et al. (76) assessed the bioactivity of rhTSH using a human fetal thyroid cell
culture. RhTSH caused a dose-related increase in human thyroid monolayer cell
cAMP release and human thyroglobulin secretion, confirming its bioactivity. They
derived an estimated biopotency for the rhTSH preparation examined of 5.6 U/mg
compared to 10 U/mg for bovine TSH. The rhTSH had an immunologic activity
similar to that of purified pituitary human TSH standards. Furthermore, rhTSH
induced thyroid epithelial cell growth, as evidenced by a decrease in thyroid cell
doubling time. Addition of rhTSH to cultures of rat FRTL-5 and bovine and fetal
human thyroid epithelial cells stimulated adenylate cyclase activity. Thus, rhTSH
appeared to be a potent glycoprotein hormone preparation when measured in a
homologous human cell culture system (76). The demonstrated in vitro bioactivi-
ty of rhTSH as assessed by cAMP production, growth stimulation and 5’-deiodi-
nase activity strongly suggested that rhTSH would be biologically active when
administered in vivo.
The presence and specific structures of the oligosaccharide-side chains of TSH
have been shown to be important for its bioactivity. Since the carbohydrate struc-
ture of a protein reflects the glycosylation apparatus of the host cells in which the
protein is expressed the choice of the host cells is important. The biological activ-
ity of the purified recombinant human TSH preparation derived from a stable
transfectant of CHO cells was studied most intensely (72,74,75,77).
The complementary DNAs for HCG-α and hTSH-β were cotransfected into CHO
cells. Stable transfectants with a high rate of rhTSH production were selected and
subsequently cultured on microcarrier beads. This genetically engineered cell line
and the development of a reproducible process for the expression and purifica-
tion of biologically active rhTSH were described by Cole et al. (78) from the
Therapeutic Protein Development Department, Genzyme, Framingham MA, USA. 
The TSH glycoprotein, which is produced by recombinant DNA technology, is at
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this moment available as Thyrogen® (thyrotropin alfa for injection). It is supplied
by Genzyme (Cambridge MA, USA) in vials, which contain each 1.1 mg thyrotropin
alfa, and after reconstitution with 1.2 mL of sterile water, the thyrotropin alfa con-
centration is 0.9 mg/mL. The biological potency of rhTSH is expressed in units (U)
that have been established in relation to the Second World Health Organization
International Reference Preparation, Thyrotropin, Human, for Bioassay (84/70):
4.9 U/mg protein.
1.4.2 In vivo studies with rhTSH in animals
Thotakura et al. (77) used an in vivo rat model to examine the metabolic clearance
of rhTSH. The recombinant TSH was derived from a stable transfectant of CHO
cells and its carbohydrate composition showed to be more highly sialylated than
cadaver-derived pituitary human TSH. No N-acetyl galactosamine was detectable
in rhTSH, which implies the absence of terminal sulfate moieties, both of which
are present in pituitary derived TSH. The investigators injected 0.5-1.0 µg of rhTSH
and measured TSH concentrations at several time points. The rhTSH had a 2-fold
lower metabolic clearance rate than pituitary TSH, resulting in a greater than 10-
fold higher serum concentration of rhTSH at 3 hours as compared to pituitary
human TSH. After sialic acid removal, the rhTSH was cleared faster (7.5-fold) than
pituitary human TSH. Therefore the longer plasma half-life of rhTSH was due to
its higher sialylation.
The same group used this in vivo rat model to investigate the role of terminal car-
bohydrate residues in organ distribution and metabolic clearance of TSH (79).
They used different 125I-labeled TSH preparations with distinct carbohydrate com-
position and injected them intravenous (iv) in the rats. At various time points
after bolus TSH injection, blood, liver, kidney, spleen, lung, heart, and thyroid sam-
ples were collected. TSH uptake was determined by trichloroacetic acid precipita-
tion of 125I-TSH in the organ homogenates. The rhTSH was distributed predomi-
nantly to the kidneys. In contrast, purified human TSH and bovine TSH were
cleared predominantly by the liver, with a later renal phase of clearance. The liver
with only minor involvement of other organs cleared asialo-rhTSH. The early liver
uptake was proportionally lowest for rhTSH, and correlated inversely with the
serum levels and the degree of sialylation. Blockade of the N-acetylgalactosamine
(GalNAc) sulfate receptors by injection of bovine LH resulted in a significant
decrease in liver uptake of purified human TSH. Similarly, liver uptake of asialo-
rhTSH was significantly inhibited by injection of asialo-fetuin. Thus, purified
human TSH and bTSH preparations containing sulphated oligosaccharide chains
are cleared at least in part by the GalNAc sulfate-specific receptors in the liver. In
contrast, rhTSH with highly sialylated oligosaccharides in both subunits accumu-
lates predominantly in the kidneys, even at the early phase of clearance, indicating
that sialylated glycoprotein hormones escape from specific receptor-mediated
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clearance mechanisms in the liver. These data indicate that terminal sialic acid
and GalNAc sulfate residues, each to a different extent, determine glycoprotein
hormone distribution and thereby its plasma level, which is a major factor in
determining the in vivo potency of TSH. 
A combined rat model of chronic catheterization and suppression of endogenous
TSH release was used to study pulsatile effects of rhTSH (80). Pulsatile secretion
of TSH is a well-characterized phenomenon in the human with only limited data
from animal studies. Quantified pulses of different preparations of thyrotropin
were applied iv with minimal interference with endogenously produced hormone.
The rats pretreated with drinking water containing T3 showed a significant 6-fold
decrease of rat TSH after four days and their free thyroxine (FT4) levels were 9-
fold below unsuppressed levels. FT4 response to exogenous TSH application
above this suppressed baseline level was selected as an endpoint. Infusion stud-
ies compared pulsatile with continuous TSH administration. A low and a high
dose of rat TSH and rhTSH were administered. Levels of FT4 were compared after
two and four days and responsiveness to a standard high bolus of rat TSH 6 h after
end of infusion was assessed. With regard to its potency for FT4 release, a gener-
al trend to superior efficacy of pulsatile TSH stimulation of the thyroid gland in
comparison to continuous stimulation could be observed in all four experiments.
More pronounced effects were seen after 2 and 4 days of infusion with high doses
of rat TSH and after 4 days of infusion with low doses of rhTSH. Comparison of
FT4 responses to rhTSH boli showed a 2- and 6-fold higher response in the pul-
satile group compared to the continuous group after low and high rhTSH infusion,
respectively.
The thyroid stimulatory effect of rhTSH has also been studied in mice (81). Like in
the rat in vivo model the mice were given T3 in their drinking water to suppress
endogenous TSH. Various doses of exogenous pituitary and rhTSH preparations
were injected intraperitoneally and blood samples were obtained from the orbital
sinus 6 h later. The T4 level served as the end-point and the maximal level of T4
after TSH stimulation was similar to that observed in normal, nonsuppressed
mice. The assay required injection of approximately 3.0 µg of pituitary human
TSH, 1.0 µg rhTSH, 0.2 µg bovine TSH, and 0.1 µg rat TSH to attain half-maximal
responses.
Colzani et al. (82) determined the biological activity of rhTSH in euthyroid and in
T3-treated, TSH-suppressed rats and mice. Doses of rhTSH based on body weight
were used (≈0.03 mg/rat and ≈0.003 mg/mouse). The rhTSH was administered
intraperitoneally and resulted in similar serum rhTSH concentrations in the rats
and mice. Euthyroid and TSH-suppressed mice responded to rhTSH administra-
tion with increases in serum T4 , but serum T4 did not increase after rhTSH admin-
istration in euthyroid rats. In TSH-suppressed rats, the increase in serum T4 was
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similar to that observed in TSH suppressed mice. These observations suggest that
rhTSH more readily displaces endogenous TSH from the mouse than from the rat
thyroid TSH receptor, because equal responses were observed when endogenous
TSH was suppressed. Three hours after administration of rhTSH, 125I was adminis-
tered to the rodents and the uptake of radioiodine in the thyroid was measured 
2 h later. These uptakes were compared to the 2-h uptakes in rats and mice with-
out rhTSH pretreatment. Euthyroid rats with and without rhTSH pretreatment did
not show differences in thyroid radioiodine uptake. In contrast, in euthyroid mice
that had received rhTSH, the 2-h 125I uptake was significantly decreased. RhTSH
administration did not affect the very low 2-h thyroid 125I uptake in TSH-suppressed
rats, but did result in a small but significant increase in TSH-suppressed mice.
Finally, in vivo animal studies were carried out in rhesus monkeys and investigat-
ed the half-life of rhTSH and its ability to stimulate thyroid function in these ani-
mals (83). The clearance of rhTSH after iv administration of 2 U rhTSH (≈0.4 mg)
in two monkeys showed a rapid first phase with a half-life of approximately 63
minutes, followed by a slow second phase with a half-life of 326 minutes. Serum
T4 and T3 concentrations increased at 3 h and remained elevated 24 h after rhTSH
administration. Intramuscular administration of the same dose of rhTSH resulted
in a marked elevation of serum TSH and increases in serum T4 and serum T3 lev-
els 2-3 times above baseline. 6-h and 20-h thyroid 123I uptake was measured at
baseline and 5 h after rhTSH administration. Both uptake values were increased in
one monkey but did not change in the other monkey. Two other monkeys received
three daily im injections of 2 U rhTSH. In these monkeys serum T4 concentrations
increased several-fold and serum T3 increased 2-3 times above basal values. The 6-
h and 20-h thyroid 123I uptake was measured at baseline and 19 h after rhTSH
administration. Both values approximately doubled in both monkeys. These
results demonstrated the biological efficacy of rhTSH administered to rhesus
monkeys and strongly suggested that rhTSH would be effective in stimulating
thyroid function in man. However, the biological potency of rhTSH in humans was
expected to be much stronger, since they would be more sensitive to rhTSH than
animals.
Since the publication of this last study, articles were published discussing the use
of rhTSH in animals for veterinary purposes. The effects of rhTSH on serum T4 in
euthyroid beagle dogs were described (84). TSH response tests were performed
by using total doses of 0.025 mg, 0.05 mg, and 0.1 mg rhTSH, administered iv.
Thereafter, TSH response tests were performed by using 0.05 mg of rhTSH admin-
istered by im and subcutanous (sc) routes, respectively. Following all the admin-
istered doses of rhTSH, an increase in the serum T4 concentration was noted,
although this increase was not always statistically significant. Based on this study,
0.05 mg was judged to be the optimal intravenous dose of rhTSH.
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Recently, the response of euthyroid cats to the administration of  rhTSH was pub-
lished (85). Seven healthy cats received each of 5 doses of rhTSH (0, 0.025, 0.050,
0.100, and 0.200 mg), iv, at 1-week intervals. Serum concentrations of T4 and FT4
were measured immediately before each injection and 2, 4, 6, and 8 hours after
administration of each dose. Overall T4 response did not differ significantly
among cats when administered doses were higher than or equal to 0.025 mg.
Serum T4 concentrations peaked 6 to 8 hours after administration for all doses
higher than or equal to 0.025 mg. For all doses higher than or equal to 0.025 mg,
mean ± SEM T4 concentrations at 0, 6, and 8 hours were 33.9 ± 1.7, 101.8 ± 5.9, and
101.5 ± 5.7 nmol/L, respectively. For all doses higher than or equal to 0.025 mg,
mean FT4 concentrations at 0, 6, and 8 hours were 38.7 ± 2.9, 104.5 ± 7.6, and 100.4
± 8.0 pmol/L, respectively. At 8 hours, the FT4 response to 0.025 and 0.050 mg
was less than the response to 0.100 and 0.200 mg. It is concluded that the TSH
stimulation test can be performed in cats by iv administration of 0.025 to 0.200
mg of rhTSH and measurement of serum T4 concentrations at time of injection
and 6 or 8 hours later.
1.4.3 In vivo studies with rhTSH in humans
Six normal volunteers, two men and four women, without evidence of thyroid dis-
ease, including normal serum free T4 indexes and TSH concentrations and nega-
tive tests for antibodies to thyroid peroxidase and Tg were studied by Ramirez et
al. (86). They were the first to report on the effects of rhTSH on serum thyroid hor-
mone and Tg concentrations in normal subjects. Each individual received 0.1 mg
rhTSH im. Blood was obtained before, 2, 4, and 8 h after, and 1, 2, 3, 4, 7, and about
21 days after rhTSH administration. Serum TSH was significantly increased at 2 h
(40.7 ± 7.4 mU/L, mean ± SE), peaked at 4 h (50.9 ± 9.3 mU/L), remained signifi-
cantly elevated for 1 day, and was significantly below baseline (0.8 ± 0.5 mU/L) 7
days after rhTSH administration. Serum T3 was significantly increased at 4 h (basal
value 115 ± 4 ng/dL; 4 h value 190 ± 14 ng/dL), peaked at 24 h (217 ± 23 ng/dL), and
remained significantly elevated for 3 days. Serum T4 was significantly increased at
8 h (basal value 7.3 ± 0.2 mg/dL; 8h value 9.8 ± 0.4 mg/dL), peaked at 24 h (11.2 ±
0.5 mg/dL), and remained significantly elevated for 4 days. Serum Tg did not
change for the first 8 h, increased significantly at 1 day (basal value 15.9± 3.9
ng/mL; 1 day value 34.7 ± 6.0 ng/mL), peaked at 2 days (44.2 ± 7.0 ng/mL), and
remained significantly elevated for 4 days. All values returned to baseline at 3
weeks. TSH antibodies were not detected at 3 weeks. Except for mild soreness at
the injection site, all subjects tolerated the rhTSH well. The study demonstrated
that a single dose of 0.1 mg rhTSH was a potent stimulator of thyroid function in
normal healthy subjects.
Torres et al. (87) determined the effects of doses higher than 0.1 mg of rhTSH on
thyroid hormone and Tg secretion. Six normal subjects with no evidence of thy-
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roid disease received either 0.3 or 0.9 mg rhTSH by im injection. Serum TSH, T4,
T3, and Tg concentrations were measured at 2, 4, and 8 h and at 1, 2, 3, 4, and 7 days
after rhTSH administration. The peak serum TSH concentrations were 82 ± 18 and
277 ± 89 mU/L, respectively, for the 0.3 mg and 0.9 mg doses of rhTSH. Serum T4,
T3, and Tg concentrations increased significantly in subjects receiving 0.3 and 0.9
mg rhTSH, with significant increases in T4 and T3 being observed before signifi-
cant increases in serum Tg.  Peak concentrations of serum T4, T3, and Tg, after 0.3
mg rhTSH administration, were 100 ± 19, 131 ± 14, and 1035 ± 724% above individ-
ual baseline values, respectively. Similarly, peak concentrations of serum T4, T3,
and Tg, after 0.9 mg rhTSH administration, were 102 ± 16, 134 ± 7, and 1890 ± 768%
above individual baseline values. These data, compared with the previously
reported data for the responses to 0.1 mg rhTSH, indicated that 0.1, 0.3, and 0.9
mg rhTSH had the same stimulatory effects on thyroid hormone and Tg secretion,
except that the T4 response was greater in groups receiving 0.3 or 0.9 mg rhTSH
than in the group receiving 0.1 mg rhTSH. According to these studies a single dose
of rhTSH greater than 0.1 mg did not seem to further enhance thyroid hormone
secretion in normal volunteers. This group of investigators also studied the effect
of rhTSH on thyroid radioactive iodine uptake (RAIU) in the group that received
0.9 mg rhTSH. The 6-h and 24-h RAIU values were significantly higher after rhTSH
(the pre-rhTSH, 6 h value was 12.5 ± 1.8% and the 24 h value was 23 ± 2.7%; the
post-rhTSH, 6 h value was 27 ± 4.8% and the 24 h value was 41 ± 4.2%). The stim-
ulatory effects of 0.9 mg rhTSH on the 6 h and 24 h RAIUs were similar. 
The next question addressed in normal subjects was whether rhTSH administra-
tion prior to 123I would increase the low thyroid RAIU in subjects treated with sodi-
um iodide (88). Nine euthyroid men were given 15 mg iodide daily for 7 days. There
was a marked increase in serum TSH values 8 and 24 hours after rhTSH adminis-
tration, which induced elevated serum T4 and T3 concentrations. A 16 hour thyroid
RAIU was measured at baseline, after 5 days of iodide administration, and either
8 or 32 hours after im administration of rhTSH. Administration of rhTSH 8 hours
before 123I to 4 subjects increased the 16 hour thyroid RAIU by 62% above the low
post iodide thyroid RAIU. Administration of rhTSH 32 hours before 123I administra-
tion to 5 subjects increased the 16 hour thyroid RAIU by 97% above the low post-
iodide thyroid RAIU. The mean increase in the 16-h thyroid RAIU was 88% in the
9 subjects. As rhTSH increased the thyroid RAIU in subjects with depressed thy-
roid RAIUs during iodide administration, rhTSH pretreatment may be useful in
preparing patients with low thyroid RAIUs due to excess iodine before radioactive
iodine treatment.
Recently the effect of 0.9 mg rhTSH on thyroid size was studied in 9 male healthy
euthyroid individuals (89). Thyroid volume was measured by ultrasonography at
baseline and 4 h and 1, 2, 4, 7 and 28 days after the administration of 0.9 mg
rhTSH. Twenty-four hours after rhTSH administration thyroid volume was
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increased by 23.5 ± 5.5% and after 48 hours by 35.5 ± 18.4%. At day 4 the thyroid
was again of normal size, and at day 28 the gland was reduced by 14.7 ± 3.8% com-
pared with baseline thyroid volume. 
1.4.4 rhTSH as an adjunct to radioiodine whole body scintigraphy and thy-
roglobulin testing after thyroidectomy for differentiated thyroid cancer 
1.4.4.1 Introduction
Five to 15% of patients treated for differentiated thyroid carcinoma will develop a
local recurrence and/or neck metastases and 10 to 15% will have distant metas-
tases during follow-up (90). Diagnostic studies used for follow-up of thyroid can-
cer patients are radioiodine whole body scintigraphy (WBS) and serum Tg meas-
urements. In patients who have been treated for differentiated thyroid carcinoma
by (near-)total thyroidectomy radioiodine WBS can show the presence of residual
normal thyroid tissue or thyroid carcinoma tissue in the neck or elsewhere in the
body. It can also help to determine whether treatment with 131I is useful.
Dosimetric calculations can be made using scintigraphic measurements and
radioactivity measurements in blood and urine samples in order to determine the
therapeutic amount of radioiodine to be administered (91,92). The introduction of
serum Tg measurements has allowed for a decrease in the frequency of radioio-
dine WBS, especially in patients at low risk for recurrence of the disease (2,90,93-
95).
Some patient preparations are important to optimize the sensitivity of radioio-
dine whole body scintigraphy. A high serum TSH level (more than 25-30 mU/L) is
needed to optimally stimulate radioiodine uptake in residual normal thyroid tis-
sue and in thyroid carcinoma tissue (96). After (near-)total thyroidectomy this is
usually reached within 4 to 6 weeks (97). In patients who use thyroid hormone,
levothyroxine (L-T4) should be stopped for about 4 weeks and levotriiodothyro-
nine (L-T3), because of its shorter half-life, for 10 to 14 days (97,98). Serum TSH lev-
els should always be verified as being at least 25-30 mU/l before imaging is carried
out. The sensitivity of serum Tg measurements for the detection of residual/recur-
rent thyroid cancer is also higher when the serum TSH level is high.
Diagnostic radioiodine whole body scintigraphy and Tg testing for detection of
residual or remnant thyroid carcinoma in thyroidectomized patients is tradition-
ally done after withdrawal of thyroid hormone therapy, subjecting the patients to
hypothyroidism for several weeks (2,90,95). This hypothyroid state often results in
discomfort and morbidity and therefore has a major negative impact on the qual-
ity of life. This is an important issue, as patients with thyroid cancer usually have
a good prognosis. Dow et al. (99) evaluated the impact of thyroid hormone with-
drawal on patients’ perceived changes in quality of life in 34 subjects (mean age
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40 years) undergoing thyroid hormone withdrawal in preparation for scanning
procedures. They used a new instrument, the Quality of Life (QOL)-Thyroid scale,
and an established instrument, the Functional Assessment in Cancer Therapy-
General, at four specific time points in relationship to scanning. Thyroid hormone
withdrawal caused significant changes in physical, psychological, and social well-
being across the four testing points. Whereas the physical symptoms related to
thyroid hormone withdrawal are generally acknowledged, this study showed that
patients also suffer from negative psychological, family, and work sequelae.
Moreover, in some patients, especially those with intracranial or intraspinal
metastases, serious complications can occur due to accelerated tumor growth
during thyroid hormone withdrawal. An elegant solution to the problems of thy-
roid hormone withdrawal is whole body scintigraphy and Tg testing after the
administration of rhTSH, which makes it possible to conduct radioiodine whole
body scintigraphy and sensitive serum Tg testing without discontinuing thyroid
hormone therapy. 
1.4.4.2 rhTSH-stimulated radioiodine whole body scintigraphy com-
bined with thyroglobulin testing after thyroidectomy for differ-
entiated thyroid cancer
In a phase I/II study (100), the preliminary efficacy of rhTSH was assessed in 19
patients with differentiated thyroid cancer. In these patients 7 different dosing
regimens of rhTSH were used: im administration of 10 U/day (≈2.0 mg; 1, 2 or 3
days), 20 U/day (1 or 2 days), 30 U/day (1 day) or 40 U/day (1 day). Twenty-four h
after the last dose of rhTSH, 1-2 mCi 131I was administered, 48 h later followed by
WBS. After discontinuing L-T3 for a median period of 19 days, the endogenous
serum TSH levels were above 25 mU/L. Then a second dose of 131I was given to the
patients and they were rescanned 48 h later. Mean peak levels of serum TSH after
a single dose of 10, 20, or 30 U of rhTSH were 127, 309 and 510 mU/L, respective-
ly, and occurred 2-8 h after injection. A single injection of 40 U in 1 patient led to
a peak TSH level of 505 mU/L. Twenty-four h after the injection mean TSH levels
decreased to 83, 173 and 463 mU/L in the respective treatment groups. The rhTSH
was tolerated well, but in the patients receiving the highest doses (30 or 40 U)
nausea and vomiting was reported (21%). In 63% of the patients, the scans after
rhTSH treatment and in the hypothyroid state showed complete concordance. In
3 patients additional sites of uptake, two in the chest and one in the thyroid bed,
not visible on the scans during hypothyroidism, were identified after rhTSH. In 1
patient, a focus of uptake was better visualized after rhTSH than after withdraw-
al. In 3 other patients, 1 lesion in the chest and 2 in the neck, were seen only after
withdrawal. Serum Tg levels more than doubled in response to rhTSH in 58% of
the patients and in 79% after withdrawal. The increase was lower after rhTSH in
93% of the patients. These data showed that rhTSH could be safely and effective-
ly given to patients after thyroidectomy for thyroid cancer to stimulate 131I uptake
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and Tg secretion. It was concluded that further investigations using different time
intervals between rhTSH injections and 131I administration or Tg measurement
were needed to define optimal conditions for these diagnostic tests.
The use of rhTSH has been investigated in two phase III studies. In the first phase
III trial (101), 127 patients with thyroid cancer underwent radioiodine WBS (using
2 to 4 mCi 131I) by two techniques: first after receiving two doses of 0.9 mg of
rhTSH administered with an interval of 24 hours while thyroid hormone therapy
was continued and second after the withdrawal of thyroid hormone therapy, while
no rhTSH was administered. In 62 of the 127 patients radioiodine WBS by one or
both techniques were positive. The scintigrams obtained after administration of
rhTSH were equivalent to the scintigrams obtained after withdrawal of thyroid
hormone in 41 of these 62 patients (66%), superior in 3 (5%), and inferior in 18
(29%). When the 65 patients with negative WBS by both techniques were includ-
ed, the two scintigrams were equivalent in 106 patients (83%). Eight patients (13%
of those with at least one positive scintigram) were treated with radioiodine on
the basis of superior scintigrams obtained after withdrawal of thyroid hormone
therapy. As expected, patients had more symptoms of hypothyroidism and dys-
phoric mood states after withdrawal of thyroid hormone than after administra-
tion of rhTSH.
In the second phase III study (102), a total of 229 patients with differentiated thy-
roid carcinoma were treated with rhTSH and randomized in either one of two dos-
ing regimes: 0.9 mg rhTSH, im, every 24 h for two doses or every 72 h for three
doses. This study also formally examined the utility of rhTSH in TSH-stimulated Tg
testing and the value of the combination of radioiodine WBS and Tg testing after
administration of rhTSH for detecting thyroid carcinoma. For this second phase III
study a higher scanning dose of 131I (4 mCi) was chosen, based on results of an
evaluation conducted in a subset of patients of the first phase III study that indi-
cated that the clearance rate of radioiodine was greater in the euthyroid state
than when patients were hypothyroid. Stricter scintigraphy protocols were used
for acquiring WBS and a more clinically relevant definition of equivalent scans
was used. Furthermore, in this trial more patients with metastatic disease were
enrolled. Radioiodine WBS and serum Tg measurements were performed after
administration of rhTSH and again after thyroid hormone withdrawal in each
patient. Like in the earlier trials, 24 h after the last rhTSH injection radioiodine
was administered and 48 h later WBS was obtained. Two weeks after the last
rhTSH dose, patients were withdrawn from thyroid hormone therapy until ade-
quate hypothyroidism (TSH > 25 mU/L) was achieved. Serum Tg was measured on
the final day of rhTSH administration and 24, 48, 72 h and 7 days after the final
dose and during the withdrawal phase on the day of radioiodine administration.
Radioiodine WBS was concordant between the rhTSH-stimulated and thyroid hor-
mone withdrawal phases in 195 of 220 patients with evaluable scans (89%). Of the
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discordant scans, 8 (3%) had superior scans after rhTSH administration ands 17
(8%) had superior scans after thyroid hormone withdrawal. There was no differ-
ence in the number of superior rhTSH or withdrawal scans within either study arm
or between the arms. Based on a serum Tg level of 2 ng/mL or more, thyroid tis-
sue or cancer was detected during thyroid hormone therapy in 22%, after rhTSH
stimulation in 52%, and after thyroid hormone withdrawal in 56% of patients with
disease or thyroid tissue limited to the thyroid bed and in 80%, 100% and 100% of
patients, respectively, with metastatic disease. The combination of radioiodine
WBS and serum Tg after rhTSH stimulation detected thyroid tissue or cancer in
93% of patients with disease or thyroid tissue limited to the thyroid bed and in
100% of patients with metastatic disease (i.e., disease outside the thyroid bed). In
both dosing regimens the combination of radioiodine WBS and Tg testing after
administration of rhTSH did not miss any patient with metastatic disease. The
patients reported a better quality of life after rhTSH administration compared
with that after thyroid hormone withdrawal. No serious adverse events were
related to rhTSH and none of the patients developed antibodies to rhTSH. 
A caveat regarding the conclusions of the two phase III trials is the fact that few
patients with distant metastases were included, raising questions about the appli-
cability to high-risk patients. Robbins et al. (103) performed a retrospective analy-
sis of a cohort of 289 patients undergoing routine follow-up testing to detect
recurrent differentiated thyroid carcinoma over a 2-year period in which one
group was prepared for testing by thyroid hormone withdrawal (161 patients), and
the other group (128 patients) received rhTSH before the diagnostic tests. The
cohort consisted of a relatively high number of high-risk patients in both arms (T4
tumors in 42% and 41% respectively, distant metastases in 18% and 23% respec-
tively). The patients were examined by both radioiodine WBS and measurement
of serum Tg. Patients with only thyroid bed uptake were excluded. The authors
were unable to demonstrate a difference in the diagnostic accuracy of diagnostic
whole body scanning and Tg testing between patients prepared by either thyroid
hormone withdrawal or rhTSH. There were however two biases in this trial. First,
patients were only offered rhTSH if they qualified for a compassionate need trial.
Second, patients who had previously experienced the hypothyroid state may have
been more likely to choose rhTSH. 
1.4.4.3 rhTSH-stimulated thyroglobulin testing without radioiodine
whole body scintigraphy after thyroidectomy for differentiated
thyroid cancer
The sensitivity of a diagnostic 131I whole body scan during follow-up after initial
thyroid ablation is limited (104,105). Therefore, the utility of rhTSH-stimulated
serum Tg measurements without radioiodine WBS in patients with undetectable
serum Tg values on thyroid hormone therapy, as a method to differentiate
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patients with persistent or recurrent disease from patients who are disease-free,
has been studied (106-111).
David et al. (106) reported the results of rhTSH administration in 33 patients who
underwent WBS and serum Tg measurement after rhTSH administration. These
patients were divided into 2 groups depending on serum Tg concentrations dur-
ing thyroid hormone therapy: 29 patients had Tg concentrations of <2 ng/mL and
4 patients had Tg values of >2 ng/mL. In the first group, Tg values remained <2
ng/mL in 25 patients and increased to 22.0 ± 5.75 ng/mL in 4 patients after rhTSH
administration. WBS did not reveal any uptake of 131I in the 25 patients without an
increase in Tg, whereas 131I uptake was evident in 2 of the 4 patients with a rise in
Tg. In the second group Tg values increased in all 4 patients from 17.3 ± 6.35 ng/mL
to 55.3 ± 12.75 ng/mL, and 131I uptake was evident in 3 of the 4 patients. In this
study it was concluded that rhTSH should be administered in TSH-suppressed
patients with basal serum Tg concentrations of <2 ng/mL, because the increment
in serum Tg concentrations can reveal the persistence of thyroid tissue in these
patients. 
In a prospective study by Pacini et al. (107) serum Tg measurement after rhTSH
was compared with diagnostic radioiodine WBS and serum Tg measurement after
thyroid hormone withdrawal in 72 patients who had a serum Tg < 1 ng/mL on thy-
roid hormone. A negative rhTSH Tg test was concordant with an undetectable Tg
after thyroid hormone withdrawal in 88% (36 of 41 patients). In 12% (5 of 41
patients) Tg was detectable (1.1–7.8 ng/mL) only after thyroid hormone withdraw-
al and not after rhTSH stimulation. This was associated with negative radioiodine
WBS (n=3) or a faint uptake in the thyroid bed (n=2). In 31 patients, Tg was
detectable both after rhTSH and after withdrawal. The authors concluded that in
patients with undetectable baseline levels of serum Tg and without anti-Tg anti-
bodies, rhTSH-stimulated Tg represents an informative test to distinguish dis-
ease-free patients from patients with local disease or distant metastases.
Haugen et al. (108) reviewed their experience using rhTSH in 83 patients to com-
pare the clinical relevance of a positive WBS and/or Tg. Ten patients had a posi-
tive WBS; eight of these patients had activity limited to the thyroid bed. rhTSH-
stimulated Tg was 2 ng/mL or more in 25 and 5 ng/mL or more in 13 patients. Of
the patients with a negative WBS, 11 of 20 patients with a Tg 2 ng/mL or more and
7 of 9 patients with a Tg 5 ng/mL or more received therapy or further evaluation
based on the Tg results alone. Conversely, only 1 of 5 patients with a serum Tg less
than 2 ng/mL received therapy or further evaluation based on a positive WBS
alone. Three of the patients who did not receive therapy or further evaluation, had
subsequent negative WBS 10-12 months later, suggesting lack of clinically signifi-
cant disease. Twenty patients had a negative WBS and serum Tg 2 ng/mL or more.
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Eleven of 20 patients had a Tg less than 5 ng/mL and 4 of these patients had fur-
ther evaluation with a neck ultrasound. One patient had a biopsy-proven recur-
rence (rhTSH-stimulated Tg 4 ng/mL). Subsequent evaluations (at least 6 months
later) have been negative for 8 patients. Of the nine patients with a Tg 5 ng/mL or
more and a negative WBS, 7 had further evaluation and in 6 of 7 disease was iden-
tified. rhTSH-stimulated WBS and Tg showed to be complementary, but Tg is a
more sensitive indicator of disease recurrence or persistence. 
Mazzaferri and Kloos (109) retrospectively studied 107 consecutive patients with
undetectable Tg levels on thyroid hormone therapy and without anti-Tg antibod-
ies, who underwent rhTSH-stimulated testing 10 months to 35 years after thy-
roidectomy and ablation. 50% of the patients were at high risk of tumor recur-
rence and 5 had developed distant metastases during the course of their disease.
Nine patients were found to have local disease or distant metastases identified by
cytology, surgical pathology, post-therapy WBS, or CT. All of these patients had
rhTSH-stimulated serum Tg levels above 2 ng/mL. In 11 other patients with rhTSH-
stimulated Tg levels above 2 ng/mL, tumor could not be found. Thus tumor
amenable to early therapy may be found when rhTSH-stimulated serum Tg rises
above 2 ng/mL without performing a WBS.
Retrospectively Robbins et al. (110) analyzed the data of 366 patients who were
evaluated with diagnostic WBS and serum Tg after preparation by rhTSH. In the
entire group, 14% of 175 patients with a stimulated Tg level ≤ 2 ng/mL, and 76% of
191 patients with a stimulated Tg level > 2 ng/mL were found to have
persistent/recurrent disease. A low risk group was defined (low probability of thy-
roid remnant, no previously diagnosed metastases, serum Tg on thyroid hormone
< 2 ng/mL, no anti-Tg antibodies, AJCC stage I or II, post 131I ablation). In this low
risk group the negative predictive value of a stimulated Tg level ≤ 2 ng/mL was
91.7% (75/90 = 83% of these patients was found to have persistent disease). The
authors concluded that a rhTSH-stimulated Tg of ≤ 2 ng/mL excluded persistent
or recurrent disease in low risk patients, especially in those who had a prior neg-
ative diagnostic WBS. 
In a meta-analysis of the studies mentioned above (112), it has been shown that
tumor is rarely found when the serum Tg level is less than 2 ng/mL after thyroid
hormone withdrawal (104,105) or after rhTSH stimulation (100-103,107,109,110,113).
Patients with residual tumor are almost always identified by a serum Tg level
above 2 ng/mL after thyroid hormone withdrawal (104,105) or rhTSH stimulation
(100-103,107,109,110,113). The sensitivity of a rhTSH-stimulated serum Tg >2 ng/mL
for the detection of thyroid cancer metastases was 91% (100-103,107,109,110,113),
whereas the sensitivity of diagnostic whole body scanning, either after rhTSH or
thyroid hormone withdrawal, was only 19%. In 168 of 784 patients whose serum Tg
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on thyroid hormone suppression therapy was less than 1 ng/mL, serum Tg rose to
>2 ng/mL after rhTSH stimulation. In 36% of these 168 patients, unsuspected
metastases were found (36% at distant sites).
1.4.4.4 rhTSH-stimulated thyroglobulin testing with neck ultrasono-
graphy after thyroidectomy for differentiated thyroid cancer 
The rhTSH-stimulated Tg test combined with neck ultrasonography appears to
have the highest diagnostic accuracy in detecting persistent disease in the follow-
up of patients with differentiated thyroid carcinoma (113,114). In the study by
Pacini et al. (113), the addition of neck US increased the sensitivity for the detec-
tion of thyroid cancer metastases of rhTSH-stimulated serum Tg measurements
from 85% to 96%. Torlontano et al. (114) also found that neck US showed metas-
tases in lymph nodes in some patients with low rhTSH-stimulated serum Tg lev-
els: in 2 of 5 patients with rhTSH-stimulated serum Tg levels 1–5 ng/mL and in 2 of
78 patients with undetectable rhTSH-stimulated serum Tg levels. Therefore, a
detectable level of serum Tg on thyroid hormone therapy, its conversion from
undetectable to detectable after rhTSH, and/or a suspicious finding at neck US
allowed the identification of patients requiring therapeutic procedures without
the need for a diagnostic WBS.
Follow-up protocols for patients with differentiated thyroid cancer are mainly
based on data from high-risk patients treated in the past. However, the spectrum
of patients with differentiated thyroid cancer has changed over the years, due to
the fact that a larger number of thyroid tumors, mainly papillary, are being discov-
ered at an earlier stage. Nowadays, the majority of patients are at low risk of
recurrence. A consensus report of mainly American thyroid cancer specialists was
published in 2003 (112), and a review article by European thyroid cancer special-
ists was published in 2004 (115), both containing new protocols for the follow-up
of patients with differentiated thyroid cancer who are at low risk of recurrence.
The new recommendations in these publications are based on three sets of data,
which have been discussed above: data on the high sensitivity of serum Tg meas-
urements after TSH-stimulation (after thyroid hormone withdrawal or after
rhTSH), data on the limited sensitivity of diagnostic WBS, and data on the high
sensitivity of ultrasound for the detection of lymph node metastases of thyroid
cancer in the neck. In both the American and the European recommendations, it
is advised in low-risk patients who are clinically disease-free 0.5 to 1 year after thy-
roidectomy and radioiodine ablation and whose serum Tg level on thyroid hor-
mone suppression therapy is undetectable, to measure a rhTSH-stimulated serum
Tg level, without WBS. Further follow-up and/or therapy are dependent on the
rhTSH-stimulated Tg level, in combination with the results of US of the neck.  
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1.4.5 rhTSH as an adjunct to positron emission tomography for differenti-
ated thyroid cancer
In differentiated thyroid cancer patients known to have disease based on an ele-
vated serum Tg level, but with a negative WBS, localization of the disease is diffi-
cult. Progressive dedifferentiation of thyroid cancer cells leads to the loss of
iodine-concentrating ability, wich results in a false negative WBS. Wang et al. (116)
performed [18F]-2-fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography
(FDG-PET) in 37 patients with differentiated thyroid cancer after surgery and 131I
ablation, who had a negative diagnostic WBS during routine follow-up. Serum Tg,
Tg autoantibodies, neck ultrasound, and other clinically indicated imaging proce-
dures were performed to detect residual disease. In patients with elevated Tg lev-
els, FDG-PET localized occult disease in 71%, was false positive in one, and false
negative in five patients. The majority of false negative FDG-PET scans occurred
in patients with minimal cervical adenopathy. Thus, FDG-PET was able to localize
residual thyroid cancer lesions in patients who had negative diagnostic 131I WBS
and elevated Tg levels, although it was not sensitive enough to detect minimal
residual disease in cervical nodes. Results of FDG-PET during TSH suppression
and during endogenous TSH stimulation were compared in two studies (117,118).
Most locally recurrent and metastatic differentiated thyroid carcinomas exhibited
a significant increase in FDG uptake on TSH stimulation. In 3 of 10 patients (117)
and 3 of 8  patients (118), respectively, TSH stimulation resulted in detection of
new lesions. Therefore it was recommended that FDG-PET examinations to detect
metastatic or locally recurrent differentiated thyroid carcinoma should be per-
formed during TSH stimulation.
These results are in line with the observation that TSH stimulates thyroidal glu-
cose transporter expression. As a next step the idea of using rhTSH to improve
the results of FDG-PET scanning has been explored. Petrich et al. (119) studied
whether the administration of rhTSH stimulates FDG uptake in thyroid carcinoma
lesions. Thirty patients with positive Tg levels and negative 131I WBS underwent
FDG-PET during TSH suppression and during rhTSH stimulation. FDG uptake was
quantitated using tumor to background ratios (TBRs) and standardized uptake
values (SUVs). During TSH suppression, there was focal FDG accumulation in 9
subjects and the total number of foci was 45. After rhTSH stimulation, the num-
ber of patients in whom FDG foci were detected was 19, and the number of foci
identified was 82. TBRs and SUVs of regions showing positive FDG contrast were
significantly higher during rhTSH stimulation than during TSH suppression.
Recently, a prospective study on the effect of rhTSH as an adjuvant to FDG-PET in
patients with residual or recurrent thyroid cancer was published (120). Seven
patients with differentiated thyroid carcinoma, negative 131I WBS, and biochemical
evidence of residual disease were randomized and prospectively studied with
FDG-PET both during thyroid hormone suppression and rhTSH stimulation. All
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lesions seen on the TSH suppression scans were seen on the rhTSH stimulation
studies. RhTSH stimulation identified four additional lesions not seen during TSH
suppression. One patient was positive during rhTSH stimulation alone. The TBRs
were significantly higher during rhTSH stimulation, compared with those during
TSH suppression. These studies provided evidence that FDG-PET is more accurate
during rhTSH stimulation than during TSH suppression to detect differentiated
thyroid carcinoma.
1.4.6 rhTSH as an adjunct to radioiodine ablation of thyroid remnants in
differentiated thyroid cancer
Radioiodine ablation of thyroid remnants after thyroidectomy for differentiated
thyroid carcinoma improves the sensitivity of subsequent serum Tg measure-
ments and radioiodine WBS for detection of residual thyroid carcinoma. The use
of 131I for radioablative treatment of thyroid remnants in patients with differenti-
ated thyroid cancer requires a sufficiently stimulated serum concentration of
TSH, for efficient uptake of radioiodine in thyroid tissue. The standard method to
increase the serum TSH level is withdrawal of thyroid hormone therapy.
A preliminary study on the use of rhTSH before thyroid remnant ablation in 10
patients was published by Robbins et al. (121). In none of the patients who
received a mean dose of 110 mCi (range 30-250 mCi) 131I after pretreatment with
rhTSH did a follow-up WBS 5-13 months later show any visible thyroid bed uptake.
In a larger retrospective study by the same group (122), 38/45 (84%) of patients
prepared by rhTSH (radioiodine dose 110 ± 65 mCi) and 34/42 (81%) of patients
prepared by thyroid hormone withdrawal (radioiodine dose 129 ± 74 mCi) had
complete resolution of visible thyroid bed uptake on follow-up diagnostic WBS.
Two prospective studies have been published in which it was assessed whether
administration of rhTSH is useful as an adjunct to radioiodine for post-surgical
ablation of thyroid remnants, using a low (30 mCi) standard dose of 131I. In the
study by Pacini et al. (123), the rate of ablation was prospectively compared
between three groups of patients consecutively assigned to one of three treat-
ment arms: in the first arm, patients (n = 50) were treated while hypothyroid, in
the second arm, patients (n = 42) were treated while hypothyroid and stimulated
in addition with rhTSH and in the third arm, patients (n = 70) were treated while
euthyroid on L-thyroxine and stimulated with rhTSH. The outcome of thyroid
ablation was assessed by a diagnostic WBS 72 h after administration of 4 mCi 131I,
performed in the hypothyroid state 6-10 months after ablation. The rate of suc-
cessful ablation, defined as the disappearance of any visible uptake in the thyroid
bed, was similar in the hypothyroid and hypothyroid/rhTSH-stimulated groups
(84% and 78.5%, respectively). A significantly lower rate of ablation (54%) was
achieved in the euthyroid, rhTSH-stimulated group. This study indicates that
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when using rhTSH in patients on L-thyroxine therapy, a 30 mCi standard dose of
131I is not sufficient for a satisfactory thyroid ablation rate. The authors mentioned
as possible reasons for this failure a lower 24-h RAIU, a lower radiation dose deliv-
ered to the residues, and an accelerated iodine clearance in the group of patients
on L-thyroxine therapy in comparison to the hypothyroid groups. 
Barbaro et al. (124) compared the efficacy of thyroid remnant ablation in 16
patients who were treated with 30 mCi 131I after rhTSH-stimulation, stopping L-
thyroxine from the day before the first injection of rhTSH to the day after 131I
administration, with that in 24 comparable historical controls who were treated
with 30 mCi 131I in the hypothyroid state after L-thyroxine withdrawal. They
hypothesized that iodine derived from L-thyroxine administered during the
rhTSH-stimulated radioiodine ablation would interfere with radioiodine uptake
causing a diminished effectiveness of the procedure. After 1 yr, all patients under-
went a diagnostic WBS and serum Tg measurement using rhTSH. The percentage
of successful ablation was 81% in patients pretreated with rhTSH and 75% in
patients pretreated by L-T4 withdrawal (not significant). None of the patients
experienced symptoms of hypothyroidism during the 4 days of L-T4 interruption,
and serum T4 remained in the normal range in the rhTSH-stimulated patients.
From these studies, it appears that rhTSH stimulated remnant ablation is a viable
option. More studies, particularly employing larger 131I doses, are required.
1.4.7 rhTSH as an adjunct to radioiodine therapy in differentiated thyroid
cancer
Recombinant human TSH has been used on a compassionate need basis to pre-
pare patients for radioiodine therapy. The first successful treatments of patients
with differentiated metastatic thyroid cancer using 131I after rhTSH stimulation
were described in case reports (125-127). The reasons to use rhTSH instead of thy-
roid hormone withdrawal to prepare for the administration of a therapeutic dose
of 131I in these patients were earlier tumor growth after discontinuation of thyroid
hormone therapy or inability to produce sufficient endogenous amounts of TSH
when hypothyroid. Luster et al. (128) used rhTSH in conjunction with radioiodine
therapy in 11 patients (16 treatments) with advanced differentiated thyroid cancer.
Indications for the use of rhTSH in these patients included inability to tolerate
withdrawal of thyroid hormones due to very poor physical condition and inability
to achieve sufficiently high serum TSH levels after withdrawal. Ten patients had
undergone thyroidectomy, and most had received prior radioablative therapy.
Baseline Tg levels ranged from 25 to nearly 30,000 ng/mL. In 7 cases, post-thera-
py Tg levels assessed at 2 to 10 months after 131I therapy had decreased by at least
30% compared to pre-therapy levels. After therapy, 3 patients showed marked
clinical improvement, and/or decreased or stabilized tumor burden on WBS. Three
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patients died of progressive disease within 2 months of therapy before follow-up
assessments could be performed. No adverse events were reported among the 8
surviving patients. Lippi et al. (129) studied 12 patients who underwent 131I treat-
ment after rhTSH administration, while euthyroid on L-thyroxine. Nine underwent
diagnostic WBS after two injections of 0.9 mg rhTSH. They then received identi-
cal rhTSH pretreatment to promote therapeutic 131I uptake. Three patients
received only rhTSH-pretreated 131I therapy. Administration of rhTSH promoted
131I uptake in all patients. Administration of rhTSH also caused a significant
increase in serum Tg concentrations. According to measurements 3-12 months
after therapy, serum Tg levels fell in 4, and stabilized in 2 out of 11 patients. RhTSH
was well tolerated but individuals with bone metastases experienced transient
pain and swelling. These results suggest that rhTSH administration offers a prom-
ising alternative to thyroid hormone withdrawal in radioiodine therapy. It has to
be determined whether cessation of thyroid hormone for 3–5 days before the
therapeutic dose of 131I (in an attempt to reduce iodine intake) results in better
retention of 131I in the lesions (130). It is also important to determine the lowest
dose of rhTSH that induces satisfactory uptake of therapy doses of 131I, since TSH
is a stimulus for thyroid tumor growth (131). Another question is whether rhTSH
can enhance the efficacy of chemotherapy in differentiated thyroid cancer. A pre-
liminary report from Santini et al. (132) suggests that the efficacy of chemothera-
py for thyroid cancer metastases is increased if the tumor is stimulated by rhTSH.
This study raises a new perspective for patients with metastatic thyroid cancer
that does not concentrate 131I, and who have few therapeutic options.
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Outline of the Thesis
In this thesis the use of recombinant human thyrotropin (rhTSH) as a possible
adjunct to radioiodine therapy for thyroid volume reduction in patients with non-
toxic, nodular goiter is explored.
Chapter 2. Radioiodine (131I) is increasingly used as treatment for volume reduc-
tion of nontoxic, nodular goiter. A high dose of 131I is often needed because of low
thyroid radioiodine uptake (RAIU). We investigated whether pretreatment with a
single, low dose of rhTSH (Thyrogen®, Genzyme) enhances RAIU in 15 patients
with nontoxic, nodular goiter. We observed that pretreatment with a single, low
dose of rhTSH in patients with nontoxic, nodular goiter increased RAIU consider-
ably. These observations hold promise that administration of rhTSH before 131I
therapy for nontoxic, nodular goiter will allow treatment with lower doses of 131I
in these patients.
In chapter 3 we investigated whether rhTSH pretreatment induces changes in the
regional distribution of radioiodine as visualized on thyroid scintigrams in these
patients. We found that a single, low dose of rhTSH caused a more homogeneous
distribution of radioiodine within the thyroid gland in patients with a nontoxic,
nodular goiter by stimulating radioiodine uptake in relatively cold areas more
than in relatively hot areas. This was most marked in patients with a low baseline
serum TSH level. Our data suggest that pretreatment with rhTSH may improve
the efficacy of radioiodine treatment for volume reduction of nodular goiters,
especially in patients with a low baseline serum TSH level.
In patients with nodular goiter, 131I therapy results in a mean reduction in thyroid
volume of approximately 40% after 1 year. In chapter 4 we studied the safety and
efficacy of therapy with a reduced dose of 131I after pretreatment with rhTSH. We
demonstrated that pretreatment with a single, low dose of rhTSH allowed approx-
imately 50–60% reduction of the therapeutic dose of radioiodine without com-
promising the efficacy of thyroid volume reduction.
Chapter 5 deals with the dosimetric aspects of therapy with a reduced dose of 131I
after pretreatment with rhTSH in patients with nontoxic, nodular goiter. 131I ther-
apy after pretreatment with a single, low dose of rhTSH, with the dose reduced
according to the rhTSH-induced increase in 24-h RAIU, caused lower radiation-
absorbed doses in extrathyroidal organs and tissues, especially bladder and stom-
ach, and no significant increase in the release of 131I-labeled thyroid hormones into
the circulation of patients with nodular goiter. We concluded that this mode of
therapy is promising, especially when the dose of radioiodine to be administered
without rhTSH pretreatment is high.
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In chapter 6 we give a summary of the studies in this thesis and we outline the
perspective of treatment of nontoxic, nodular goiter by radioiodine focusing on
the role of pretreatment with rhTSH.
Finally chapter 7 presents the summary and perspective in Dutch.
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Abstract
Radioiodine (131I) is increasingly used as treatment for volume reduction of non-
toxic, nodular goiter. A high dose of 131I is often needed because of low thyroid
radioiodide uptake (RAIU). We investigated whether pretreatment with a single,
low dose of recombinant human TSH (rhTSH; Thyrogen, Genzyme Transgenics
Corp.) enhances RAIU in 15 patients with nontoxic, nodular goiter (14 women and
1 man; aged 61 ± 11 yr). Four patients were studied twice, and 1 patient was stud-
ied 3 times. RAIU was measured both under basal conditions and after pretreat-
ment (im) with rhTSH, given either 2 h (0.01 mg; n = 7) or 24 h [0.01 mg (n = 7) or
0.03 mg (n = 7)] before 131I administration (20–40 µCi). Serum levels of TSH, free
T4 (FT4), and total T3 were measured at 2, 5, 8, 24, 48, 72, 96, and 192 h after rhTSH
administration.
After administration of 0.01 mg rhTSH, serum TSH rose from 0.7 ± 0.5 to a peak
level of 4.4 ± 1.1 mU/L (P < 0.0001), FT4 rose from 16.0 ± 2.6 to 18.5 ± 3.7 pmol/L (P
< 0.0001), and T3 rose from 2.10 ± 0.41 to 2.63 ± 0.66 nmol/L (P < 0.0001). After
administration of 0.03 mg rhTSH, TSH rose from 0.6 ± 0.4 to 15.8 ± 2.3 mU/L (P <
0.0001), FT4 rose from 15.2 ± 1.5 to 21.7 ± 2.9 pmol/L (P < 0.0001), and T3 rose from
1.90 ± 0.43 to 3.19 ± 0.61 nmol/L (P < 0.0001). Peak TSH levels were reached at 5–8
h and peak FT4 and T3 levels at 8–96 h after rhTSH administration.
Administration of 0.01 mg rhTSH 2 h before 131I increased 24-h RAIU from 30 ± 11%
to 42 ± 10% (P < 0.02), 0.01 mg rhTSH administered 24 h before 131I increased 24-
h RAIU from 29 ± 10% to 51 ± 10% (P < 0.0001), and 0.03 mg rhTSH administered
24 h before 131I increased 24-h RAIU from 33 ± 11% to 63 ± 9% (P < 0.0001). After
administration of 0.01 mg rhTSH 2 h before 131I, 24-h RAIU did not increase in 1
patient, whereas the increase in 24-h RAIU was less than 10% in 2 other patients.
In contrast, administration of rhTSH 24 h before 131I increased 24-h RAIU by more
than 10% in all 14 patients (by >20% in 10 and by >30% in 6).
In conclusion, pretreatment with a single, low dose of rhTSH in patients with non-
toxic, nodular goiter increased RAIU considerably. Our observations hold promise
that administration of rhTSH before 131I therapy for nontoxic, nodular goiter will
allow treatment with lower doses of 131I in these patients.
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Introduction
A number of studies, using ultrasonography, computed tomography, or magnetic
resonance imaging for accurate measurements of thyroid volume, have shown
that radioiodine (131I) therapy in patients with nontoxic, nodular goiter results in a
mean reduction in thyroid volume of approximately 40% after 1 yr (1, 2, 3, 4, 5) and
of 50–60% after 3–5 yr (2, 6, 7). In the majority of patients radioiodine treatment
decreases not only thyroid volume, but also compressive symptoms (3). The
improvement in compressive symptoms is accompanied by substantial tracheal
widening, as measured by magnetic resonance imaging (3), and improvement in
respiratory function (3, 8).
The amount of radioiodine administered depended on thyroid weight and radioac-
tive iodide uptake (RAIU) in the thyroid in the reported studies. Doses of approx-
imately 100 µCi [3.7 megabecquerels (MBq)] radioiodine/g thyroid tissue correct-
ed for RAIU at 24 h were usually given. As patients with nontoxic, nodular goiter
usually have a rather low RAIU, high doses of radioiodine are often needed, caus-
ing considerable irradiation of extrathyroidal organs and tissues (9). Therefore, it
is of interest to explore strategies to enhance RAIU in these patients.
One of the causes of a low RAIU in patients with nontoxic, nodular goiter is the
fact that the serum TSH level is in the low normal range or even below normal in
most of these patients. It might be possible to enhance radioiodide uptake in
patients with nontoxic, nodular goiter by pretreatment with either bovine TSH or
human cadaver TSH. However, bovine TSH is no longer used in humans, because
it frequently causes adverse reactions. Human cadaver TSH cannot be used in
humans, because of the risk of development of Creutzfeld-Jacob disease.
Recently, recombinant human TSH (rhTSH) has become available for diagnostic use
in patients with thyroid cancer. It has been shown that rhTSH stimulates 131I uptake
in thyroid remnants that persisted after thyroidectomy and in metastatic thyroid
cancer, providing an alternative for thyroid hormone withdrawal for patients under-
going evaluation for thyroid cancer persistence and recurrence (10, 11).
A study in euthyroid mice and rats showed that ip administration of rhTSH (0.1
µg/g BW) given 3 h before administration of radioiodide did not increase RAIU
(12). In mice, but not in rats, that were TSH suppressed by prior administration of
T3, a significant increase in RAIU was found (12). In two rhesus monkeys, im admin-
istration of 0.2 mg rhTSH given 5 h before radioiodide administration increased
RAIU (by a factor of 1.85) in only one monkey (13). Administration of 0.2 mg rhTSH
on 3 consecutive days in two other monkeys resulted in a doubling of RAIU in both
monkeys (13).
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To date, no observations have been reported on the influence of rhTSH adminis-
tration on RAIU in healthy human subjects or patients with benign thyroid dis-
eases. In the present study we investigated whether the administration of a single
low dose of rhTSH enhances RAIU in patients with nontoxic, nodular goiter. If so,
administration of rhTSH before 131I therapy for nontoxic, nodular goiter holds
promise in allowing treatment with lower doses of 131I in these patients.
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Subjects and Methods
Patients
Fifteen patients, 14 women and 1 man, aged 61 ± 11 yr (mean ± SD; range, 44–73 yr),
referred for radioiodine therapy for volume reduction of nontoxic, nodular goiter,
were studied. Four patients were studied twice, and 1 patient was studied 3 times.
The mean thyroid weight, as estimated from planar thyroid scintigraphy, was 181 ±
77 g (range, 60–300 g). All patients had normal serum levels of free T4 (FT4; chemi-
luminescent immunoassay; ACS:180 FrT4, Chiron Corp., Fernwald, Germany; nor-
mal values in our laboratory, 9.0–22.3 pmol/L) and total T3 (chemiluminescent
immunoassay; ACS T3, Ciba Diagnostics Corp., Medfield MA; normal values in our
laboratory, 1.0–3.0 nmol/L), whereas the serum TSH level was normal (n = 12
patients) or below normal (n = 3 patients; two-site chemiluminometric immunoas-
say; ACS TSH-3, Ciba Diagnostics Corp.; normal values in our laboratory, 0.2–5.5
mU/L). Based on the results of careful palpation of the thyroid followed by fine
needle aspiration biopsy of dominant nodules and of those that had a different
consistency from other nodules within the gland, there was no suspicion of thy-
roid cancer in any of the patients. None of the patients had a history of significant
cardiopulmonary disease or a recent history of taking any medications known to
affect thyroid function or to interfere with hormone measurements or RAIU. None
of the patients had received iodine-containing agents in the last 6 months. An
electrocardiogram, complete blood count, liver enzyme determinations, plasma
creatinine and glucose measurements, and screening urinalysis did not show
abnormalities in any of the patients. The study was approved by the institutional
human research committee. Written informed consent was obtained from all
patients.
Baseline investigations
On the day before radioiodide administration, 24-h urine was collected for meas-
urement of iodide and creatinine excretion. Iodide excretion was 163 ± 46 µg/24 h
(range, 102–273 µg/24 h). Immediately before radioiodide administration, blood
was drawn for measurements of serum FT4, T3, and TSH. A diagnostic dose of 20
µCi (0.8 MBq) sodium (131I) iodide was administered as an oral solution [together
with 1 mCi (40 MBq) sodium (123I) iodide for thyroid scintigraphy]. RAIU as a per-
centage of the administered dose of 131I, corrected for physical decay, was meas-
ured at 3, 6, 24, 48, 72, and 168 h, using a 3 x 3-in. NaI(Tl) detector. Deadtime cor-
rections were made using standard software. The use of the net area under the
364-keV peak of 131I was checked to prohibit any interference of the low energy
photons of 123I with RAIU measurements. Thyroid scintigraphy in the 159-keV win-
dow of 123I was performed 24 h after radioiodide administration (results not
included in the present report).
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Investigations with rhTSH
The influence of rhTSH on thyroid hormone levels and RAIU was investigated in
each patient at least 2 weeks after radioiodide administration for the baseline
investigations. On the day before the administration of rhTSH, 24-h urine was col-
lected for measurements of iodide and creatinine excretion. Iodide excretion was
177 ± 48 µg/24 h (range, 112–265 µg/24 h). Immediately before the administration
of rhTSH, blood was drawn for measurement of serum FT4, T3, and TSH. After
reconstitution of freeze-dried rhTSH (ampoules containing 0.9 mg rhTSH;
Thyrogen, Genzyme Transgenics Corp., Cambridge, MA) with 1.2 mL sterile water,
part of the obtained solution was diluted with saline to a final concentration of
0.05 mg/mL. Immediately after dilution, 0.01 mg (0.2 mL; n = 14) or 0.03 mg (0.6
mL; n = 7) rhTSH was injected im in the quadriceps muscle. Vital signs (blood pres-
sure, pulse rate, and body temperature) were recorded, and blood was drawn for
measurement of serum FT4, T3, and TSH 2, 5, 8, 24, 48, 72, 96, and 192 h after
administration of rhTSH. A diagnostic dose of 20–40 µCi (0.8–1.6 MBq) sodium 131I
was administered as an oral solution [together with 1 mCi (40 MBq) sodium 123I for
thyroid scintigraphy] either 2 h after the administration of rhTSH (0.01 mg; n = 7)
or 24 h after the administration of rhTSH [0.01 mg (n = 7) or 0.03 mg (n = 7)]. RAIU
as a percentage of the administered dose of 131I, corrected for background activity
from the radioiodine from the baseline investigation and for physical decay, was
measured at 3, 6, 24, 48, 72, and 168 h. Thyroid scintigraphy was performed 24 h
after radioiodide administration (results not included in the present report).
Statistical analyses
The mean ± SD are given. Statistical analyses were performed using the Mann-
Whitney U test for unpaired observations (P values denoted as P), the Wilcoxon
sign-rank test for paired observations (P values denoted as P*), and the Spearman
rank correlation test (P values denoted as P**). The level of significance was 0.05.
2.1
76
A
dm
inistration of a Single Low
 D
ose of Recom
binant H
um
an Thyrotropin Significantly Enhances Thyroid Radioiodide U
ptake in N
ontoxic N
odular G
oiter
Proefschrift WA Nieuwlaat H2  23-03-2005  15:13  Pagina 76
2.1
77
A
dm
in
is
tr
at
io
n 
of
 a
 S
in
gl
e 
Lo
w
 D
os
e 
of
 R
ec
om
bi
na
nt
 H
um
an
 T
hy
ro
tr
op
in
 S
ig
ni
fic
an
tl
y 
En
ha
nc
es
 T
hy
ro
id
 R
ad
io
io
di
de
 U
pt
ak
e 
in
 N
on
to
xi
c 
N
od
ul
ar
 G
oi
te
r
Results
No symptoms and signs of thyrotoxicosis or other adverse effects were observed
after rhTSH administration, and blood pressure, pulse rate and body temperature
did not change (P * > 0.05 at all time points compared to values immediately
before rhTSH administration).
Effect of rhTSH administration on serum TSH, FT4, and T3 levels
After 0.01 mg rhTSH, serum TSH rose from 0.7 ± 0.5 mU/L (range, <0.03 to 1.7
mU/L) to a peak of 4.4 ± 1.1 mU/L (range, 2.2–6.3 mU/L; P * < 0.0001). After 0.03
mg rhTSH, TSH rose from 0.6 ± 0.4 mU/L (range, < 0.03–1.2 mU/L) to a peak of 15.8
± 2.3 mU/L (range, 13.6–20.0 mU/L; P * < 0.0001). Peak TSH levels were reached at
5–8 h after administration of either dose of rhTSH (Fig. 1). Thereafter, TSH declined
rapidly, and in all patients a transient decrease in serum TSH below the baseline
level was observed. One week after rhTSH administration, TSH levels did not dif-
fer significantly from baseline levels in both groups of patients.
After 0.01 mg rhTSH, serum FT4 rose from 16.0 ± 2.6 pmol/L (range, 12.6–20.7
pmol/L) to a peak of 18.5 ± 3.7 pmol/L (range, 14.1–26.7 pmol/L; P * < 0.0001), and
T3 rose from 2.10 ± 0.41 nmol/L (range, 1.60–2.90 nmol/L) to a peak of 2.63 ± 0.66
nmol/L (range, 1.90–3.80 nmol/L; P * < 0.0001). After 1 week, FT4 and T3 had
returned to baseline levels. After 0.03 mg rhTSH, FT4 rose from 15.2 ± 1.5 pmol/L
(range, 13.9–17.3 pmol/L) to a peak of 21.7 ± 2.9 pmol/L (range, 18.7–26.6 pmol/L; P *
< 0.0001), and T3 rose from 1.90 ± 0.43 nmol/L (range, 1.40–2.70 nmol/L) to a peak
of 3.19 ± 0.61 nmol/L (range, 2.30–3.90 nmol/L; P * < 0.0001). After 1 week, serum
FT4 (17.5 ± 3.2 pmol/L; range, 14.4–22.4 pmol/L) and T3 (2.01 ± 0.43 nmol/L; range,
1.50–2.80 nmol/L) were still significantly above baseline levels (P * < 0.0001). Peak
levels of FT4 occurred 8–96 h, and peak T3 levels occurred 5–96 h after administra-
tion of rhTSH. Increases in TSH and FT4 levels (i.e. peak level minus baseline level)
were significantly larger in the patients who received 0.03 mg rhTSH than in the
patients who received 0.01 mg rhTSH (P < 0.0001).
Effect of rhTSH administration on RAIU (Table 1)
Administration of 0.01 mg rhTSH 2 h before 131I increased 24-h RAIU from 30 ± 11%
to 42 ± 10% (P * < 0.02); 0.01 mg rhTSH administered 24 h before 131I increased 24-
h RAIU from 29 ± 10% to 51 ± 10% (P * < 0.0001), and 0.03 mg rhTSH administered
24 h before 131I increased 24-h RAIU from 33 ± 11% to 63 ± 9% (P * < 0.0001).
The ratio between 24-h RAIU after rhTSH and baseline 24-h RAIU was 1.5 ± 0.5
(range, 1.0–2.4) in patients who received 0.01 mg rhTSH 2 h before radioiodide, 1.9
± 0.5 (range, 1.2–2.7) in those who received 0.01 mg rhTSH 24 h before radioiodide,
and 2.0 ± 0.5 (range, 1.4–2.6) in those who received 0.03 mg rhTSH 24 h before
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Figure 1. Serum TSH levels (left panels) and FT4 levels (right panels) before (0 h) and after im administration of 0.01 mg
(upper panels) and 0.03 mg (lower panels) rhTSH in 15 patients with nontoxic, nodular goiter. rhTSH was administered
immediately after blood withdrawal at 0 h. The dotted line indicates the upper level of the normal range for serum FT4.
Table 1.  Thyroid radioactive iodide uptake (RAIU; mean ± 1 SD) at 3, 6, and 24 h in the baseline investigation (without
rhTSH administration) and in the investigation after rhTSH administration
0.01 mg rhTSH 0.01 mg rhTHS 0.03 mg rhTSH 
2 h before radioiodine 24 h before radioiodine 24 h before radioiodine
3-h RAIU without rhTSH (%) 11 ± 4 12 ± 5 13 ± 4
3-h RAIU after rhTSH (%) 14 ± 6 32 ± 10 35 ± 8
Ratio 1.3 ± 0.5 2.6 ± 0.5 2.8 ± 0.8
6-h RAIU without rhTSH (%) 17 ± 6 18 ± 8 20 ± 6
6-h RAIU after rhTSH (%) 23 ± 8 40 ± 10 44 ± 11
Ratio 1.4 ± 0.4 2.4 ± 0.5 2.4 ± 0.9
24-h RAIU without rhTSH (%) 30 ± 11 29 ± 10 33 ± 11
24-h RAIU after rhTSH (%) 42 ± 10 51 ± 10 63 ± 9
Ratio 1.5 ± 0.5 1.9 ± 0.5 2.0 ± 0.5
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Figure 2.  Baseline 24-h radioactive iodide uptake ( ) and 24-h radioactive iodide uptake after administration of recom-
binant human TSH ( ) in 15 patients with nontoxic, nodular goiter. Patients are identified at the bottom of the figure as
a to o. Four patients (a, d, e, and f) were studied twice; one patient (g) was studied 3 times. Serum TSH levels (milliunits
per L) immediately before administration of rhTSH are also given at the bottom of the figure.
Figure 3. Twenty-four-hour radioactive iodide uptake in 5 patients with nontoxic, nodular goiter, in whom rhTSH was
given at 2 and 24 h before radioiodide administration on two different occasions. , Baseline 24-h radioactive iodide
uptake; , 24-h radioactive iodide uptake after 0.01 mg rhTSH given 2 h before radioiodide; , 24-h radioactive iodide
uptake after 0.01 mg rhTSH given 24 h before radioiodide.
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radioiodide (P < 0.003, 0.01 mg rhTSH 2 h before radioiodide vs. 0.03 mg rhTSH 24
h before radioiodide).
The ratio between 24-h RAIU after rhTSH and baseline 24-h RAIU showed a sig-
nificant inverse correlation with baseline 24-h RAIU (r = -0.79; P ** < 0.04 for
patients who received 0.01 mg rhTSH 2 or 24 h before radioiodide and r = -0.89;
P ** < 0.007 for patients who received 0.03 mg rhTSH). The ratio between 24-h
RAIU after rhTSH and baseline 24-h RAIU was not significantly correlated with the
baseline TSH level.
The biological half-time of radioiodine in the thyroid, as estimated from the RAIU
values of time points 48–168 h after the administration of radioiodide, was 61.3 ±
27.3 days in the baseline investigation and 56.6 ± 31.4 days in the investigation
after rhTSH (P * = NS).
Baseline 24-h RAIU and 24-h RAIU after rhTSH in individual patients are shown
(Fig. 2). Of note, after administration of 0.01 mg rhTSH 2 h before 131I, 24-h RAIU
did not increase in 1 patient, whereas the increase in 24-h RAIU was less than 10%
in 2 other patients. In contrast, administration of rhTSH 24 h before 131I increased
24-h RAIU by more than 10% in all 14 patients (by >20% in 10 and by >30% in 6).
Individual values of 24-h RAIU are shown in five patients who received 0.01 mg
rhTSH both 2 and 24 h before radioiodide on different occasions (Fig. 3). The ratio
between 24-h RAIU after rhTSH and baseline 24-h RAIU was significantly higher
for the 24-h interval between rhTSH and radioiodide administration than for the
2-h interval (P * < 0.0001).
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Discussion
It has been convincingly demonstrated that administration of rhTSH increases
RAIU in thyroid remnants and thyroid cancer metastases (10, 11). However, to date
there are no observations on the effects of administration of rhTSH on RAIU in
benign thyroid diseases. In the present study we demonstrate that a single im
injection of rhTSH given 24 h before radioiodide administration doubled RAIU in
patients with nontoxic, nodular goiter. Our study was performed in an area with
borderline sufficient iodine intake, where further restriction of iodine intake did
not result in any significant enhancement of RAIU (Huysmans, D. A., et al., unpub-
lished observations).
The doubling of RAIU was reached by the use of remarkably low doses of rhTSH
(0.01 or 0.03 mg). For comparison, a single im injection of 0.1 mg rhTSH was used
in a study of the effects of rhTSH on serum thyroid hormone levels in six normal
volunteers (14), whereas im injections of 0.9 mg rhTSH were used in two phase 3
studies in patients with thyroid cancer (10, 11). Accordingly, we found considerably
lower peak levels of TSH (4.4 ± 1.1 mU/L after 0.01 mg rhTSH and 15.8 ± 2.3 mU/L
after 0.03 mg rhTSH) than observed in normal volunteers after 0.1 mg rhTSH (50.9
± 22.8 mU/L) (14) and in thyroid cancer patients after 0.9 mg rhTSH (101 ± 60
mU/L) (10).
In our study, the interval between the administration of rhTSH and radioiodide
appeared to be an important factor for increasing RAIU; a 24-h interval between
rhTSH administration and radioiodide administration was significantly more
effective than a 2-hinterval. This finding is in accordance with the results of in
vitro studies using FRTL-5 cells (15, 16). Weiss et al. (15) demonstrated that 12–24 h
were needed for the onset of stimulation of iodide transport by a purified prepa-
ration of TSH. Kogai et al. (16) demonstrated that rhTSH (1 mU/mL) increased
iodide-125 uptake only after 12 h of incubation, reaching a maximum after an incu-
bation period of 72 h.
Iodide uptake across the basolateral membrane of thyroid follicular cells is cat-
alyzed by the Na+/I- symporter (NIS). Immunohistochemical studies have demon-
strated that under normal conditions, there is only limited expression of the Na+/I-
symporter in the plasma membrane of thyroid follicular cells (17, 18). Kogai et al.
(16) have shown that in FRTL-5 cells rhTSH induces a significant increase in NIS
messenger ribonucleic acid at 3–6 h, reaching a maximum at 24 h. NIS protein lev-
els were significantly increased only after 36 h, reaching a maximum at 72 h. Thus,
optimal expression and/or activation of the Na+/I- symporter may take some time,
which might explain our observation that a 24-h interval between rhTSH adminis-
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tration and radioiodide administration was significantly more effective in increas-
ing RAIU than a 2-h interval.
We found that the effects of administration of 0.03 and 0.01 mg rhTSH on RAIU
were not significantly different. In contrast, 0.03 mg rhTSH caused a significantly
greater maximal increase in serum thyroid hormone levels (42% increase in FT4,
69% increase in T3) than did 0.01 mg rhTSH (15% increase in FT4, 25% increase in
T3). In only 8 of 21 observations was serum FT4 and/or T3 increased beyond the nor-
mal range after rhTSH administration, and in none of the patients were symptoms
or signs of thyrotoxicosis (or any other side-effect) observed. For comparison, the
increases in serum thyroid hormone levels after either dose of rhTSH appeared to
be less than those found in normal volunteers after the administration of 0.1 mg
rhTSH (54% increase in total T4 and 89% increase in total T3) (14).
No adverse effects of the administration of a single low dose of rhTSH were
observed in our study. However, before rhTSH can be advised as an adjunct to
radioiodine therapy in patients with nontoxic, nodular goiter, the safety of the
administration of a therapeutic dose of radioiodine after pretreatment with rhTSH
has to be investigated thoroughly. First, it has to be determined that pretreatment
with rhTSH does not exacerbate the mild increases in serum thyroid hormone lev-
els and thyroid volume commonly seen after radioiodine treatment of nontoxic,
nodular goiter (19). Second, it has to be shown that administration of rhTSH
before radioiodine therapy does not induce a rapid release of 131I-labeled thyroid
hormones and/or thyroglobulin from the thyroid into the circulation, thereby
increasing total body irradiation.
Our observations hold promise for rhTSH as an adjunct to radioiodine treatment
for thyroid volume reduction in patients with nontoxic, nodular goiter, as it may
allow treatment with lower doses of 131I. Furthermore, the administration of rhTSH
may alter the distribution of radioiodine within the thyroid gland, which may be
particularly advantageous if it enhances the uptake of radioiodide in cold areas.
Our study was performed in an area with borderline sufficient iodine intake. The
effect of rhTSH pretreatment on RAIU may be even greater in areas with a higher
iodine intake. However, randomized studies comparing the efficacies of radioio-
dine therapies with and without rhTSH pretreatment need to be performed
before its use can be advised.
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Addendum
In the study reported in chapter 2.1 we found that the interval between the
administration of rhTSH and radioiodine was an important factor for increas-
ing radioactive iodine uptake (RAIU): a 24-h interval between rhTSH adminis-
tration and radioiodine administration was significantly more effective than a
2-h interval. Iodine uptake across the basolateral membrane of thyroid follicu-
lar cells is catalyzed by the Na+/I- symporter (NIS). Stimulation of NIS mRNA
levels (and stimulation of NIS protein levels and translocation of the NIS pro-
tein to the basolateral membrane) by rhTSH may take some time, which might
explain our observation. The figure shows results of a pilot experiment we per-
formed in mice. RhTSH administration increased NIS mRNA levels 5-fold with
peak levels reached after 9 hours. This observation in mice is in line with our
hypothesis. 
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Figure.  Effect of rhTSH administration on NIS mRNA expression in mice. Twenty-one mice received 3 µg rhTSH iv and
after 0, 3, 6, 9, 12, 48, or 72 hours they were killed (3 mice per time point), their thyroids removed and frozen at -80 ºC.
The thyroids were homogenized to measure mouse (m)NIS mRNA levels (courtesy to Dr. J.W. Smit, Leiden University
Medical Center, Leiden, The Netherlands).
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3 .1
Pretreatment with Recombinant Human TSH Changes 
the Regional Distribution of Radioiodine on Thyroid
Scintigrams of Nodular Goiters 
Willy-Anne Nieuwlaat, Ad R. Hermus, 
Ferida Sivro-Prndelj, Frans H. Corstens,
and Dyde A. Huysmans 
Department of Nuclear Medicine (W.-A.N., F.S.-P., D.A.H.), 
Catharina Hospital, Eindhoven; 
Departments of Endocrinology (W.-A.N., A.R.H.) and Nuclear Medicine
(F.H.C.), Radboud University Nijmegen Medical Center, Nijmegen, 
The Netherlands 
The Journal of Clinical Endocrinology & Metabolism 2001; 86(11):5330-5336
Proefschrift WA Nieuwlaat H3  23-03-2005  15:14  Pagina 91
Abstract 
In a recent study, we demonstrated that pretreatment with a single, low dose of
recombinant human TSH (rhTSH) doubles 24-h thyroid radioactive iodine uptake
in patients with nodular goiter. The purpose of the present study was to investi-
gate whether rhTSH pretreatment induces changes in the regional distribution of
radioiodine as visualized on thyroid scintigrams in these patients.
Anterior planar thyroid 123I scintigrams were obtained in 26 patients with a nodu-
lar goiter (23 women and 3 men; age, 62 ± 9 yr, mean ± SD; thyroid weight, 165 ±
72 g) 24 h after administration of a diagnostic dose of radioiodine. All patients
were studied twice: first, without rhTSH pretreatment (baseline study), and sec-
ond, after an im injection of 0.01 mg (n = 10) or 0.03 mg rhTSH (n = 16), given 24 h
before radioiodine administration (rhTSH study). For quantification of regional
differences in radioiodine uptake, a region of interest method was used.
Upon visual inspection, baseline scintigrams showed a heterogeneous uptake of
radioiodine. In general, rhTSH scintigrams also showed heterogeneous radioio-
dine uptake. In some patients, the distribution of radioiodine in the rhTSH scinti-
gram was considerably more homogeneous than in the baseline scintigram. In a
few patients, originally “cold” areas had changed into “hot” ones, whereas origi-
nally hot areas had changed into cold ones. Quantification of regional radioiodine
uptake showed that pretreatment with rhTSH caused a larger increase in radioio-
dine uptake in relatively cold areas and a smaller increase in radioiodine uptake in
relatively hot areas, compared with the increase in radioiodine uptake in the
entire thyroid. In patients with a baseline serum TSH level of 0.5 mU/liter or lower,
the increase in radioiodine uptake in relatively cold areas was significantly larger
than in patients with a baseline serum TSH level higher than 0.5 mU/liter.
In conclusion, a single, low dose of rhTSH not only doubled 24-h radioactive
iodine uptake but also caused a more homogeneous distribution of radioiodine
within the thyroid gland in patients with a nodular goiter by stimulating radioio-
dine uptake in relatively cold areas more than in relatively hot areas. This was
most marked in patients with a low baseline serum TSH level. Our data suggest
that pretreatment with rhTSH may improve the efficacy of radioiodine treatment
for volume reduction of nodular goiters, especially in patients with a low baseline
serum TSH level.
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Introduction
Radioiodine treatment is effective in reducing thyroid volume in most patients
with nontoxic, nodular goiter. In a number of reports in which ultrasonography,
computed tomography, or magnetic resonance imaging for accurate measure-
ments of thyroid volume were used, decreases in goiter size of approximately
40%, on average, after 1 yr, (1, 2, 3, 4, 5, 6) and of 50–60% after 3–5 yr have been
described (2, 7, 8). In most patients, compressive symptoms improved as well (3).
The improvement in compressive symptoms was accompanied by significant tra-
cheal widening, as measured by magnetic resonance imaging (3), and improve-
ment in respiratory function (3, 9).
In the reported studies, a single dose of approximately 100 µCi (3.7 MBq) of 131I per
gram of thyroid tissue corrected for radioactive iodine uptake (RAIU) at 24 h was
given. In patients with nontoxic, nodular goiter, RAIU is usually rather low. As a
result, high doses of 131I are often needed, causing a relatively high radiation bur-
den to extrathyroidal tissues (10). One of the causes of a low RAIU in these
patients is a low-normal or below normal serum level of TSH.
In the last few years, recombinant human TSH (rhTSH) has become available for
diagnostic use in patients with differentiated thyroid cancer (11, 12, 13). In these
patients, rhTSH stimulates RAIU in thyroid remnants or thyroid cancer tissue.
Recently, we reported that the administration of a single, low dose of rhTSH also
considerably increases RAIU in patients with nodular goiter. A dose of 0.01 mg
rhTSH given 24 h before 131I administration increased 24-h RAIU from 29 to 51%,
on average, and 0.03 mg rhTSH given 24 h before 131I administration increased 24-
h RAIU from 33 to 63%, on average (14). These observations suggest that adminis-
tration of rhTSH before 131I therapy for nodular goiter might allow treatment with
lower doses of 131I without diminishing the radiation-absorbed dose in the thyroid.
Nodular goiters are characterized not only by a relatively low uptake of radioiodine
but also by an irregular distribution of radioiodine on thyroid scintigrams. The
regional distribution of radioiodine in nodular goiters is likely to be dependent on
the level of TSH stimulation, with some parts of the goiter needing higher circulat-
ing TSH levels to reach sufficient radioiodine uptake than other parts. It is
unknown whether giving rhTSH before radioiodine administration preferentially
stimulates radioiodine uptake in areas with a relatively high baseline uptake (hot
areas) or in those with a relatively low baseline uptake (cold areas) or that radioio-
dine uptake in hot and cold areas is equally stimulated. If radioiodine uptake in at
least some of the cold areas of the goiter would be increased by pretreatment with
rhTSH, thyroid volume reduction of nodular goiters by radioiodine therapy might
be improved by pretreatment with rhTSH. Therefore, the purpose of this study was
to investigate whether pretreatment with rhTSH causes changes in the regional
distribution of radioiodine on thyroid scintigrams in patients with nodular goiter.
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Patients and Methods 
Patients
Twenty-six patients with nodular goiter (23 females and 3 males; age, 62 ± 9 yr,
mean ± SD; range, 45–74 yr), who were referred for radioiodine therapy to reduce
thyroid volume, participated in the study. All patients had a negative test result (<1
IU/liter) for serum levels of TSH receptor binding antibodies (DYNOtestTRAK
human, Brahms Diagnostica GmbH, Hennigsdorf, Germany). The mean thyroid
weight, as estimated from planar thyroid scintigraphy (15), was 165 ± 72 g (mean ±
SD; range, 60–300 g). All patients had normal serum levels of free T4 (FT4; chemi-
luminescent immunoassay; ACS:180 FrT4, Chiron Corp., Fernwald, Germany) and
total T3 (chemiluminescent immunoassay; ACS T3, Ciba Diagnostics Corp.,
Medfield MA), whereas the serum TSH level (two-site chemiluminometric
immunoassay; ACS TSH-3, Ciba Diagnostics Corp.; normal range, 0.2–5.5 mU/liter)
was either normal (22 patients) or below normal (4 patients). Based on the results
of careful palpation of the thyroid, followed by fine needle aspiration biopsy of
dominant nodules and of those that had a different consistency from other nod-
ules within the gland, there was no suspicion of thyroid malignancy in any of the
patients. None of the patients had a history of significant cardiopulmonary dis-
ease or a recent history of taking any medication known to affect thyroid function
or RAIU. Patients had not received iodine-containing agents in the last 6 months.
An electrocardiogram, complete blood count, liver enzyme determinations, plas-
ma creatinine and glucose measurements, and screening urinalysis did not show
abnormalities in any of the patients. The study was approved by the institutional
human research committee, and written informed consent was obtained from all
patients.
Baseline planar thyroid scintigraphy and RAIU measurements
For thyroid scintigraphy, all 26 patients received a dose of 1 mCi (40 MBq) sodium
(123I) iodide as an oral solution. In 17 patients, administration of 123I was combined
with administration of 20 µCi (0.8 MBq) sodium (131I) iodide for measurements of
RAIU and effective half-time of radioiodine in the thyroid (results of effective half-
time measurements not included in the present report). In the remaining nine
patients, RAIU measurements were performed with 123I, and the effective half-
time of radioiodine in the thyroid was not measured.
Twenty-four hours after radioiodine administration, the thyroid region was
imaged in the anterior plane for a preset time of 10 min with a single-headed gam-
macamera (Philips Medical Systems, Eindhoven, The Netherlands), using a low-
energy general purpose collimator. A 20% energy window around the 159 keV
photon peak of 123I and a 256 x 256 matrix were used.
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In the patients who had received both 123I and 131I, RAIU was measured as percent-
age of the administered dose of 131I, corrected for physical decay, at 3, 6, 24, 48, 72,
and 168 h, using a 3-inch x 3-inch NaI(Tl) detector. Deadtime corrections were
made using standard software. It was checked that the use of the net area under
the 364 keV peak of 131I prohibited any interference of the low-energy photons of
123I with RAIU measurements. In the patients who had received 123I only, RAIU was
measured as percentage of the administered dose of 123I, corrected for physical
decay, at 3, 6, 24, and 48 h using the same 3-inch x 3-inch NaI(Tl) detector. The net
area under the 159 keV peak of 123I was used.
Thyroid planar scintigraphy and RAIU measurements after administration
of rhTSH
At least 2 wk after the baseline investigation, a second thyroid scintigraphy and
RAIU measurement were performed as described before, but this time after pre-
treatment with rhTSH. Twenty-four hours before radioiodine administration,
rhTSH was injected in the quadriceps muscle in a dose of either 0.01 mg (n = 10)
or 0.03 mg (n = 16). Before injection, freeze-dried rhTSH (ampoules containing 0.9
mg rhTSH; Thyrogen, Genzyme Transgenics Corp., Cambridge, MA) was reconsti-
tuted with 1.2 ml sterile water. Then, part of the obtained solution was diluted with
saline to a final concentration of 0.05 mg/ml.
The 17 patients who had received the combination of 131I and 123I in the baseline
investigation received again both 131I (20–40 µCi; 0.8–1.6 MBq) and 123I (1 mCi; 40
MBq). Ten of these patients were pretreated with 0.01 mg rhTSH, and 7 with 0.03
mg rhTSH. The nine patients who had received only 123I in the baseline investiga-
tion received again only 123I (1 mCi; 40 MBq) and were pretreated with 0.03 mg
rhTSH.
Comparison of baseline planar thyroid scintigraphy and planar thyroid
scintigraphy after administration of rhTSH
To compare the thyroid scintigram after rhTSH administration (rhTSH scintigram)
of each patient with the baseline scintigram, all scintigrams were corrected for
background activity using a region immediately below the thyroid as background.
Then, rhTSH scintigrams were moved into exactly the same position in the field of
view as the baseline scintigrams, using standard software.
In the baseline scintigrams, regions of interest (ROIs) of 1 cm2 were placed in the
region corresponding with the highest number of counts per square centimeter
(ROImax). Then, a ROI corresponding with 90% of counts of ROImax was sought,
thereafter a ROI corresponding with 80% of counts of ROImax, etc., until ROImin,
the region with the lowest number of counts per square centimeter, was reached.
The number of counts in each ROI was recorded. The ROIs were saved and then
placed in exactly the same position in the rhTSH scintigrams. Again, the numbers
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of counts in the ROIs were recorded. For each ROI, the ratio between the number
of counts in the rhTSH scintigram and that in the baseline scintigram was calcu-
lated. This ratio was corrected for the difference in the total number of counts in
the entire thyroid in the rhTSH scintigram and that in the baseline scintigram,
resulting in a normalized count ratio in each ROI, according to the following for-
mula:
Normalized count ratio in each ROI
[counts ROI (rhTSH study) / counts ROI (baseline study)]
[counts entire thyroid (rhTSH) / counts entire thyroid (baseline)]
To compare the uniformity of uptake of radioiodine throughout the whole thyroid
gland, for each individual patient the mean and SD of the numbers of counts per
pixel in the thyroid scintigram were calculated in the baseline study as well as in
the rhTSH study. Thereafter, the coecient of variation [CV = (SD/mean) x 100%]
was calculated for each thyroid scintigram.
Statistical analyses
The mean values ± SD are given. Statistical analyses were done using the Mann-
Whitney U test for unpaired observations (P values denoted as P) and the
Wilcoxon sign-rank test for paired observations (P values denoted as P*). The level
of significance was 0.05.
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Results 
On visual inspection, baseline planar thyroid scintigrams showed the typical
scintigraphic appearance of a nodular goiter, i.e. heterogeneous uptake of radioio-
dine with areas of increased and decreased radioiodine uptake, in all patients. In
general, the rhTSH scintigrams also showed heterogeneous uptake of radioiodine.
In some patients (e.g. no. 15 and 20; Fig. 1), the distribution of radioiodine in the
rhTSH scintigram was considerably more homogeneous than in the baseline
scintigram. Interestingly, in a few patients (e.g. no. 11 and 15; Fig. 1) originally cold
areas had changed into hot ones, whereas originally hot areas had changed into
cold ones.
Figure 2 shows the normalized count ratios in the ROIs of all 26 patients. A nor-
malized count ratio of more than 1.00 in a ROI indicates an increase of radioiodine
uptake in this ROI relative to the uptake in the entire thyroid gland, and a normal-
ized count ratio of less than 1.00 indicates a decrease of radioiodine uptake in the
ROI relative to the uptake in the entire thyroid gland. In most patients, pretreat-
ment with rhTSH caused a relatively larger increase in radioiodine uptake in cold
areas, compared with the increase in radioiodine uptake in the entire thyroid.
Furthermore, in most patients rhTSH pretreatment led to a relatively smaller
increase in radioiodine uptake in hot areas, compared with the increase in radioio-
dine uptake in the entire thyroid.
Table 1 shows that the ratio between 24-h RAIU after rhTSH administration and
the baseline 24-h RAIU (RAIU ratio) was 2.12 ± 0.53 (range, 1.23–3.11). Table 1 also
shows that the normalized count ratio in the ROI with the lowest number of
counts in the baseline study (normalized count ratio ROImin) was 1.30 ± 0.29
(range, 0.93–2.04), which is significantly different from 1.00 (P* < 0.0001). The nor-
malized count ratio in the ROI with the highest number of counts in the baseline
study (normalized count ratio ROImax) was 0.87 ± 0.16 (range, 0.50–1.11), which is
also significantly different from 1.00 (P* < 0.0005). The normalized count ratio in
ROImin was more than 1.00 in 81%, more than 1.10 in 69%, and more than 1.20 in
58% of the 26 patients, respectively. The normalized count ratio in ROImax was
lower than 1.00 in 77%, lower than 0.90 in 54%, and lower than 0.80 in 27% of the
26 patients, respectively. The combination of a normalized count ratio in ROImin of
more than 1.00 and a normalized count ratio in ROImax of less than 1.00 was found
in 73% of patients. Using cut-off levels of 1.10/0.90 and 1.20/0.80, respectively, this
percentage was 50 and 23%. There were no significant differences in normalized
count ratios in ROImin or ROImax among the patients who had received 0.01 mg
rhTSH and the combination of 123I and 131I, those who had received 0.03 mg rhTSH
and the combination of 123I and 131I, and those who had received 0.03 mg rhTSH
and only 123I (P > 0.1 for all comparisons).
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Patients with a serum TSH level of 0.5 mU/liter or lower in the baseline study had
a significantly higher normalized count ratio in ROImin than patients with a serum
TSH level higher than 0.5 mU/liter [1.40 ± 0.31 (n = 16) vs. 1.14 ± 0.16 (n = 10); P <
0.02]. All five patients with a normalized count ratio in ROImin of 1.5 or more had
a baseline serum TSH level of 0.5 mU/liter or less. The normalized count ratio in
ROImax did not differ significantly between patients with a baseline serum TSH
level of 0.5 mU/liter or lower (0.85 ± 0.19) and those with a baseline serum TSH
level higher than 0.5 mU/liter (0.91 ± 0.09).
The coefficient of variation of the numbers of counts per pixel in the thyroid
scintigram was 60 ± 11% in the baseline study and 55 ± 11% in the rhTSH study (P
< 0.001), indicating a significantly more homogeneous uptake of radioiodine
throughout the thyroid gland after rhTSH administration.
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Figure 1. Examples of planar anterior scintigrams of the thyroid in the baseline study (left pan-
els) and in the rhTSH study (right panels). In patients 15 (upper panels) and 20 (middle panels), the
distribution of radioiodine in the rhTSH scintigram is much more homogeneous than in the base-
line scintigram. In patient 15, the rhTSH study shows, in comparison with the baseline study, not
only an increased uptake in relatively cold areas but also a decreased uptake in the hot area in the
left lobe. In patient 11 (lower panels), the rhTSH study shows, in comparison with the baseline
study, an increased uptake in both upper poles, whereas the left lower pole shows a decreased
uptake.
BASELINE STUDY rhTSH STUDY
pat. 15
pat. 20
pat. 11
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Discussion 
The present study demonstrates that administration of a single, low dose of
rhTSH before a diagnostic dose of radioiodine not only doubles 24-h thyroid RAIU
but also induces significant changes in the regional distribution of radioiodine on
thyroid scintigrams in patients with nodular goiter. In most patients, pretreat-
ment with rhTSH caused a larger increase in radioiodine uptake in relatively cold
areas and a smaller increase in radioiodine uptake in relatively hot areas, com-
pared with the increase in radioiodine uptake in the entire thyroid. As a result, the
distribution of radioiodine on the rhTSH scintigram was significantly more homo-
geneous than that on the baseline scintigram, as demonstrated by a significantly
lower mean coefficient of variation of the numbers of counts per pixel in the thy-
roid scintigram after rhTSH administration. In patients with a baseline serum TSH
level of 0.5 mU/liter or lower, the increase in radioiodine uptake in relatively cold
areas was significantly larger than in patients with a baseline serum TSH level
higher than 0.5 mU/liter. This suggests that especially in patients with a low base-
line serum TSH level, a more homogeneous distribution of radioiodine on the thy-
roid scintigram can be reached by pretreatment with rhTSH.
Our observations have important consequences when rhTSH pretreatment is con-
sidered as an adjunct to radioiodine therapy for volume reduction of nodular goi-
ters. From our study, one may derive that the effects of rhTSH pretreatment for
this purpose will depend on the decision whether or not the therapeutic dose of
radioiodine is lowered according to the rhTSH-induced increase in 24-h RAIU.
When the therapeutic dose of radioiodine is lowered according to the rhTSH-
induced increase in 24-h RAIU, in a number of areas with relatively low baseline
radioiodine uptake the 24-h retained amount of radioiodine per gram of thyroid
tissue will nevertheless increase, which might improve the efficacy of radioiodine
therapy for volume reduction of the goiter. In contrast, in a number of areas with
relatively high baseline radioiodine uptake, the 24-h retained amount of radioio-
dine per gram of thyroid tissue will decrease. However, it is not likely that this will
negatively influence the efficacy of radioiodine therapy; without rhTSH pretreat-
ment, the 24-h retained amount of radioiodine per gram in these hot areas would
have been considerably higher than the average retained amount per gram in the
entire thyroid, and with rhTSH pretreatment, in most of these areas at least the
average amount of radioiodine per gram in the entire thyroid will be retained at
24 h.
When the therapeutic dose of radioiodine is not lowered according to the rhTSH-
induced increase in 24-h RAIU, but based on the baseline 24-h RAIU, most areas
in the goiter, cold as well as hot ones, will retain a higher amount of radioiodine
per gram of thyroid tissue with pretreatment with rhTSH than without pretreat-
ment with rhTSH. This conclusion can be drawn from multiplying the normalized
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count ratio with the RAIU ratio (see Table 1). This multiplication indicates the dif-
ference in uptake in a ROI between the rhTSH study and the baseline study when
the dose of radioiodine in both studies is the same. From the calculation “normal-
ized count ratio x RAIU ratio” in ROImin and ROImax in the individual patients, one
may derive that 24-h radioiodine uptake in the area with the lowest baseline
radioiodine uptake (ROImin) will increase by a factor of three (normalized count
ratio ROImin x RAIU ratio, 2.81 ± 1.08, mean ± SD; range, 1.21–5.23) and that 24-h
radioiodine uptake in the area with the highest baseline radioiodine uptake
(ROImax) will increase 2-fold (normalized count ratio ROImax x RAIU ratio, 1.84 ±
0.55, mean ± SD; range, 1.03–2.96). Not lowering the therapeutic dose of radioio-
dine according to the rhTSH-induced increase in 24-h RAIU may be advantageous
for the efficacy of the therapy. However, this dosage regimen carries a higher risk
of inducing radiation thyroiditis.
It should be noted that in a significant number of patients, rhTSH-induced increas-
es in radioiodine uptake in areas with a relatively low baseline radioiodine uptake
were small or even absent. This is not surprising, because part of these cold areas
represent mainly cystic or fibrotic tissue or thyroid follicular cells that have (par-
tially) lost their ability to express the Na+/I- symporter protein (16, 17). Such parts
of the goiter cannot take up radioiodine, not even after heavy TSH stimulation.
Furthermore, a relative increase in radioiodine uptake in cold areas on a planar
scintigram should be cautiously interpreted because planar scintigraphy is a two-
dimensional method. It cannot be excluded that an increase in radioiodine uptake
in a relatively cold area by pretreatment with rhTSH is caused by an increase in
radioiodine uptake in thyroid tissue lying anteriorly or posteriorly of a cold area
that itself does not increase in uptake. In a small number of the patients described
in the present study, single photon emission computed tomography (SPECT), a
three-dimensional imaging method, was performed (our unpublished observa-
tions). Transaxial SPECT slices showed that in some cold areas rhTSH administra-
tion increased radioiodine uptake only in a rim of thyroid tissue, whereas the cen-
tral part of the area showed no change in uptake. However, in other cold areas,
SPECT images showed an increase in radioiodine uptake in the entire area, from
anterior to posterior.
Seventeen of the 26 patients in our study received the combination of 123I and 131I.
The high energy photons of 131I will have caused some scatter in the 123I thyroid
scintigrams. However, the dose of 131I was only a small fraction of the dose of 123I,
and the regional distribution of 131I within the thyroid is the same as that of 123I.
Therefore, the effect of scatter of 131I on normalized count ratios will have been
negligible. This was confirmed by the results in the patients who received only 123I,
which were not different from those in the patients who received both 123I and 131I.
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Our results do not allow the conclusion that 0.01 mg is the minimally effective
dose of rhTSH in stimulating 24-h RAIU. However, the peak serum TSH level
reached after administration of 0.01 mg rhTSH was only 4.64 mU/liter, on average.
It is not likely that administration of a lower dose of rhTSH, resulting in peak
serum TSH levels significantly lower than 4 mU/liter, will effectively elevate 24-h
RAIU in these patients. Our data also do not demonstrate that the 0.03 mg dose
is the maximally effective dose of rhTSH in stimulating 24-h RAIU. In fact, it is like-
ly that a higher dose will increase 24-h RAIU even more. However, even when a
higher dose of rhTSH is more effective in stimulating 24-h RAIU, it is doubtful
whether this is clinically relevant, because with the 0.01 and 0.03 mg doses
already a doubling of 24-h RAIU can be reached. Furthermore, larger amounts of
thyroid hormones may be released after administration of higher doses of rhTSH.
In conclusion, a single, low dose of rhTSH not only doubled 24-h RAIU in patients
with nodular goiter but also caused a more homogeneous distribution of radioio-
dine within the thyroid gland in the majority of these patients by stimulating
radioiodine uptake in relatively cold areas more than in relatively hot areas. This
was most marked in patients with a low baseline serum TSH level. Our data sug-
gest that pretreatment with rhTSH might allow treatment with lower doses of 131I.
Furthermore, they suggest that despite lowering of the dose of 131I, pretreatment
with rhTSH might improve the efficacy of radioiodine treatment for volume
reduction of nodular goiters, especially in patients with a low baseline serum TSH
level. However, randomized studies comparing the efficacy of radioiodine thera-
py with and without rhTSH pretreatment have to be awaited before its use can be
advised.
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Abstract
In patients with nodular goiter, radioiodine (131I) therapy results in a mean
reduction in thyroid volume (TV) of approximately 40% after 1 yr. We have
demonstrated that pretreatment with a single, low dose of recombinant
human TSH (rhTSH) doubles 24-h radioactive iodine uptake (RAIU) in these
patients. We have now studied the safety and efficacy of therapy with a
reduced dose of 131I after pretreatment with rhTSH.
Twenty-two patients with nodular goiter received 131I therapy, 24 h after im
administration of 0.01 (n = 12) or 0.03 (n = 10) mg rhTSH. In preceding diagnos-
tic studies using tracer doses of 131I, 24-h RAIU without and with rhTSH pre-
treatment (either 0.01 or 0.03 mg) were compared. Therapeutic doses of 131I
were adjusted to the rhTSH-induced increases in 24-h RAIU and were aimed at
100 µCi/g thyroid tissue retained at 24 h. Pretreatment with rhTSH allowed
dose reduction of 131I therapy by a factor of 1.9 ± 0.5 in the 0.01-mg and by a
factor of 2.4 ± 0.4 in the 0.03-mg rhTSH group (P < 0.05, 0.01 vs. 0.03 mg
rhTSH). Before and 1 yr after therapy, TV and the smallest cross-sectional area
of the tracheal lumen were measured with magnetic resonance imaging.
During the year of follow-up, serum TSH, free T4 (FT4), T3, and TSH receptor
antibodies were measured at regular intervals.
TV before therapy was 143 ± 54 ml in the 0.01-mg group and 103 ± 44 ml in the
0.03-mg rhTSH group. One year after treatment, TV reduction was 35 ± 14%
(0.01 mg rhTSH) and 41 ± 12% (0.03 mg rhTSH). In both groups, smallest cross-
sectional area of the tracheal lumen increased significantly. In the 0.01-mg
rhTSH group, serum FT4 rose, after 131I treatment, from 15.8 ± 2.8 to 23.2 ± 4.4
pM. In the 0.03-mg rhTSH group, serum FT4 rose from 15.5 ± 2.5 to 23.5 ± 5.1 pM.
Individual peak FT4 levels, reached between 1 and 28 d after 131I treatment,
were above the normal range in 12 patients. TSH receptor antibodies were neg-
ative in all patients before therapy and became positive in 4 patients.
Hyperthyroidism developed in 3 of these 4 patients between 23 and 25 wk after
therapy.
In conclusion, in patients with nodular goiter pretreatment with a single, low
dose of rhTSH allowed approximately 50–60% reduction of the therapeutic
dose of radioiodine without compromising the efficacy of TV reduction.
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Introduction
Radioiodine (131I) is an effective therapy for thyroid volume (TV) reduction in
patients with nontoxic, nodular goiter. In a number of studies, it has been
reported that 131I treatment leads to a decrease in goiter size of approximately
40% after 1 yr (1, 2, 3, 4, 5, 6, 7) and of 50–60% after 3–5 yr (2, 8, 9). In most
patients, compressive symptoms improved as well (3). The reduction of com-
pressive symptoms was accompanied by significant tracheal widening and
improvement in respiratory function (3, 10).
In the reported studies, a single dose of approximately 100 µCi (3.7 MBq) of 131I
per gram of thyroid tissue, corrected for radioactive iodine uptake (RAIU) at 24
h, was given. In patients with nontoxic, nodular goiter, RAIU is usually rather
low. As a result, high doses of 131I are often needed, causing a relatively high
radiation burden to extrathyroidal tissues (11). One of the causes of a low RAIU
in these patients is a low-normal or below-normal serum level of TSH.
Recently, we reported that, in patients with nodular goiter, administration of a
single, low dose of 0.01 or 0.03 mg recombinant human TSH (rhTSH) doubled
24-h RAIU (12). We also described that pretreatment with rhTSH caused a more
homogeneous distribution of radioiodine on the thyroid scintigrams of nodu-
lar goiters (13). These observations suggest that administration of rhTSH
before 131I therapy for volume reduction of nontoxic, nodular goiter may allow
treatment with lower doses of 131I in these patients without diminishing the
radiation-absorbed dose in the thyroid.
Before rhTSH can be advised as an adjunct to 131I therapy in patients with non-
toxic, nodular goiter, the safety of the administration of a therapeutic dose of
131I after pretreatment with rhTSH has to be investigated. First, it has to be
ascertained that pretreatment with rhTSH does not exacerbate the increases
in serum thyroid hormone levels commonly seen in the first weeks after 131I
treatment of nontoxic, nodular goiter. Second, it has to be determined that this
therapy does not cause acute enlargement of the goiter, compressing the tra-
chea further (14). Therefore, the first aim of this study was to determine the
short-term safety of the administration of a therapeutic dose of 131I after pre-
treatment with a single, low dose (0.01 or 0.03 mg) of rhTSH. In this study, the
therapeutic dose of 131I was adjusted to the rhTSH-induced increase in 24-h
RAIU, as determined in a diagnostic study using a tracer dose of 131I. The sec-
ond aim was to determine the efficacy of this therapy in terms of TV reduction
and increase of the smallest cross-sectional area of the tracheal lumen (SCAT)
after 1 yr.
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Patients and Methods
Patients
Twenty-two patients with nodular goiter (18 females and 4 males; 60 ± 9 yr old;
mean ± SD; range, 45–73 yr), who were referred for 131I therapy to reduce TV,
participated in this study. All patients had a negative test result (<1 IU/liter) for
serum levels of TSH receptor antibodies (TRAbs) (DYNOtest TRAK human;
Brahms Diagnostica GmbH, Hennigsdorf, Germany). All patients had normal
serum levels of free T4 (FT4) (chemiluminescent immunoassay, ACS:180 FrT4;
Chiron Corp., Fernwald, Germany; normal values, 9.0–22.3 pM) and total T3
(chemiluminescent immunoassay, ACS T3; Ciba Diagnostics Corp., Medfield,
MA; normal values, 1.0–3.0 nM), whereas the serum TSH level (2-site chemilu-
minometric immunoassay, ACS TSH-3; Ciba Diagnostics Corp.; normal values,
0.2–5.5 mU/liter) was normal (19 patients) or below normal (3 patients). Based
on the results of careful palpation of the thyroid, followed by fine-needle aspi-
ration biopsy of dominant nodules and of those that had a different consisten-
cy from other nodules within the gland, there was no suspicion of thyroid
malignancy in any of the patients. None of the patients had a recent history of
taking any medication known to affect thyroid function or RAIU. Patients had
not received iodine-containing agents in the last 6 months. Twenty-four-hour
iodide excretion was 169 ± 71 µg (range, 80–330 µg). An electrocardiogram,
complete blood count, liver enzyme determinations, plasma creatinine and
glucose measurements, and screening urinalysis did not show abnormalities in
any of the patients. The institutional human research committee approved the
study, and written informed consent was obtained from all patients.
Diagnostic investigations 
A diagnostic dose of 20 µCi (0.8 MBq) sodium (131I) iodide was administered as
an oral solution, together with 1 mCi (40 MBq) sodium (123I) iodide for thyroid
scintigraphy. RAIU as a percentage of the administered dose of 131I, corrected
for physical decay, was measured at 24 h using a 3 x 3-in. NaI(Tl) detector.
Deadtime corrections were made using standard software. The use of the net
area under the 364-kiloelectron volts peak of 131I was checked to prohibit any
interference of the low-energy photons of 123I with RAIU measurements.
Thyroid scintigraphy in the 159-kiloelectron volts window of 123I was performed
24 h after radioiodide administration. All thyroid scintigrams showed a hetero-
geneous uptake.
The influence of rhTSH on RAIU was investigated in each patient at least 2 wk
after radioiodine administration for the baseline RAIU. After reconstitution of
freeze-dried rhTSH (ampoules containing 0.9 mg rhTSH, Thyrogen; Genzyme
Transgenics Corp., Cambridge, MA) with 1.2 ml sterile water, part of the
obtained solution was diluted with saline to a final concentration of 0.05
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mg/ml. Immediately after dilution, 0.01 mg (0.2 ml; n = 12) or 0.03 mg (0.6 ml;
n = 10) rhTSH was injected in the quadriceps muscle. A diagnostic dose of
20–40 µCi (0.8–1.6 MBq) sodium 131I was administered as an oral solution
[together with 1 mCi (40 MBq) sodium 123I for thyroid scintigraphy] 24 h after
the administration of rhTSH. RAIU as a percentage of the administered dose of
131I, corrected for background activity from the radioiodine from the baseline
investigation and for physical decay, was measured at 24 h. Thyroid scintigra-
phy was performed 24 h after radioiodine administration (results not included
in the present report).
Radioiodine therapy 
Thirty-five ± 21 d (range, 13–84 d) after the diagnostic rhTSH study, patients
received a second injection of rhTSH in the quadriceps muscle, using the same
rhTSH dose as was given for the diagnostic study. Twenty-four hours later,
radioiodine was given as a single oral dose on an inpatient basis. The therapeu-
tic dose of 131I was adjusted to the rhTSH-induced increase in 24-h RAIU, as
determined for each individual patient in the preceding diagnostic study, and
was aimed at delivering 100 µCi (3.7 MBq) 131I/g of thyroid tissue retained at 24
h, according to the following formula: administered activity (GBq) = [thyroid
weight (g) x 0.37]/24-h thyroid RAIU (%) (15). For calculation of the therapeutic
dose of radioiodine, we estimated thyroid weight from the planimetric surface
on the baseline scintigram, using the formula of Doering and Kramer (16): thy-
roid weight (g) = 0.326 x (surface in cm2)3/2. Mean thyroid weight, as estimated
from the planar thyroid scintigraphies, was 148 ± 62 g (range, 70–265 g).
Follow-up investigations 
Symptoms and signs of thyrotoxicosis, thyroiditis, or tracheal compression and
vital signs (blood pressure, pulse rate, and body temperature) were recorded
immediately before and 2, 5, and 8 h after rhTSH pretreatment, as well as
immediately before and 1, 2, 3, 7, 10, 14, 21, 28, 56, and 84 d after 131I therapy.
Before and 1 wk and 1 yr after radioiodine treatment, TV and the SCAT were
measured. TV was measured by magnetic resonance imaging (MRI) (MRI Intera
software release 8.1.3; Philips Medical Systems, Best, The Netherlands) operat-
ing at a field strength of 1.5 tesla. Transversal, sagittal, and coronal T1-weight-
ed images [TR (repetition time) = 600 ms; echo time = 14 ms] were obtained by
using a standard quadrature neck coil. The slices had a thickness of 4 mm (with
an interslice gap of 0.4 mm) in the transversal plane and 3 mm (with an inter-
slice gap of 0.3 mm) in the coronal and sagittal planes and covered the entire
thyroid gland. The thyroid outline was drawn manually on each slice, and the
surface of the traced areas was calculated (Easy Vision software; Philips
Medical Systems). To calculate the TV, we multiplied the sum of the traced sur-
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faces in each plane by the sum of the slice thickness and interslice gap. TV, as
used hereafter, is the mean of the measurements in the three imaging planes.
The precision of TV measurement by MRI is high. The intraobserver coefficient
of variation is 2.2% ± 2.0%, and the interobserver coefficient of variation is
4.1% ± 2.2% (17). SCAT, a measure of tracheal compression (18), was determined
by manually drawing a line along the outer contour of the trachea in the trans-
versal T1-weighted images. All measurements were done blinded.
Serum TSH, FT4, and T3 levels were measured immediately before rhTSH pre-
treatment and 2, 5, and 8 h after rhTSH administration, as well as immediately
before and 1, 2, 3, 7, 10, 14, 21, 28, and 56 d and 3, 6, 9, and 12 months after 131I
treatment. Serum levels of C-reactive protein (CRP) (BNII hs-CRP; Dade
Behring, Deerfield, IL; normal value < 12.5 mg/liter) was measured immediately
before and 7, 10, 14, 21, 28, 42, and 56 d and 3 months after 131I treatment. Serum
levels of TRAbs (DYNOtest TRAK human; Brahms Diagnostica GmbH; negative
value < 1 IU/liter and positive value > 1.5 IU/liter) and of anti-TPO antibodies
(DYNOtest anti-TPOn; Brahms Diagnostica GmbH; negative value < 60 U/ml)
were measured before and 3, 6, 9, and 12 months after 131I therapy.
Statistical analyses 
The mean ± SD values are given. Statistical analyses were done using the
Mann-Whitney U test for unpaired observations (P values denoted as P), the
Wilcoxon sign-rank test for paired observations (P values denoted as P*), and
Spearman’s test for nonparametric correlations (P values denoted as P**). The
level of significance was 0.05.
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Results 
Diagnostic investigations 
Effect of rhTSH administration on RAIU (Table 1). In the diagnostic studies, using
a tracer dose of 131I, administration of 0.01 mg rhTSH, 24 h before 131I, increased
24-h RAIU from 27 ± 8% to 50 ± 11% (P* < 0.005). Administration of 0.03 mg
rhTSH, 24 h before 131I, increased 24-h RAIU from 22 ± 4% to 54 ± 9% (P* <
0.01). The ratio between 24-h RAIU after rhTSH and baseline 24-h RAIU (RAIU
ratio) was significantly higher (P < 0.05) in patients who received 0.03 mg
rhTSH (2.4 ± 0.4) than in those who received 0.01 mg rhTSH (1.9 ± 0.5).
Calculation of dose reduction of radioiodine therapy (Table 1, Fig. 1). In each
patient, the therapeutic dose of 131I was reduced according to the calculated
RAIU ratio in that patient. This resulted in a dose reduction with a factor of 1.9
± 0.5 (range, 1.2–2.6) in the 0.01-mg rhTSH group and of 2.4 ± 0.4 (range,
2.0–3.1) in the 0.03-mg rhTSH group (P < 0.05). 131I doses were reduced from
68.9 ± 28.1 mCi (2550 ± 1041 MBq) to 39.4 ± 16.8 mCi (1457 ± 621 MBq) in the
0.01-mg rhTSH group and from 52.1 ± 33.3 mCi (1927 ± 1233 MBq) to 22.8 ± 5.7
mCi (843 ± 210 MBq) in the 0.03-mg rhTSH group.
Follow-up investigations 
Effect of rhTSH administration on serum TSH levels (Fig. 2). After administration
of 0.01 mg rhTSH, serum TSH rose from 0.68 ± 0.50 mU/liter (range, <0.03–1.70
mU/liter) to a peak of 4.49 ± 2.03 mU/liter (range, 2.20–9.80 mU/liter; P* <
0.005). After administration of 0.03 mg rhTSH, serum TSH rose from 0.53 ±
0.54 mU/liter (range, <0.03–1.80 mU/liter) to a peak of 11.10 ± 2.59 mU/liter
(range, 7.00–15.10 mU/liter; P* < 0.01). Peak levels of serum TSH were signifi-
cantly higher (P < 0.0001) after administration of 0.03 mg rhTSH than after
administration of 0.01 mg rhTSH. In both groups, peak levels of serum TSH
were reached at 5–8 h after administration of rhTSH. Thereafter, serum TSH
declined rapidly; and, in all patients, a decrease in serum TSH below the base-
line level was observed.
Short-term safety of rhTSH administration followed by 131I therapy. Blood pres-
sure, pulse rate, and body temperature were not significantly different at any
time point until 84 d after 131I treatment, compared with values immediately
before rhTSH administration. No symptoms and signs of thyrotoxicosis, thy-
roiditis, (worsening of) tracheal compression, or other adverse effects were
observed, either in the first 24 h after rhTSH administration or in the first 3
months after 131I therapy.
Serum FT4 and T3 levels after rhTSH administration followed by 131I therapy (Table 2).
In the 0.01-mg rhTSH group, serum FT4 rose from 15.8 ± 2.8 pM (range,
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11.4–20.7 pM) before rhTSH administration, to 17.7 ± 3.1 pM (range, 13.2-22.9
pM) immediately before 131I therapy, i.e. 24 h after rhTSH administration (P* <
0.005). Serum FT4 levels at 2, 5, and 8 h after rhTSH administration were 15.8 ±
3.2 pM, 16.3 ± 3.1 pM, and 17.5 ± 2.9 pM, respectively. After 131I administration,
serum FT4 levels increased further, to a peak level of 23.2 ± 4.4 pM (range,
16.2–32.4 pM; P* < 0.005 vs. FT4 levels immediately before 131I administration;
Fig. 2). Serum T3 rose from 2.22 ± 0.38 nM (range, 1.80–2.90 nM) before rhTSH
administration to 2.63 ± 0.42 nM (range, 1.90-3.40 nM) immediately before 131I
therapy (P* < 0.005). Serum T3 levels at 2, 5, and 8 h after rhTSH administration
were 2.33 ± 0.49, 2.59 ± 0.45, and 2.73 ± 0.43 nM, respectively. After 131I admin-
istration, serum T3 increased further, to a peak level of 3.12 ± 0.58 nM (range,
2.60–4.60 nM; P* < 0.005 vs. T3 levels immediately before 131I administration).
In the 0.03-mg rhTSH group, serum FT4 rose from 15.5 ± 2.5 pM (range,
12.6–20.7 pM) before rhTSH administration to 20.4 ± 4.6 pM (range, 15.6-28.5
pM) immediately before 131I therapy (P* < 0.005). Serum FT4 levels at 2, 5, and 8
h after rhTSH administration were 15.6 ± 2.2, 17.1 ± 2.7, and 18.3 ± 3.1 pM, respec-
tively. After 131I administration, serum FT4 levels increased further, to a peak
level of 23.5 ± 5.1 pM (range, 17.4-32.4 pM; P* < 0.005 vs. FT4 levels immediate-
ly before 131I administration). Serum T3 rose from 2.05 ± 0.36 nM (range,
1.60–2.80 nM) before rhTSH administration to 2.82 ± 0.72 nM (range, 1.90–4.50
nM) immediately before 131I therapy (P* < 0.005). Serum T3 levels at 2, 5, and 8
h after rhTSH administration were 2.16 ± 0.42, 2.33 ± 0.57, and 2.73 ± 0.64 nM,
respectively. After 131I administration, serum T3 increased further, to a peak
level of 3.26 ± 0.82 nM (range, 2.20–4.70 nM; P* < 0.005 vs. T3 levels immedi-
ately before 131I administration).
Individual peak FT4 and T3 levels were reached between 1 and 28 d after 131I
administration and were above the normal range in 12 (0.01-mg rhTSH group, n
= 7; and 0.03-mg rhTSH group, n = 5) and 11 (0.01-mg rh TSH group, n = 5; and
0.03-mg rhTSH group, n = 6) patients, respectively.
TV and SCAT, 1 wk after 131I therapy (Table 2). Before 131I therapy, TV (as measured
with MRI) was 143 ± 54 ml (range, 70–209 ml) in the 0.01-mg rhTSH group and
103 ± 44 ml (range, 44–172 ml) in the 0.03-mg rhTSH group [P = NS (not signif-
icant), 0.01 mg rhTSH vs. 0.03 mg rhTSH]. SCAT was 1.18 ± 0.42 cm2 (range,
0.55–2.12 cm2) in the 0.01-mg rhTSH group and 1.07 ± 0.52 cm2 (range, 0.16–1.91
cm2) in the 0.03-mg rhTSH group (P = NS, 0.01 mg rhTSH vs. 0.03 mg rhTSH).
One week after 131I therapy, TV was 151 ± 61 ml (range, 74–240 ml) in the 0.01-
mg rhTSH group and 114 ± 44 ml (range, 47–179 ml) in the 0.03-mg rhTSH
group. Compared with the pretreatment TV, the increase of TV was 5% ± 8%
(range, -6%–15%) in the 0.01-mg rhTSH group (P* = NS) and 5% ± 6% (range, 
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Figure 1. Reduction of the therapeutic 131I dose in the individual patients by pretreatment with
0.01 mg rhTSH (patients 1–12, ) or 0.03 mg rhTSH (patients 13–22, ). In each patient, the ther-
apeutic dose of 131I was reduced according to the calculated RAIU ratio in that patient (RAIU ratio
= ratio between 24-h RAIU after rhTSH and baseline 24-h RAIU, as determined before in diagnos-
tic studies using tracer doses of 131I).
-4%–17%) in the 0.03-mg rhTSH group (P* < 0.05). SCAT was 1.23 ± 0.50 cm2
(range, 0.61–2.53 cm2) in the 0.01-mg rhTSH group and 1.07 ± 0.58 cm2 (range,
0.14–1.88 cm2) in the 0.03-mg rhTSH group. In both groups, SCAT did not
change significantly after 1 wk. Compared with the pretreatment SCAT, change
of SCAT was 3% ± 8% (range, -13%–19%) in the 0.01-mg rhTSH group (P* = NS)
and 0% ± 9% (range, -11%–19%) in the 0.03-mg rhTSH group (P* = NS).
Serum hs-CRP levels after rhTSH administration followed by 131I therapy. In most
patients, serum hs-CRP levels were undetectable both before and after 131I
therapy. Only in 1 patient in the 0.01-mg rhTSH group and in 1 patient in the
0.03-mg rhTSH group did hs-CRP levels exceed the upper level of the normal
range after 131I therapy (peak levels were 33.2 mg/liter at 7 d and 20.3 mg/liter
at 10 d after 131I therapy, respectively).
TV and SCAT, 1 yr after 131I therapy (Table 1, Fig. 3). One year after 131I treatment,
TV was 91 ± 41 ml (range, 50–170 ml) in the 0.01-mg rhTSH group and 62 ± 35
ml (range, 23–127 ml) in the 0.03-mg rhTSH group. Compared with pretreat-
ment TV, TV 1 yr after 131I therapy was lower in all patients. Volume reduction
after 1 yr was 35% ± 14% (range, 13%–68%) in the 0.01-mg rhTSH group (P* <
0.005) and 41% ± 12% (range, 26%–61%) in the 0.03-mg rhTSH group (P* < 0.01).
TV reduction was not significantly different between the two groups.
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One year after 131I therapy, SCAT was 1.36 ± 0.43 cm2 (range, 0.81–2.45 cm2) in
the 0.01-mg rhTSH group and 1.37 ± 0.58 cm2 (range, 0.47–2.31 cm2) in the 0.03-
mg rhTSH group. Compared with pretreatment SCAT, the increase in SCAT
after 1 yr was 17% ± 14% (range, 1%–46%) in the 0.01-mg rhTSH group (P* <
0.005) and 44% ± 56% (range, 7%–194%) in the 0.03-mg rhTSH group (P* <
0.01). The increase of SCAT was not significantly different between the two
groups.
In the total group of 22 patients, there was no correlation between TV reduc-
tion and increase of SCAT (correlation coefficient = 0.12, P** = NS). TV reduc-
tion achieved 1 yr after 131I therapy was not significantly correlated with base-
line TV (correlation coefficient = 0.09, P** = NS).
Thyroid function after 131I therapy. Serum levels of TRAbs became positive (>1.5
IU/liter) in four patients (0.01-mg rhTSH group, n = 3; and 0.03-mg rhTSH
group, n = 1) 6 months after 131I therapy. The individual peak levels were 2.8, 15.5,
4.1, and 2.2 IU/liter. Three of them (all in the 0.01-mg rhTSH group) developed
symptoms and signs of hyperthyroidism between 23 and 25 wk after 131I thera-
py. At the time of diagnosis of hyperthyroidism, serum TSH levels were less
than 0.03 mU/liter, and serum FT4 levels were 52.5, 58.0, and 35.7 pM.
Figure 2. Serum TSH levels (left) and FT4 levels (right) before and after administration of 0.01 mg (top) and 0.03 mg (bot-
tom) rhTSH, followed by an 131I dose adjusted to the rhTSH-induced increase in 24-h RAIU, in 22 patients with nodular goi-
ter; rhTSH was administered immediately after the first blood withdrawal at d -1, and 131I was administered immediately
after blood withdrawal at d 0. Dotted lines: upper and lower limits of the normal range for serum TSH and FT4.
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In the year after 131I therapy, L-thyroxine therapy was started in 8 patients
(0.01-mg rhTSH group, n = 4; and 0.03-mg rhTSH group, n = 4) because, during
follow-up, an elevated serum TSH level was measured. Pretreatment serum
TSH levels were significantly (P < 0.05) higher in these 8 patients (0.99 ± 0.56
mU/liter; range 0.27–1.80 mU/liter) than in the other 14 patients (0.39 ± 0.31
mU/liter; range, <0.03–1.30 mU/liter). There was no significant difference in
pretreatment TVs between the two groups. TV reduction tended to be higher
(P = 0.05) in the patients in whom the serum TSH level became elevated dur-
ing follow-up. Before therapy, anti-TPO antibodies were positive (>60 U/ml) in
3 patients of the total group. One year after therapy, anti-TPO antibodies were
still positive in these 3 patients and had become positive in one other patient.
There was no significant relation between the presence of anti-TPO antibodies
and the development of an elevated serum TSH level: anti-TPO antibodies
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Patient Serum Maximum  Serum  Maximum  Thyroid volumea SCATa
FT4 just before serum FT4 T3 just before serum T3 change at change at
131I (pM) after 131I (pM) 131I (nM) after 131I (nM) 1 wk (%) 1 wk (%)
1 16.2 24.4 3.40 4.60 14 3
2 13.7 18.7 3.00 3.00 14 19
3 13.2 16.2 1.90 2.60 -5 9
4 17.1 22.9 2.60 2.60 6 2
5 21.5 26.6 2.70 3.10 9 9
6 15.7 27.1 2.40 3.40 15 -1
7 21.9 25.4 3.00 3.20 9 10
8 17.9 21.7 2.00 2.60 -3 1
9 18.6 23.3 2.40 2.90 13 -13
10 22.9 32.4 2.80 3.80 -6 -5
11 16.6 19.7 2.80 2.90 -2 2
12 16.6 19.5 2.50 2.80 -2 1
Mean ± SD 17.7 ± 3.1 23.2 ± 4.4b 2.63 ± 0.42 3.12 ± 0.58b 5 ± 8 3 ± 8
13 22.0 28.0 2.90 3.10 2 5
14 18.7 20.0 2.70 2.90 Not done Not done
15 28.5 28.9 3.20 3.60 5 -1
16 22.7 23.5 2.10 2.20 1 -11
17 15.6 17.4 2.70 3.30 7 -3
18 27.5 32.4 4.50 4.50 17 19
19 16.8 20.3 1.90 2.30 4 -3
20 15.6 18.4 2.90 2.90 -4 4
21 18.1 20.2 3.00 3.10 1 2
22 18.6 25.8 2.30 4.70 6 -7
Mean ± SD 20.4 ± 4.6 23.5 ± 5.1b 2.82 ± 0.72 3.26 ± 0.82b 5 ± 6 0 ± 9
0.01-mg vs. P = NS P = NS P = NS P = NS P = NS P = NS
0.03-mg group
Table 2. Short-term safety parameters of 131I therapy after pretreatment with a single dose of 0.01 mg (patients 1–12) or
0.03 mg (patients 13–22) rhTSH in 22 patients with nodular goiter 
a Determined by MRI. 
b P* < 0.005, compared with serum values just before 131I, i.e. 24 h after rhTSH administration.
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were positive both before and 1 yr after 131I therapy in 2 of the 8 patients, who
started with L-thyroxine during the first year after 131I therapy. In the other 6
patients in whom the serum TSH level became elevated during follow-up, anti-
TPO antibodies were negative both before and 1 yr after therapy.
Figure 3. TV (top), and SCAT (bottom) measured before and 1 yr after radioiodine therapy in 22
patients with nodular goiter who were pretreated with a single dose of rhTSH (0.01 mg, n = 12; or
0.03 mg, n = 10). The data are expressed as percentages of pretreatment values. 
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Discussion
In the present study, radioiodine therapy after pretreatment with a single, low
dose of rhTSH in patients with nodular goiter resulted in a reduction in TV, 1 yr
after therapy, of 35% (on average) in the group pretreated with 0.01-mg rhTSH
group and of 41% (on average) in the group pretreated with 0.03 mg rhTSH.
This was accompanied by an increase of the SCAT of 17% and 44% (on average),
respectively. Although TV reduction and increase of the SCAT seemed to be
better in the 0.03-mg rhTSH group than in the 0.01-mg rhTSH group, these dif-
ferences were not statistically significant. Furthermore, initial goiter size in
the 0.01-mg rhTSH group was approximately 40% greater than in the 0.03-mg
rhTSH group, and this may have influenced the results of 131I therapy, because
the efficacy of 131I therapy diminishes with increasing goiter size (19).
Our results are in line with those in earlier studies on TV reduction by radioio-
dine therapy in patients with nodular goiter, showing that radioiodine treat-
ment results in a reduction of goiter volume by approximately 40% after 1 yr
(3, 6, 7). In these studies, like in our study, single doses of approximately 100
µCi (3.7 MBq) 131I per gram of thyroid tissue, corrected for the percentage
uptake of radioiodine in the thyroid at 24 h, were given. However, an impor-
tant difference between the present study and the earlier reports is that, in our
study, pretreatment with rhTSH allowed reduction of the therapeutic dose of
radioiodine by a factor of 1.9 (on average) in the group pretreated with 0.01 mg
rhTSH and of 2.4 (on average) in the group pretreated with 0.03 mg rhTSH.
The radiation burden of radioiodine therapy to extrathyroidal organs is direct-
ly related to the dose of radioiodine administered (11). In our study, pretreat-
ment with rhTSH allowed approximately 50–60% reduction of the therapeutic
dose of radioiodine. Such a dose reduction may have important practical con-
sequences. Until now, most clinicians have restricted radioiodine therapy for
nontoxic, nodular goiter to elderly patients, especially those who have a high
operative risk or refuse surgery. In these patients, the benefits of noninvasive
radioiodine treatment outweigh the lifetime risk of this mode of therapy.
However, because pretreatment with rhTSH may substantially lower the dose
of radioiodine to be administered, this therapy may become more attractive
for younger patients.
A main goal of the present study was to investigate the safety of the adminis-
tration of a therapeutic dose of 131I after pretreatment with rhTSH. We investi-
gated whether pretreatment with a low dose of rhTSH did not exacerbate the
mild increases in serum thyroid hormone levels and TV commonly seen after
radioiodine treatment of nodular goiter (14). This proved to be not the case:
only mild increases in serum FT4 and T3 were observed, and no symptoms and
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signs of thyrotoxicosis occurred. Therefore, in our opinion, routine β blockade
is not necessary.
In the 0.03-mg rhTSH group, a small increase in TV was observed 1 wk after 131I
therapy, but this was not accompanied by further narrowing of the tracheal
lumen. We observed no symptoms or signs of thyroiditis in our patients, and
serum CRP levels after radioiodine therapy did exceed the normal range in only
2 of the 22 patients. From our data, it seems that, in patients with nontoxic,
nodular goiter, 131I therapy after pretreatment with a low dose of rhTSH is safe.
In our study, three patients developed hyperthyroidism between 23 and 25 wk
after 131I therapy, which was accompanied by the presence of positive serum
levels of TRAbs. Autoimmune hyperthyroidism may occur several months after
radioiodine therapy for nontoxic, nodular goiter in approximately 5% of
patients (20). It is of note that all three cases of autoimmune hyperthyroidism
occurred in the group pretreated with the lowest dose of rhTSH, making a rela-
tionship with rhTSH pretreatment less likely.
In the year after 131I therapy, L-thyroxine was started in eight patients, because,
during follow-up, an elevated serum TSH level was measured. Reported inci-
dences of posttreatment hypothyroidism after radioiodine therapy for nontox-
ic, nodular goiter in literature vary from 8–100% (1, 2, 4, 5, 6, 7, 19, 21). Nygaard
et al. (2), using the life table method, calculated a cumulative risk of hypothy-
roidism of 22% at 5 yr after radioiodine treatment for small nontoxic goiters.
However, in more recent studies, higher incidences were found, e.g. 22% after
1 yr (6) and 45% after 2 yr (7). Posttreatment hypothyroidism seems to be more
common in patients with small goiters and in those with high pretreatment
serum anti-TPO antibody concentrations (19). In our study, there was no corre-
lation between the presence of anti-TPO antibodies before radioiodine treat-
ment and the development of an elevated serum TSH level during follow-up,
and there was no significant difference in pretreatment TV between patients
who developed an elevated TSH level during follow-up and those who did not.
Our study has a number of limitations. First, it is an observational study, not a
randomized trial comparing the safety and efficacy of 131I therapy after pre-
treatment with different doses of rhTSH with that of standard 131I therapy, i.e.
without pretreatment with rhTSH. For this reason, our finding that a dose of
0.03 mg rhTSH resulted in a significantly higher increase in 24-h RAIU than a
dose of 0.01 mg rhTSH has to be confirmed in a randomized setting. Second, it
was not investigated whether doses of rhTSH higher than 0.03 mg rhTSH
resulted in even higher increases of 24 h RAIU and whether pretreatment with
such higher doses of rhTSH before radioiodine therapy is safe and more effec-
tive than pretreatment with the doses used in our study. Third, this study was
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performed in an area with sufficient iodide intake. We cannot exclude that the
effect of rhTSH pretreatment may be greater in areas with a higher iodide
intake than in The Netherlands. Fourth, our study cannot answer the question
of whether radioiodine therapy after pretreatment with rhTSH, but without
diminishing the dose of 131I according to the rhTSH-induced increase in 24-h
RAIU, resulting in a higher radiation dose to the thyroid, may improve the
effect of radioiodine therapy with respect to TV reduction.
In conclusion, pretreatment with a single, low dose of rhTSH in patients with
nodular goiter allows a 50–60% reduction of the therapeutic dose of radioio-
dine without compromising the efficacy of TV reduction. Further studies are
needed to assess whether treatment with larger doses of rhTSH and/or 131I
results in larger TV reduction in these patients.
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To the Editor: 
We have with great interest read the paper by Nieuwlaat et al. (1). Their study and
the recent one by Duick and Baskin (2), are the first demonstrating that recombi-
nant human TSH (rhTSH) may be highly useful in relation to 131I therapy for benign
goiter. Nieuwlaat et al. (1) show that prestimulation with a very small amount of
rhTSH (0.01 or 0.03 mg) in patients with a nontoxic nodular goiter allowed the 131I
activity to be halved, while still attaining a goiter reduction of approximately 40%.
Such an effect of the 131I therapy was to be expected, because the same group pre-
viously reported that an increased radioiodine uptake by the goiter can be
obtained after rhTSH stimulation (3). However, before rhTSH stimulation is rou-
tinely used by clinicians to optimize the 131I therapy in benign thyroid disorders,
we wish to emphasize that several aspects with this combination have not yet
been sufficiently enlightened. Furthermore, both studies (1, 2) have serious short-
comings.
Although the use of rhTSH has been extensively evaluated in the monitoring and
therapy of differentiated thyroid cancer, complications may arise when patients
with an intact thyroid function and/or goiter are stimulated with this agent.
Although 131I therapy is used routinely in some countries (e.g. Denmark and The
Netherlands) for treatment of nontoxic goiter, this is clearly not the case in many
parts of the world, as documented by recent questionnaire surveys (4).
Additionally, the evidence for this strategy almost exclusively relies on uncon-
trolled studies (4). Therefore, before introducing a novel principle in this setting,
indisputable evidence based on well-designed controlled trials should be provid-
ed. Unfortunately, no control group was included in the study by Nieuwlaat et al.
(1) which predisposes to overlook confounding factors. For example, the goiter-
reducing effect obtained by the 131I therapy may have been blurred by a possible
dependency on the pretreatment goiter volume, as described in other studies (4).
An issue largely overlooked is the fact that upper airway obstruction is present in
a large fraction of patients with goiter, despite absence of symptoms (4). Some
reports have suggested that stimulation with rhTSH causes significant swelling of
tumor tissue in patients with papillary thyroid carcinoma (5, 6). It is plausible, but
not proved, that a similar situation can occur in patients with a benign goiter.
Considering that 131I therapy in some cases causes a transient goiter growth (with-
out prior rhTSH stimulation) of 15–25% within the first week (4), the combination
with rhTSH may lead to severe tracheal compression resulting in acute respirato-
ry distress in susceptible individuals. In the study by Nieuwlaat et al. (1), the goi-
ter enlargement as well as the smallest tracheal cross-sectional area was estimat-
ed by magnetic resonance 1 wk after the 131I therapy. On average, both structures
were insignificantly altered, although a goiter growth up to 17% and a tracheal
area reduction by 13% were observed (1). These figures are very similar to previous
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findings by us (7). However, it is our experience that the thyroid gland in some
individuals may respond profoundly to rhTSH stimulation per se by an acute
enlargement of more than 100% (8). This appears within 48 h and is fortunately
followed by a rapid reversion to normal size. Thus, it is possible that a transient
but significant goiter increase in fact did occur immediately before or during the
131I therapy in the study by Nieuwlaat et al. (1) but was overlooked because
patients were scanned at the earliest 1 wk after therapy. It is reassuring that rhTSH
stimulation in the low doses that were used in that study seemingly was well tol-
erated, but the number of patients was small (n = 22) and only few suffered from
a goiter larger than 150 ml (1). Should it be confirmed that rhTSH stimulation may
give rise to a significant acute thyroid enlargement, it must be investigated in
detail whether this can be prevented successfully by e.g. corticosteroids or non-
steroid antiinflammatory drugs, as suggested by two recent reports (2, 8).
Besides this potential problem of goiter swelling and tracheal compression due to
rhTSH stimulation, particularly in combination with 131I therapy, other issues also
need to be clarified. The aim in the study by Nieuwlaat et al. (1) was to reduce the
131I activity through a higher rhTSH-induced radioiodine thyroid uptake. The aver-
age goiter reduction obtainable by 131I therapy is 35–50% (4), which still may leave
some patients with compressive symptoms, particularly those with large goiters.
Although some studies have indicated a dose-relationship between 131I and goiter
reduction (4), this remains to be proven in a prospective controlled set-up.
Because some areas in a goiter simply may not be susceptible to 131I therapy due
to inactive and degenerated nodular tissue, it may well be that the thyroid irradi-
ation usually employed (approximately 100 Gy) is sufficient to obtain the maxi-
mum goiter reduction. Thus, it is presently an open question whether the goiter
reduction can be amplified by the use of rhTSH prestimulation. A previous study
by Nieuwlaat et al. (9) demonstrating a more homogenous distribution of 131I in
the nodular goiter after rhTSH stimulation holds promise in this setting. To esti-
mate the impact of rhTSH stimulation on the thyroid irradiation, it would have
been highly interesting if Nieuwlaat et al. (1) had measured the 131I kinetics during
the 131I therapy of the patients with nontoxic multinodular goiter and compared
data with a control group not receiving rhTSH prestimulation. Finally, the optimal
dose of rhTSH remains to be determined. By using small amounts of rhTSH, thy-
rotoxicosis can be avoided in most individuals with an intact thyroid gland (1), but
this must of course be balanced against the overall purpose of a sufficient
increase of thyroid 131I uptake.
Thus, evidence of a beneficial effect of rhTSH prestimulation awaits properly con-
ducted randomized trials before routine use can be recommended. In addition,
cost-benefit, optimum rhTSH dose, and most important, safety issues need to be
clarified.
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To the Editor: 
We thank Dr. Bonnema and colleagues for their comments. Indeed, our study (1) is
an observational study, not a randomized trial, comparing the safety and efficacy
of 131I therapy after treatment with various doses of recombinant human TSH
(rhTSH) with that of standard 131I therapy, i.e. without pretreatment with rhTSH.
As Bonnema et al. emphasize, rhTSH administration in patients with nodular goi-
ters might induce acute increases in serum thyroid hormone levels and thyroid
size. At the start of our study, no data on this issue were available. Therefore, the
principal aim of our study was to explore the short-term safety of the administra-
tion of a therapeutic dose of 131I after pretreatment with a single dose of rhTSH.
For safety reasons, we used low doses of rhTSH (0.01 or 0.03 mg), and we adjust-
ed the therapeutic dose of 131I to the rhTSH-induced increase in 24-h radioactive
iodine uptake, as determined in a diagnostic study, using a tracer dose of 131I. We
did not aim at doses higher than 100 µCi (3.7 MBq) 131I per gram of thyroid tissue
retained at 24 h. We agree that thyroid volume measurements in the first few days
after rhTSH administration would have been informative. However, because in our
study a therapeutic dose of 131I was given 24 h after rhTSH administration, radia-
tion safety regulations in our hospital precluded such early measurements.
Anyhow, we did not observe symptoms and signs of (worsening of) tracheal com-
pression in the first days after rhTSH administration.
We fully agree with Bonnema et al. that further studies are needed before rhTSH
can be advised as an adjunct to 131I therapy in nodular goiter. First, it has to be
determined in a formal dose-response study which dose of rhTSH is optimal for
this purpose. This study is currently being performed in the United States. The
optimal rhTSH dose should stimulate radioactive iodine uptake considerably, but
should not cause unacceptable increases in serum thyroid hormone levels and
thyroid volume. Then, radioiodine therapy with and without pretreatment with
that particular dose of rhTSH should be investigated in randomized studies. Such
studies should look carefully at dose-response relationships with respect to effi-
cacy and adverse effects, especially when 131I treatment with rhTSH prestimula-
tion is intended to reach higher radiation-absorbed doses in the thyroid than in
our study, with the aim of achieving larger volume reductions.
Proefschrift WA Nieuwlaat H4  23-03-2005  15:15  Pagina 134
4.2
135
Pr
et
re
at
m
en
t 
w
it
h 
a 
Si
ng
le
, L
ow
 D
os
e 
of
 R
ec
om
bi
na
nt
 H
um
an
 T
hy
ro
tr
op
in
 A
llo
w
s 
D
os
e 
Re
du
ct
io
n 
of
 R
ad
io
io
di
ne
 T
he
ra
py
 in
 P
at
ie
nt
s 
w
it
h 
N
od
ul
ar
 G
oi
te
r
Reference
1 Nieuwlaat WA, Huysmans DA, Van Den Bosch HC, Sweep CG, Ross HA, Corstens
FH, Hermus AR 2003 Pretreatment with a single, low dose of recombinant human
thyrotropin allows dose reduction of radioiodine therapy in patients with nodular
goiter. J Clin Endocrinol Metab 88:3121–3129
Proefschrift WA Nieuwlaat H4  23-03-2005  15:15  Pagina 135
4.2
136
Pretreatm
ent w
ith a Single, Low
 D
ose of Recom
binant H
um
an Thyrotropin A
llow
s D
ose Reduction of Radioiodine Therapy in Patients w
ith N
odular G
oiter
Proefschrift WA Nieuwlaat H4  23-03-2005  15:15  Pagina 136
5chapter
Proefschrift WA Nieuwlaat H5  23-03-2005  15:16  Pagina 137
Proefschrift WA Nieuwlaat H5  23-03-2005  15:16  Pagina 138
5 .1
Dosimetry of Radioiodine Therapy in Patients 
with Nodular Goiter After Pretreatment with 
a Single, Low Dose of Recombinant Human 
Thyroid-Stimulating Hormone
Willy-Anne Nieuwlaat, Ad R. Hermus, H. Alec Ross,
Wilhelmina C. Buijs, Michela A. Edelbroek, 
Jo W. Bus, Frans H. Corstens, 
and Dyde A. Huysmans 
Department of Nuclear Medicine (W.-A.N., M.A.E., J.W.B., D.A.H.),
Catharina Hospital, Eindhoven; 
Departments of Endocrinology (W.-A.N., A.R.H.), Chemical
Endocrinology (H.A.R.), and Nuclear Medicine (W.C.B., F.H.C.), 
Radboud University Nijmegen Medical Center, Nijmegen, 
The Netherlands  
The Journal of Nuclear Medicine 2004; 45(4):626-633
Proefschrift WA Nieuwlaat H5  23-03-2005  15:16  Pagina 139
Abstract
A single, low dose of recombinant human thyroid-stimulating hormone (rhTSH)
doubles 24-h RAIU and causes a more homogeneous distribution of radioiodine
on thyroid scintigrams of patients with nodular goiter. Pretreatment with rhTSH
allows the therapeutic dose of 131I to be reduced by 50%–60% without compromis-
ing the result of thyroid volume reduction. The present study focused on the dosi-
metric aspects of therapy with a reduced dose of 131I after pretreatment with
rhTSH in patients with nodular goiter. 
Methods: Thirty-six patients were treated with 131I to reduce thyroid volume. Nine
patients were pretreated with a single dose of 0.01 mg of rhTSH, and 9 patients,
with 0.03 mg of rhTSH. Two control groups of 9 patients, matched for thyroid
weight and 24-h radioactive iodide uptake, were not pretreated with rhTSH. The
therapeutic dose of 131I was aimed at being sufficient to result in retention of 3.7
MBq of 131I per gram of thyroid tissue at 24 h. Thyroid radioactivity after 131I admin-
istration was measured every 24 h for 3 d and on days 7, 10, 14, 21, and 28. A model
of iodine biokinetics was used to estimate absorbed doses in organs. Protein-
bound 131I activity was measured at 1, 2, 3, 7, and 10 d and at 2, 3, and 4 wk after 131I
therapy. 
Results: The administered activities were 1.5 times lower in the 0.01-mg rhTSH
group and 1.9 times lower in the 0.03-mg rhTSH group than in the control groups.
The absorbed dose in the thyroid was similar in the rhTSH-pretreated groups and
in the control groups. In the organs of excretion (bladder) and uptake (stomach)
of inorganic iodide, the absorbed doses were 2- to 3-fold lower in the pretreated
groups than in the control groups. The effective dose equivalent outside the thy-
roid was considerably lower in the rhTSH-pretreated groups than in their respec-
tive control groups (1.6-fold in the 0.01-mg rhTSH group and 2.3-fold in the 0.03-
mg rhTSH group). The time course of protein-bound 131I activity in serum and the
cumulated protein-bound 131I activity in serum did not differ significantly between
rhTSH-pretreated and control groups. 
Conclusion: 131I therapy after pretreatment with a single, low dose of rhTSH, with
the dose reduced according to the rhTSH-induced increase in 24-h radioactive
iodide uptake, caused lower radiation-absorbed doses in extrathyroidal organs
and tissues, especially bladder and stomach, and no significant increase in the
release of 131I-labeled thyroid hormones into the circulation of patients with nodu-
lar goiter. Thus, this mode of therapy can be recommended, especially when the
dose of radioiodine to be administered without rhTSH pretreatment is high.
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Introduction
Radioiodine (131I) therapy is effective for reduction of thyroid volume in patients
with nontoxic, nodular goiter. Several studies have found that 131I treatment
decreased goiter size by approximately 40% after 1 y (1–7) and by 50%–60% after
3–5 y (2,8,9).
In the reported studies, a single dose of approximately 3.7 MBq (100 µCi) of 131I per
gram of thyroid tissue, corrected for thyroid radioactive iodide uptake (RAIU) at
24 h, was given. In patients with nontoxic, nodular goiter, RAIU is usually rather
low. As a result, high doses of 131I are often needed, causing a relatively high radi-
ation burden to extrathyroidal tissues (10). Therefore, exploration of strategies to
enhance RAIU in these patients would be of interest. A method to enhance RAIU
in patients with nodular goiter is to increase the serum level of thyroid-stimulat-
ing hormone, which is often low normal or below normal.
In 2000, we reported that pretreatment with 0.01 or 0.03 mg of recombinant
human thyroid-stimulating hormone (rhTSH) doubled 24-h RAIU in patients with
nodular goiter (11). We also found that pretreatment with rhTSH caused a more
homogeneous distribution of radioiodine on thyroid scintigrams of nodular goi-
ters (12). Pretreatment with a single, low dose of rhTSH allowed us to reduce the
therapeutic dose of radioiodine in patients with nodular goiter by 50%–60% with-
out compromising the result of thyroid volume reduction (13).
The present study focused on the dosimetric aspects of therapy with a reduced
dose of radioiodine after rhTSH pretreatment of patients with nodular goiter. We
hypothesized that therapy with a reduced dose of 131I after pretreatment with
rhTSH would decrease the radiation burden to extrathyroidal tissues. Absorbed
doses in the thyroid and in extrathyroidal organs and tissues were estimated for
patients treated with radioiodine with and without rhTSH pretreatment, using
thyroid radioactivity measurements and a model of iodine kinetics in the body as
described by Robertson and Gorman (14).
Furthermore, we investigated whether pretreatment with rhTSH increased the
release of 131I-labeled thyroid hormones or thyroglobulin into the circulation after
radioiodine therapy. If this were the case, the advantage of lowering the amount
of free inorganic 131I in the circulation by using lower therapeutic doses of 131I after
rhTSH pretreatment might be outweighed by an increase in circulating protein-
bound 131I levels (PB131I).
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Materials and Methods
Patients
Thirty-six patients with nodular goiter, who were referred for radioiodine therapy
to reduce thyroid volume, participated in this study. All patients had normal
serum levels of free thyroxine (9.0–22.3 pmol/L) and total triiodothyronine
(1.0–3.0 nmol/L). Serum thyroid-stimulating hormone levels were normal (0.2–5.5
mU/L) in 24 patients and below normal in 12 patients. The results of careful palpa-
tion of the thyroid, followed by fine-needle aspiration biopsy of dominant nodules
and of those that had a different consistency from other nodules within the gland
gave no suggestion of thyroid malignancy in any of the patients. None of the
patients had recently taken medication known to affect thyroid function or RAIU.
Patients had not received iodine-containing agents in the last 6 mo. An electro-
cardiogram, complete blood count, liver enzyme determination, plasma creatinine
and glucose measurement, and screening urinalysis did not show abnormalities in
any patients.
Twenty-four hours before radioiodine therapy, a first group of 9 consecutive
patients received 0.01 mg of rhTSH and a second group of 9 consecutive patients
received 0.03 mg of rhTSH. Afterward, 18 consecutive patients were treated with
radioiodine without rhTSH pretreatment; from these, 2 control groups of 9
patients each were selected, matching the rhTSH-pretreated groups with respect
to thyroid weight and 24-h RAIU.
The institutional human research committee approved the study, and all patients
gave written informed consent to participate.
Diagnostic investigations preceding radioiodine therapy
A diagnostic dose of 40 MBq of sodium (123I) iodide was administered as an oral
solution. RAIU, as a percentage of the administered dose of 123I corrected for phys-
ical decay, was measured at 24 h using a 7.62 x 7.62 cm (3 x 3 in.) NaI (Tl) detector.
Dead-time corrections were made using standard software. Thyroid scintigraphy
in the 159-keV window of 123I was performed 24 h after radioiodine administration.
All thyroid scintigrams showed heterogeneous uptake.
In 18 patients, the influence of rhTSH on RAIU was investigated at least 2 wk after
radioiodine administration for the baseline investigation. After reconstitution of
0.9 mg of freeze-dried rhTSH (Thyrogen ampules; Genzyme) with 1.2 mL of sterile
water, part of the obtained solution was diluted with saline to a final concentra-
tion of 0.05 mg/mL. Immediately after dilution, 0.01 mg (0.2 mL; n = 9) or 0.03 mg
(0.6 mL; n = 9) of rhTSH was injected in the quadriceps muscle. Twenty-four hours
after the administration of rhTSH, a diagnostic dose of 40 MBq of sodium 123I was
administered as an oral solution. RAIU, as a percentage of the administered dose
of 123I corrected for physical decay, was measured at 24 h.
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Radioiodine therapy
Twenty-three days (median; range, 5–84 d) after the last diagnostic 24-h RAIU
measurement, radioiodine therapy was given as a single oral dose to all 36
patients on an in-patient basis. The therapeutic dose of 131I was aimed at being suf-
ficient to result in retention of 3.7 MBq (100 µCi) of 131I per gram of thyroid tissue
at 24 h, according to the following formula: administered activity (GBq) = [thyroid
weight (g) x 0.37 (GBq/g)]/24-h thyroid RAIU (%) (15). Thyroid weight was estimat-
ed from the planimetric surface on the baseline scintigram using the formula of
Doering and Kramer (16): thyroid weight (g) = 0.326 x surface (cm2)3/2.
The 18 patients who were treated with rhTSH before radioiodine therapy again
received an injection of rhTSH in the quadriceps muscle, using the same rhTSH
dose as was given for the diagnostic investigation. The therapeutic dose of
radioiodine was given 24 h later. In the rhTSH-pretreated patients, the therapeu-
tic dose of 131I was adjusted to the 24-h RAIU after rhTSH pretreatment, as deter-
mined for the individual patients in the preceding diagnostic investigations. The
RAIU ratio is defined as the ratio between the 24-h RAIU after rhTSH pretreat-
ment and the baseline 24-h RAIU (Table 1). Neither group of 9 control patients
received rhTSH pretreatment.
Thyroid radioactivity measurements and dosimetric calculations
In all 36 patients, thyroid radioactivity was measured every 24 h for 3 d after the
administration of the therapeutic dose of radioiodine and on days 7, 10, 14, 21, and
28. A 7.62 x 7.62 cm (3 x 3 in.) NaI (Tl) detector was used, with a lead shield placed
in front of it to reduce the counting rate and avoid dead-time effects.
Measurements were corrected for a standard with a known activity of 131I, and all
values were corrected for background radioactivity and for physical decay.
Thyroid radioactivity measurements were implemented in a simplified model for
iodine biokinetics as described by Robertson and Gorman (14), with some amend-
ments, as previously described by Huysmans et al. (10). Serum creatinine levels
were within the reference range in all patients. Therefore, a normal urinary excre-
tion rate of radioiodide was assumed for all patients (17). The rate of uptake of
radioiodine into the thyroid was calculated from the radioactivity measurements
at 24 h and from the radioiodide excretion rate. The fractional excretion of
radioiodinated thyroid hormones from the thyroid into the circulation was calcu-
lated from thyroid radioactivity measurements from day 2 onward, fitted as a
monoexponential function.
Radiation-absorbed doses in organs were calculated using the MIRD method (18).
The calculated cumulated fractional activities in the source organs thyroid, uri-
nary bladder, stomach, small intestine, and total body were entered in the MIR-
DOSE3.1 computer program (Oak Ridge Institute for Science and Education).
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Absorbed doses in the thyroid were corrected for the ratio of normal thyroid
weight (20 g) to individual thyroid weight estimated by thyroid scintigraphy.
Tissue weighting factors were used to determine the effective dose equivalent
outside the thyroid (19).
Hormone assays
Free thyroxine and total triiodothyronine were measured by chemiluminescent
immunoassay and serum thyroid-stimulating hormone by 2-site immunochemilu-
minometric assay using an ACS:180 Automated Chemiluminescence System
(Bayer).
PB131I measurements
Blood samples were drawn from all patients at 1, 2, 3, 7, and 10 d and at 2, 3, and 4
wk after radioiodine administration. From each serum sample, 0.3 mL was taken
for measurement of total 131I activity in the serum and 0.3 mL for measurement of
PB131I activity. The latter 0.3-mL sample was prediluted with 0.9 mL of a solution
of 0.05 mol/L phosphate buffer (pH 7.4) and 0.1 mol/L sodium chloride. Protein-
bound iodine was precipitated by addition of 1.5 mL of cold trichloroacetic acid,
20%. The resulting samples were left standing for 10 min at room temperature and
then centrifuged for 2 min at 2,000 rpm. The precipitate was washed twice with
the trichloroacetic acid solution. By this method, 89% ± 6% of the total serum free
thyroxine is precipitated (H.A. Ross, unpublished data, 1999). All samples (total
serum and precipitate) were measured in a universal γ-counter (1282
Compugamma CS; Wallac). Radioactivity in all samples was compared with a stan-
dard curve of sodium-131I with known activity, to calculate the activity in MBq/L.
Time–activity curves were created for total 131I activity and PB131I activity in each
individual patient (Fig. 1). The area under each PB131I time–activity curve was cal-
culated. This area under the curve represents the cumulated PB131I activity in each
serum fraction and is expressed in GBq·L–1·d. The cumulated total 131I activity in
the serum was not calculated because, in view of radiation safety regulations in
the hospital, measurements on the day of radioiodine therapy had not been per-
formed and because total 131I activity in the serum is highest in the first hours after
radioiodine administration, in contrast to PB131I activity, which is low during the
first day after radioiodine therapy.
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Statistical analyses
The mean value ± SD is given, unless otherwise stated. Statistical analyses were
done using the Mann–Whitney U test (with probability values denoted as P) and
the Spearman rank correlation test (with probability values denoted as P *). Areas
under the time–activity curves obtained from the subjects who received rhTSH
were compared with those of the matched controls by means of the
Mann–Whitney U test. The time–activity curves themselves were compared by
repeated-measures ANOVA, with time after 131I administration as the within-sub-
ject factor and rhTSH pretreatment as the between-subjects factor. Probability
values < 0.05 were considered to indicate statistical significance.
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Results
Table 1 shows the characteristics of all patients and the data on their thyroid
radioactivity measurements. As expected, because rhTSH-pretreated groups and
control groups were matched for thyroid weight and thyroid 24-h RAIU, thyroid
weight, based on planimetric thyroid scintigrams, and baseline thyroid 24-h RAIU
were similar in the rhTSH groups and their respective control groups. rhTSH-stim-
ulated 24-h RAIU in the pretreated groups was considerably higher than baseline
RAIU in the control groups. Therefore, the average administered activities in the
rhTSH-pretreated groups were considerably lower than those in the control
groups (in the 0.01-mg rhTSH group, 67% of that in the control group; in the 0.03-
mg rhTSH group, 53% of that in the control group; both P < 0.05).
Thyroid radioactivity measurements after radioiodine therapy showed somewhat
lower 24-h RAIU of the therapeutic doses when compared with the 24-h RAIU of
the previous diagnostic doses. However, this trend was observed not only in the
rhTSH-pretreated groups but also in the control groups (Table 1). The effective
half-time of 131I in the thyroid did not significantly differ between rhTSH-pretreat-
ed patients and control patients (Table 1). The cumulated fractional activity
(MBq·h/administered MBq) in the thyroid was approximately 1.7 times higher in
the 0.01-mg rhTSH-pretreated group and 2.2 times higher in the 0.03-mg rhTSH-
pretreated group than in their respective control groups (Table 1). The cumulated
fractional activity in the liver, as calculated from thyroid radioactivity measure-
ments and the biokinetic model (14) with modifications (10), was also longer in the
pretreated groups, because their higher thyroid RAIU caused the component of
radioiodinated thyroid hormones to be larger. Cumulated fractional activities in
the other source organs, mainly determined by inorganic iodide (stomach, small
intestine, rest of body, urinary bladder), were significantly lower in the rhTSH-pre-
treated patients (0.01 mg and 0.03 mg rhTSH) than in their controls.
Table 2 shows the calculated absorbed doses in the tissues and organs for which a
tissue-weighting factor has been determined (19), expressed as dose per unit of
administered radioiodine (in mGy/MBq) and as dose resulting from the total
administered activities of radioiodine (in Gy). The absorbed dose in the thyroid
per unit of administered activity was higher in the pretreated groups than in the
control groups because of the higher cumulated fractional activity in the thyroid
of the pretreated groups.
Outside the thyroid gland, the highest absorbed doses calculated per megabec-
querel of administered 131I were in urinary bladder, followed by the stomach. For
these organs, the absorbed doses per megabecquerel were significantly higher
without than with rhTSH pretreatment (P < 0.0001). Absorbed doses per
megabecquerel of administered radioiodine inversely correlated with 24-h RAIU
for the urinary bladder (r = –0.73; P* < 0.0001) and the stomach (r = –0.74; P* <
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0.0001). Absorbed doses per megabecquerel of administered radioiodine in some
of the other target organs (bone surface, breast, lungs, red bone marrow, and skin)
were determined predominantly by the cumulated fractional activity in the thy-
roid and were therefore higher in the pretreated groups than in the control
groups.
The absorbed dose in the thyroid resulting from the total administered activity
was similar in the pretreated groups and their respective control groups. Outside
the thyroid, the highest absorbed doses resulting from the total administered
activities were in the urinary bladder and the stomach. In these organs of excre-
tion (bladder) and uptake (stomach) of inorganic iodide, the absorbed doses
resulting from the total administered activity were 2- to 3-fold lower in the pre-
treated groups than in their control groups. In all other extrathyroidal organs and
tissues, somewhat lower absorbed doses were found in the pretreated groups
than in the control groups, but the differences did not reach significance, except
for those in colon and gonads.
The effective dose equivalent for the combined organs and tissues outside the
thyroid gland was considerably lower in the rhTSH-pretreated groups than in their
control groups (0.01-mg rhTSH group vs. control group, 0.21 ± 0.09 Gy vs. 0.33 ±
0.10 Gy [P < 0.05]; 0.03-mg rhTSH group vs. control group, 0.12 ± 0.03 Gy vs. 0.27
± 0.14 Gy [P < 0.05]).
The cumulated PB131I activity in serum did not differ significantly between pre-
treated groups and their respective control groups. The cumulated PB131I activity
in serum was 0.93 ± 0.15 GBq·L–1·d in the 0.01-mg rhTSH group versus 0.70 ± 0.13
GBq·L–1·d in the control group and 0.85 ± 0.12 GBq·L–1·d in the 0.03-mg rhTSH
group versus 0.52 ± 0.13 GBq·L–1·d in the control group (mean value ± SEM; n = 9).
Figure 1 shows the time–activity curves of total 131I activity and PB131I activity in
serum after radioiodine therapy in the 2 groups of rhTSH-pretreated patients and
in the 2 control groups. The time course of PB131I activities did not significantly dif-
fer between pretreated and control groups.
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Discussion
Our study, based on thyroid radioactivity measurements and the iodine biokinet-
ic model of Robertson and Gorman (14), shows that radioiodine therapy after pre-
treatment with rhTSH, with the dose of 131I reduced according to the rhTSH-
induced increase in 24-h RAIU, caused a lower radiation burden to the extrathy-
roidal tissues than did radioiodine therapy without rhTSH pretreatment in
patients with nodular goiter. The reduction in radiation burden was largest for the
urinary bladder and the stomach. These are the extrathyroidal organs that receive
the highest radiation doses from radioiodine therapy.
The therapeutic 131I doses given to the rhTSH-pretreated patients were reduced
according to the individual increases in diagnostic 24-h RAIU after rhTSH adminis-
tration. RAIU measurements after therapy showed that the 24-h RAIU of the ther-
apeutic dose was somewhat lower than the 24-h RAIU of the preceding diagnostic
dose in most patients. However, this occurred in all 4 groups of patients to a simi-
lar degree, and the 24-h RAIU of the therapeutic dose was considerably higher in
the rhTSH-pretreated groups than in the control groups. The effective half-time of
Figure 1.  Total 131I activity and PB131I activity per liter of serum on day 0 after radioiodine therapy in patients with nodu-
lar goiter. (A and B) Nine patients were pretreated with 0.01 mg of rhTSH (A), and 9 with 0.03 mg of rhTSH (B). The results
for each rhTSH group were compared with those for 9 control patients. Mean value + SEM is given. = total 131I activity
in rhTSH-pretreated patients; = total 131I activity in control patients; = PB131I activity in rhTSH-pretreated patients; 
= PB131I activity in control patients.
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Absorbed dose per unit administered activity (mGy/MBq)
0.01 mg rhTSH 0.03 mg rhTSH
Target organ Treatment Control P Treatment Control P
Thyroida 92.60 ± 42.72 54.24 ± 19.59 <0.05 139.40 ± 55.76 82.60 ± 48.84 <0.05
Bone surface 0.17 ± 0.02 0.11 ± 0.02 <0.0001 0.18 ± 0.03 0.11 ± 0.01 <0.0001
Breast 0.06 ± 0.01 0.05 ± 0.01 <0.05 0.07 ± 0.01 0.05 ± 0.00 <0.0001
Colonb 0.05 ± 0.01 0.06 ± 0.00 <0.0001 0.07 ± 0.09 0.06 ± 0.00 <0.005
Liver 0.07 ± 0.02 0.05 ± 0.01 <0.05 0.07 ± 0.01 0.05 ± 0.01 <0.0001
Lungs 0.13 ± 0.02 0.09 ± 0.01 <0.001 0.15 ± 0.03 0.09 ± 0.01 <0.0001
Ovaries 0.05 ± 0.00 0.06 ± 0.00 <0.0001 0.04 ± 0.01 0.06 ± 0.00 <0.0001
Red bone marrow 0.12 ± 0.02 0.09 ± 0.01 <0.0001 0.13 ± 0.02 0.08 ± 0.01 <0.0001
Skin 0.12 ± 0.04 0.09 ± 0.02 NS 0.13 ± 0.04 0.08 ± 0.01 <0.05
Stomach 0.34 ± 0.03 0.45 ± 0.04 <0.0001 0.31 ± 0.05 0.47 ± 0.02 <0.0001
Testes 0.02 ± 0.00 0.02 ± 0.00
Urinary bladder 0.55 ± 0.08 0.71 ± 0.04 <0.0001 0.51 ± 0.09 0.73 ± 0.03 <0.0001
Remainderc 0.10 ± 0.01 0.10 ± 0.00 NS 0.11 ± 0.02 0.09 ± 0.00 <0.05
EDE outside 
thyroid (Sv)
Table 2. Radiation-Absorbed Doses in Target Organs After Radioiodine Treatment With and Without rhTSH
Pretreatment in Patients with Nodular Goiter
a Thyroid absorbed doses as calculated with MIRDOSE3.1 are corrected for the ratio of normal thyroid weight (20 g) to measured actual thyroid weight determined 
by scintigraphy. 
b 0.57 x dose to upper large intestine + 0.43 x dose to lower large intestine. 
c The absorbed dose in the remainder of the body is the average dose in the following organs and tissues: adrenals, brain, upper large intestine, small intestine, 
kidney, muscle, pancreas, spleen, thymus, and uterus. 
EDE = effective dose equivalent. 
Data are mean ± SD (n = 9 patients in each group).
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Absorbed dose (Gy)
0.01 mg rhTSH 0.03 mg rhTSH
Treatment Control P Treatment Control P
113.41 ± 16.30 107.42 ± 12.69 NS 108.94 ± 15.52 109.75 ± 23.25 NS
0.24 ± 0.09 0.25 ± 0.08 NS 0.15 ± 0.03 0.19 ± 0.10 NS
0.09 ± 0.04 0.11 ± 0.03 NS 0.06 ± 0.01 0.09 ± 0.04 NS
0.07 ± 0.03 0.13 ± 0.04 <0.005 0.06 ± 0.07 0.11 ± 0.06 <0.05
0.10 ± 0.04 0.11 ± 0.03 NS 0.06 ± 0.02 0.08 ± 0.04 NS
0.19 ± 0.07 0.21 ± 0.06 NS 0.12 ± 0.03 0.15 ± 0.08 NS
0.06 ± 0.03 0.13 ± 0.04 <0.01 0.04 ± 0.01 0.10 ± 0.05 <0.01
0.17 ± 0.07 0.19 ± 0.06 NS 0.11 ± 0.02 0.15 ± 0.08 NS
0.17 ± 0.07 0.20 ± 0.06 NS 0.11 ± 0.03 0.15 ± 0.08 NS
0.50 ± 0.24 0.99 ± 0.33 <0.005 0.27 ± 0.09 0.81 ± 0.43 <0.001
0.05 ± 0.00 0.02 ± 0.00
0.80 ± 0.37 1.55 ± 0.50 <0.005 0.44 ± 0.16 1.27 ± 0.66 <0.005
0.14 ± 0.06 0.21 ± 0.06 <0.05 0.09 ± 0.02 0.17 ± 0.09 NS
0.21 ± 0.09 0.33 ± 0.10 <0.05 0.12 ± 0.03 0.27 ± 0.14 <0.05
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radioiodine in the thyroid did not differ significantly between pretreated and con-
trol groups. Therefore, although we calculated increased absorbed doses in the thy-
roid per unit of administered activity in the pretreated groups, the total absorbed
doses in the thyroid were similar in the rhTSH-pretreated groups and their respec-
tive control groups. Thyroid volume reduction by radioiodine has been shown to
correlate positively with the administered amount of radioiodine per gram of thy-
roid tissue corrected for 24-h RAIU (5) and consequently with the absorbed dose in
the thyroid. Therefore, reducing the therapeutic dose of radioiodine after rhTSH
administration is not likely to have negatively influenced thyroid volume reduction.
This is in accordance with recently published data by our group (13).
We used the MIRDOSE3.1 program to calculate the doses that extrathyroidal tis-
sues absorbed from the total administered activity of radioiodine.
Extrathyroidally absorbed doses after radioiodine therapy were by far highest in
the urinary bladder and stomach, as was expected because inorganic iodine is
excreted through the bladder and is concentrated (although not made organic) in
the stomach. Enhanced uptake of radioiodine in the thyroid of rhTSH-pretreated
patients resulted in lower amounts of circulating inorganic radioiodine during the
first days after therapy and in lower cumulated fractional activities of radioiodine
in the inorganic radioiodine compartment (including the stomach) and the blad-
der. Therefore, the absorbed doses in urinary bladder and stomach were reduced
by a factor of 2 in the 0.01-mg rhTSH group and by a factor of 3 in the 0.03-mg
rhTSH group in comparison with their respective control groups. These reduc-
tions are important, because the risk of cancer of the stomach has been reported
to be slightly increased after radioiodine therapy in patients with toxic, nodular
goiter (20,21). In other studies, the incidences of bladder cancer and breast cancer
have been reported to be increased in patients with toxic nodular goiter treated
with radioiodine (22–24).
The liver is the organ in which 131I incorporated in thyroid hormones is collected
and metabolized. This was accounted for by assigning 40% of the extrathyroidal
thyroid hormone compartment to the liver. The amount of 131I-labeled thyroid hor-
mone per megabecquerel of radioiodine administered was higher in the rhTSH-
pretreated groups than in the control groups, resulting in a higher cumulated frac-
tional activity of 131I in the liver in the rhTSH-pretreated groups. However, the
absorbed dose in the liver was similar in rhTSH-pretreated and control groups
because of the reduction in administered dose of radioiodine in the rhTSH-pre-
treated groups.
Absorbed doses in all extrathyroidal organs were lower in the rhTSH-pretreated
groups than in the control groups. However, in the organs, in which the absorbed
dose is predominantly determined by the cumulated activity in the thyroid, the
difference did not reach statistical significance, because the cumulated activity in
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the thyroid was similar in rhTSH-pretreated and control groups. The effective
dose equivalent outside the thyroid was considerably lower in the rhTSH-pretreat-
ed groups than in their respective control groups (1.6-fold in the 0.01-mg rhTSH
group and 2.3-fold in the 0.03-mg rhTSH group).
Not only thyroid iodine uptake but also thyroid hormone release is stimulated by
thyroid-stimulating hormone. Thyroid stimulation predominantly releases thyroid
hormones incorporating iodine that was recently taken up, not iodine that was
stored for a longer time (last-come, first-served principle of thyroid iodine release)
(25). Therefore, it might be that the administration of rhTSH before radioiodine
therapy increases the release of radiolabeled thyroid hormones from the thyroid
into the circulation. It has been argued that such an increase in radiolabeled thy-
roid hormones in the serum (PB131I) might outweigh the advantage of a reduction
in radioiodine dose after rhTSH pretreatment (26). Our measurements were reas-
suring, because no significant difference in the time course of circulating PB131I
levels was observed between the rhTSH-pretreated groups and the control groups
and because the cumulated PB131I activities did not differ significantly between
pretreated and control groups. This is in accordance with our thyroid RAIU meas-
urements after radioiodine therapy, which showed no significant difference in
effective half-times of 131I in the thyroid between rhTSH-pretreated patients and
control patients.
During the first days after radioiodine therapy, the amount of PB131I was still low
and the total 131I activity in serum was determined predominantly by the amount
of inorganic 131I in the serum. During these first days, we measured much higher
total 131I activities in the control groups than in the rhTSH-pretreated groups. The
difference at 24 h after radioiodine therapy exceeded by far the difference in ther-
apeutic dose of radioiodine between rhTSH-pretreated groups and control
groups, because the higher uptake of inorganic 131I by the thyroid in the pretreat-
ed groups increased the removal rate of radioiodine from the circulation into the
thyroid, whereas the removal rate to the urinary compartment was the same in
both pretreated and control groups. This finding is in accordance with the iodine
biokinetic model of Robertson and Gorman (14).
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Conclusion
After pretreatment with a single, low dose of rhTSH, radioiodine therapy - of a
dose reduced in accord with the rhTSH-induced increase in 24-h RAIU - caused
lower radiation-absorbed doses in extrathyroidal organs and tissues, especially in
the bladder and stomach, of patients with nodular goiter. No significant increase
in the release of 131I-labeled thyroid hormones from the thyroid into the circulation
was observed after radioiodine therapy in rhTSH-pretreated patients. Thus, this
mode of therapy can be recommended, especially when the dose of radioiodine to
be administered without rhTSH pretreatment is high.
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Summary
In this thesis the use of recombinant human thyrotropin (rhTSH) as a possible
adjunct to radioiodine therapy for thyroid volume reduction in patients with
nontoxic, nodular goiter is explored.
In chapter 1 the clinical manifestations, the diagnostic evaluation and the current
treatment options (thyroidectomy, L-thyroxine treatment, and radioiodine thera-
py) for patients with nontoxic, nodular goiter are discussed. Thyroidectomy leads
to rapid decompression of vital structures and provides tissue for pathologic
examination. The efficacy of L-thyroxine treatment in patients with nontoxic,
nodular goiter is, at best, modest and lifelong L-thyroxine treatment may cause
bone loss and cardiac adverse effects. Radioiodine treatment is effective in more
than 90% of patients with nontoxic, nodular goiter and results in a mean thyroid
volume reduction of 40% after 1 year and of 50% to 60% after 3 to 5 years. In most
patients compressive symptoms improve. Early side effects (radiation thyroiditis
and esophagitis) are usually mild and transient. Exacerbation of compressive
symptoms after radioiodine administration is rare. The development of autoim-
mune hyperthyroidism is the most important late complication, occurring sever-
al months after radioiodine therapy in approximately 5% of patients. The inci-
dence of posttreatment hypothyroidism is 20% to 50% at 5 years. For each indi-
vidual patient the estimated risks of both surgery and radioiodine therapy should
be weighed carefully. At the moment surgery is preferred for younger patients,
especially when the amount of radioiodine to be administered is high. However,
for elderly patients, especially those with cardiopulmonary disease, the profits of
radioiodine treatment will outweigh the lifetime risk for this mode of therapy.
Next the current knowledge on thyrotropin (TSH) is reviewed, followed by a dis-
cussion of studies using TSH extracted from bovine pituitary glands to augment
radioiodine uptake in thyroid cancer patients. Because of the occurrence of aller-
gic reactions and the relative ineffectiveness with multiple dosing due to the
development of anti-TSH antibodies, bovine TSH has been abandoned for use in
humans and is no longer available. Therefore thyroid hormone withdrawal leading
to high endogenous serum TSH levels became the method of choice to stimulate
radioiodine uptake in thyroid cancer patients.
Work from the laboratory of Weintraub in the late 1980s provided the primary
sequence of the β-subunit of human TSH (hTSH). The human pituitary α-glyco-
protein subunit and the human TSH β-subunit were coexpressed in Chinese ham-
ster ovary cells resulting in the production of recombinant human TSH (rhTSH).
The process of rhTSH production was modified and scaled up with assistance of
scientists at Genzyme (Framingham MA, USA). RhTSH is now available as
Thyrogen® (thyrotropin alfa for injection, Genzyme; Cambridge MA, USA).
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Next, the in vitro en vivo studies (in animals and humans) with rhTSH are
reviewed  as well as the literature on the use of rhTSH in patients with differenti-
ated thyroid cancer.
Chapter 2 to 5 contain our original studies on the use of rhTSH in patients with
nontoxic, nodular goiter. In chapter 2 we investigated whether pretreatment with
a single, low dose of rhTSH enhances radioactive iodine uptake (RAIU) in 15
patients with nontoxic, nodular goiter (14 women and 1 man; aged 61 ± 11 yr). Four
patients were studied twice, and 1 patient was studied 3 times. RAIU was meas-
ured both under basal conditions and after pretreatment (im) with rhTSH, given
either 2 h (0.01 mg; n = 7) or 24 h [0.01 mg (n = 7) or 0.03 mg (n = 7)] before 131I
administration (20–40 µCi). Serum levels of TSH, free T4 (FT4), and total T3 were
measured at 2, 5, 8, 24, 48, 72, 96, and 192 h after rhTSH administration.
After administration of 0.01 mg rhTSH, serum TSH rose from 0.7 ± 0.5 to a peak
level of 4.4 ± 1.1 mU/L (P < 0.0001), FT4 rose from 16.0 ± 2.6 to 18.5 ± 3.7 pmol/L (P
< 0.0001), and T3 rose from 2.10 ± 0.41 to 2.63 ± 0.66 nmol/L (P < 0.0001). After
administration of 0.03 mg rhTSH, TSH rose from 0.6 ± 0.4 to 15.8 ± 2.3 mU/L (P <
0.0001), FT4 rose from 15.2 ± 1.5 to 21.7 ± 2.9 pmol/L (P < 0.0001), and T3 rose from
1.90 ± 0.43 to 3.19 ± 0.61 nmol/L (P < 0.0001). Peak TSH levels were reached at 5–8
h and peak FT4 and T3 levels at 8–96 h after rhTSH administration.
Administration of 0.01 mg rhTSH 2 h before 131I increased 24-h RAIU from 30 ± 11%
to 42 ± 10% (P < 0.02), 0.01 mg rhTSH administered 24 h before 131I increased 24-
h RAIU from 29 ± 10% to 51 ± 10% (P < 0.0001), and 0.03 mg rhTSH administered
24 h before 131I increased 24-h RAIU from 33 ± 11% to 63 ± 9% (P < 0.0001). After
administration of 0.01 mg rhTSH 2 h before 131I, 24-h RAIU did not increase in 1
patient, whereas the increase in 24-h RAIU was less than 10% in 2 other patients.
In contrast, administration of rhTSH 24 h before 131I increased 24-h RAIU by more
than 10% in all 14 patients (by >20% in 10 and by >30% in 6). 
We concluded that pretreatment with a single, low dose of rhTSH in patients with
nontoxic, nodular goiter increased RAIU considerably. These observations hold
promise that administration of rhTSH before 131I therapy for nontoxic, nodular goi-
ter would allow treatment with lower doses of 131I in these patients.
The purpose of the study described in chapter 3 was to investigate whether rhTSH
pretreatment induces changes in the regional distribution of radioiodine as visu-
alized on thyroid scintigrams in patients with nontoxic, nodular goiter.
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Anterior planar thyroid 123I scintigrams were obtained in 26 patients with a nodu-
lar goiter (23 women and 3 men; age, 62 ± 9 yr, mean ± SD; thyroid weight, 165 ±
72 g) 24 h after administration of a diagnostic dose of radioiodine. All patients
were studied twice: first, without rhTSH pretreatment (baseline study), and sec-
ond, after an im injection of 0.01 mg (n = 10) or 0.03 mg rhTSH (n = 16), given 24 h
before radioiodine administration (rhTSH study). For quantification of regional
differences in radioiodine uptake, a region of interest method was used.
Upon visual inspection, baseline scintigrams showed a heterogeneous uptake of
radioiodine. In general, rhTSH scintigrams also showed heterogeneous radioio-
dine uptake. In some patients, the distribution of radioiodine in the rhTSH scinti-
gram was considerably more homogeneous than in the baseline scintigram. In a
few patients, originally “cold” areas had changed into “hot” ones, whereas origi-
nally hot areas had changed into cold ones. Quantification of regional radioiodine
uptake showed that pretreatment with rhTSH caused a larger increase in radioio-
dine uptake in relatively cold areas and a smaller increase in radioiodine uptake in
relatively hot areas, compared with the increase in radioiodine uptake in the
entire thyroid. In patients with a baseline serum TSH level of 0.5 mU/L or lower,
the increase in radioiodine uptake in relatively cold areas was significantly larger
than in patients with a baseline serum TSH level higher than 0.5 mU/L.
We concluded that a single, low dose of rhTSH caused a more homogeneous dis-
tribution of radioiodine within the thyroid gland in patients with a nodular goiter
by stimulating radioiodine uptake in relatively cold areas more than in relatively
hot areas. This was most marked in patients with a low baseline serum TSH level.
Our data suggest that pretreatment with rhTSH may improve the efficacy of
radioiodine treatment for volume reduction of nodular goiters, especially in
patients with a low baseline serum TSH level.
In chapter 4 we studied the safety and efficacy of therapy with a reduced dose of
131I after pretreatment with rhTSH. Twenty-two patients with nodular goiter
received 131I therapy 24 h after intramuscular administration of 0.01 (n = 12) or 0.03
(n = 10) mg rhTSH. In preceding diagnostic studies using tracer doses of 131I, 24-h
RAIU without and with rhTSH pretreatment (either 0.01 or 0.03 mg) were com-
pared. Therapeutic doses of 131I were adjusted to the rhTSH-induced increases in
24-h RAIU and were aimed at 100 µCi/g thyroid tissue retained at 24 h.
Pretreatment with rhTSH allowed dose reduction of 131I therapy by a factor of 1.9
± 0.5 in the 0.01 mg and by a factor of 2.4 ± 0.4 in the 0.03 mg rhTSH group (P <
0.05, 0.01 vs 0.03 mg rhTSH). Before and 1 year after therapy thyroid volume and
the smallest cross-sectional area of the tracheal lumen (SCAT) were measured
with MRI. During the year of follow-up, serum TSH, FT4, T3 and TSH receptor anti-
bodies (TRAb) were measured at regular intervals.
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Thyroid volume before therapy was 143 ± 54 mL in the 0.01 mg and 103 ± 44 mL in
the 0.03 mg rhTSH group. One year after treatment thyroid volume reduction was
35 ± 14% (0.01 mg rhTSH) and 41 ± 12% (0.03 mg rhTSH). In both groups SCAT
increased significantly.  In the 0.01 mg rhTSH group, serum FT4 rose after 131I treat-
ment from 15.8 ± 2.8 to 23.2 ± 4.4 pmol/L. In the 0.03 mg rhTSH group, serum FT4
rose from 15.5 ± 2.5 to 23.5 ± 5.1 pmol/L. Individual peak FT4 levels, reached
between 1 and 28 days after 131I treatment, were above the normal range in 12
patients. TRAbs were negative in all patients before therapy and became positive
in 4 patients. Hyperthyroidism developed in 3 of these 4 patients between 23 and
25 weeks after therapy. We concluded that in patients with nodular goiter pre-
treatment with a single, low dose of rhTSH allowed approximately 50% to 60%
reduction of the therapeutic dose of radioiodine without compromising the effi-
cacy of thyroid volume reduction.
In chapter 5 dosimetric aspects of therapy with a reduced dose of 131I after pre-
treatment with rhTSH in patients with nontoxic, nodular goiter were investigated.
In this study 36 patients were treated with 131I to reduce thyroid volume. Nine
patients were pretreated with a single dose of 0.01 mg rhTSH, and 9 patients with
0.03 mg rhTSH. There were 2 control groups of 9 patients, matched for thyroid
weight and 24-h RAIU, who were not pretreated with rhTSH. The therapeutic dose
of 131I was aimed at delivering 3.7 MBq of 131I/g of thyroid tissue retained at 24 h.
Thyroid radioactivity measurements after the administration of 131I were per-
formed every 24 hours for 3 days, and on days 7, 10, 14, 21, and 28. A model of
iodine biokinetics was used to estimate absorbed doses in organs. Protein-bound
131I activity was measured at 1, 2, 3, 7, and 10 days and at 2, 3, and 4 weeks after 131I
therapy.
The administered activities were 1.5 times lower in the 0.01 mg rhTSH group and
1.9 times lower in the 0.03 mg rhTSH group compared to those in the control
groups. The absorbed dose in the thyroid was similar in the rhTSH-pretreated
groups and in the control groups. In the organs of excretion (bladder) and uptake
(stomach) of inorganic iodide the absorbed doses were 2- to 3-fold lower in the
pretreated groups than in the control groups. The effective dose equivalent out-
side the thyroid was considerably lower in the rhTSH-pretreated groups than in
their respective control groups (1.6 fold in the 0.01 mg rhTSH group and 2.3 fold in
the 0.03 mg rhTSH group). The time course of protein-bound 131I activity in serum
and the cumulated protein-bound 131I activity in serum did not differ significantly
between rhTSH-pretreated and control groups.
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From this study it can be concluded that 131I therapy after pretreatment with a sin-
gle, low dose of rhTSH, with a dose reduced according to the rhTSH-induced
increase in 24-h RAIU, caused lower radiation-absorbed doses in extrathyroidal
organs and tissues, especially bladder and stomach, and no significant increase in
the release of 131I-labeled thyroid hormones from the thyroid into the circulation
in patients with nodular goiter. Thus, this mode of therapy can be recommended,
especially when the dose of radioiodine to be administered without rhTSH pre-
treatment is high.
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Towards larger volume reduction of nodular goiters by 131I: a role for pretreat-
ment with recombinant human TSH?
A drawback of radioiodine therapy for nodular goiter (with 131I doses aimed at
approximately 100–150 µCi retained per gram of thyroid tissue at 24 h) is that
mean thyroid volume reduction is not greater than approximately 40% after 1
year, and not all patients respond. Preliminary data by Le Moli et al. (1) suggest
that goiter reduction might be augmented by increasing the radiation-absorbed
dose in the thyroid.  Such an increase can be achieved by simply enlarging the
administered dose of radioiodine, but this will further increase the radiation bur-
den to extrathyroidal organs. Alternatively, it should be possible to increase the
radiation-absorbed dose in the thyroid without increasing the administered dose
of radioiodine, by stimulating thyroid radioiodine uptake by pretreatment with
recombinant human TSH (rhTSH). 
A first study on this issue has recently been published (2). Thirty-four patients
with large, multinodular goiters (80–728 mL), of whom 22 were subclinically
hyperthyroid and 7 overtly hyperthyroid, were randomized in two groups.
Patients of group 1 (n = 17) were treated with radioiodine only, using a quite rough
dosing regimen (30–50 mCi for goiters <140 g, 58–80 mCi for goiters 150–190 g,
and 150 mCi for goiters 200-728 g). Patients of group 2 (n = 17) received compara-
ble doses of radioiodine 24 h after pretreatment with 0.45 mg rhTSH. This rhTSH
dose is higher than used in our studies. Thyroid volume measurements before and
6 and 12 months after therapy were done with CT.
The administered doses of radioiodine were 73 ± 12 µCi/g retained at 24 h in the
control patients and 191 ± 75 µCi/g in the patients pretreated with rhTSH. High
peak levels of FT4 were reached in group 2 (59 ± 22 pmol/L, compared with 24 ± 7
pmol/L in group 1). Not surprisingly, symptoms of thyroiditis (pain in the thyroid
region in 52% of patients of group 2, compared to 23% of patients in group 1) and
esophagitis (17% versus 11%) were more frequent in the pretreated patients.
Surprisingly, no symptoms of hyperthyroidism or worsening of heart diseases
were observed. 
Interestingly, 1 year after therapy thyroid volume reduction was 58% ± 13% in
group 2 patients in comparison with 40% ± 12% in group 1 patients (P < 0.05). The
obtained volume reduction after rhTSH administration was considerably more
than in previous studies using radioiodine in doses of 100-150 µCi/g without
rhTSH pretreatment. 
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We published in the March 2004 issue of Clinical Endocrinology the following
commentary (3) on the study by Silva et al.: 
In the last two decades it has been demonstrated that radioiodine
(131I) is an effective therapy for thyroid volume reduction in patients
with toxic and non-toxic nodular goiter. In these patients, 131I treat-
ment leads to a significant decrease in goiter size. In most patients
compressive symptoms improve as well. The decrease in compressive
symptoms is accompanied by significant tracheal widening and
improvement of respiratory function (4). 
131I treatment is especially attractive in elderly patients who have a
high operative risk and in those who refuse surgery. However, in
patients with nontoxic, nodular goiter thyroid radioactive iodide
uptake (RAIU) is usually rather low, especially in areas with a high
iodine intake. As a result, high doses of 131I are often needed for thy-
roid volume reduction, causing a relatively high radiation burden to
extrathyroidal organs (5). Therefore, it is of interest to explore strate-
gies to enhance RAIU in these patients.
In the last decade rhTSH has become available for diagnostic use in
patients with differentiated thyroid cancer. It has been shown that
rhTSH stimulates RAIU in thyroid remnants and thyroid cancer tis-
sue (6,7). Recently, we reported that rhTSH stimulates RAIU also in
patients with nodular goiter: the administration of a single, low dose
of 0.01 or 0.03 mg rhTSH doubled 24-h RAIU in these patients (8).
Pretreatment with rhTSH also caused a more homogeneous distribu-
tion of radioiodine on the thyroid scintigrams of nodular goiters by
stimulating radioiodine uptake in relatively cold areas more than in
relatively hot areas, especially in patients with a low baseline serum
TSH level (9). These observations suggest that administration of
rhTSH before 131I therapy for volume reduction of nodular goiter may
allow treatment with lower doses of 131I without diminishing the radi-
ation-absorbed dose in the thyroid and the efficacy of this mode of
therapy. Indeed, pretreatment with a single, low dose of 0.01 or 0.03
mg rhTSH allowed approximately 50-60% reduction of the therapeu-
tic dose of radioiodine without compromising the efficacy of thyroid
volume reduction (10). As the radiation burden of radioiodine thera-
py to extrathyroidal organs is directly related to the administered 131I
dose (5), such a dose reduction may render radioiodine therapy more
attractive for younger patients and may allow for more patients to
be treated on an out-patient basis.
“
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A major drawback of radioiodine therapy for nodular goiter (with 131I
doses aimed at approximately 100-150 µCi retained per gram of thy-
roid tissue at 24 h) is that mean thyroid volume reduction is not
greater than approximately 40% after 1 year, and 50-60% after 3-5
years (4). Moreover, not all patients respond. Preliminary data by Le
Moli et al. (1) suggest that goiter reduction can be augmented by
increasing the radiation-absorbed dose in the thyroid. Such an
increase can be achieved by simply enlarging the administered dose
of radioiodine, but this will further increase the radiation burden to
extrathyroidal organs. Alternatively, it should be possible to increase
the radiation-absorbed dose in the thyroid without increasing the
administered dose of radioiodine, by stimulating RAIU using pre-
treatment with rhTSH. 
Silva et al. (2) report 34 patients with large, nodular goitres (22 were
subclinically hyperthyroid and 7 overt hyperthyroid) who were ran-
domized to radioiodine therapy alone or to radioiodine therapy in
comparable doses but with pretreatment with a relatively high dose
of rhTSH (0.45 mg), given 24 h before radioiodine administration.
Patients pretreated with rhTSH had a significantly larger thyroid vol-
ume reduction after 1 year (58 ± 13%) than patients given radioiodine
without rhTSH pretreatment (40 ± 12%). 
From data provided in tables 1 and 2 of their report, we calculated the
dose retained in the thyroid at 24 h for individual patients in both
groups. This parameter was considerably higher in the rhTSH-pre-
treated patients (191 ± 75 µCi per gram of thyroid tissue) than in the
patients not pretreated with rhTSH (73 ± 22 µCi/g). It seems likely
that the higher thyroid volume reduction in the rhTSH-pretreated
group can be explained by the higher retention of radioiodine in the
thyroid. An alternative explanation is that pretreatment with rhTSH
improves thyroid volume reduction by causing a more homogeneous
distribution of radioiodine within the thyroid, especially increasing
the uptake of radioiodine in relatively cold areas (9). 
It may be anticipated that a higher dose of radioiodine retained in
the thyroid will be accompanied by more severe early adverse effects
due to radiation-induced thyroiditis and esophagitis.  Indeed, in com-
parison with patients not pretreated with rhTSH, rhTSH-pretreated
patients had a higher incidence of pain in the thyroid region (52%
versus 23%), complaints due to esophagitis (17% versus 11%), and
weight loss (65% versus 52%). 
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Another consequence of thyroiditis is acute enlargement of the thy-
roid gland with (further) compression of the trachea. For radioiodine
doses aimed at approximately 100-150 µCi retained per gram of thy-
roid tissue at 24 h, increases in thyroid volume 1 week after radioio-
dine therapy up to 25% have been found (9,11,12). Silva et al. did not
quantify thyroid volume changes in the first period after radioiodine
therapy. Therefore, it remains to be investigated whether the larger
131I doses retained in the thyroid as used by Silva et al. cause larger
increases in thyroid volume in the first period after radioiodine treat-
ment.
Mild increases in serum thyroid hormone levels due to radiation-
induced thyroiditis are commonly seen in the first weeks after
radioiodine treatment of nodular goitre, with maximum levels
reached at approximately 2 weeks after therapy (11). It has also been
demonstrated that administration of low doses of rhTSH (0.01 or
0.03 mg) in patients with nodular goiter results in mild increases in
serum thyroid hormone levels, with maximum levels reached at 1 to
4 days after administration of rhTSH (8). It may be anticipated that
pretreatment with a relatively high dose of rhTSH followed by a full
dose of radioiodine, leading to a high radiation-absorbed dose in the
thyroid, will result in larger increases in serum thyroid hormone lev-
els. Indeed, peak FT4 levels reached in the rhTSH-pretreated patients
studied by Silva et al. were much higher than those in the patients
treated with radioiodine alone (59 ± 22 versus 24 ± 7 pmol/L), despite
a low-iodine diet in all patients and methimazole pretreatment in the
7 overtly hyperthyroid patients. The highest FT4 levels were reached
already at 1 to 3 days after radioiodine therapy, suggesting that
rhTSH administration was the most important cause of the rise.
Fortunately, no hyperthyroid symptoms or worsening of heart dis-
eases were observed. The authors give 3 possible explanations: the
rise in thyroid hormone levels was of short duration, most patients
had cardiac medications, and all patients were confined to their beds
for 5 to 9 days after radioiodine therapy.
A late adverse effect of radioiodine treatment of nodular goiter is
development of hypothyroidism. Probably related to the higher
radioiodine dose retained in the thyroid, Silva et al. found that
hypothyroidism 1 year after radioiodine therapy was more frequent
in the rhTSH-pretreated patients than in the patients not pretreated
with rhTSH (65% versus 21%).
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The study of Silva et al. is the first to show that the efficacy of
radioiodine therapy of nodular goiters can be improved by pretreat-
ment with rhTSH. However, conclusions are based on small numbers
of patients and both toxic (4 of them had used amiodarone) and non-
toxic patients were included. Moreover, no attempt was made to cal-
culate precisely the radioiodine doses to be administered (radioiodine
doses were based on a rather simple algorithm with estimated thy-
roid volume as the only parameter). 
Before rhTSH can be advised as an adjunct to improve the efficacy of
radioiodine therapy in nodular goiter, further studies are needed.
First, it has to be determined in a formal dose-response study which
dose of rhTSH is optimal for this purpose. Such a dose should stimu-
late RAIU considerably, but should not cause unacceptable rises in
serum thyroid hormone levels. Then, radioiodine therapy with and
without pretreatment with that particular dose of rhTSH should be
investigated in randomized studies. Such studies should look careful-
ly at dose-response relationships with respect to efficacy and adverse
effects. Given the heterogeneity of nodular goiters, large groups of
patients will be needed.
Recently, two studies were presented showing results of treatment of patients
with nontoxic, nodular goiter with an ambulatory dose of 30 mCi 131I after prestim-
ulation with rhTSH. Duick and Baskin (13) prepared 6 patients with 0.3 mg rhTSH
72 hours before radioiodine therapy and 10 patients with 0.9 mg rhTSH 24 hours
before radioiodine therapy. Baseline thyroid volume was 81 ± 25 mL. In the 6
patients who received 0.3 mg rhTSH, 4-h radioactive iodine uptake 72 hours after
rhTSH increased 4-fold (from 4% ± 1% to 17% ± 8%). Estimated gland size reduc-
tion was 30–40% after 3–7 months in 15 of 16 patients. 
Graf and co-workers (14) prepared 26 patients with 2 injections of 0.1 mg rhTSH,
given 48 and 24 hours before radioiodine therapy. Baseline thyroid volume was
116 ± 37 ml. 24-h uptake of a dose of radioiodine given 24 hours after the last dose
of rhTSH increased 4-fold (from 12% to 54%). FT4 levels increased to a peak level
of 3.2 ± 1.1 ng/dL, 24 h after the last dose of rhTSH. Mean thyroid volume reduc-
tion, as assessed by CT, was 39% after 6 months.
However, before rhTSH can be advised as an adjunct to improve the efficacy of
radioiodine therapy in nodular goiter, two key questions should be answered.
First, at the moment we do not know which dose of rhTSH is optimal for this pur-
pose. Such a dose should not cause unacceptable rises in serum thyroid hormone
levels and thyroid volume, and, at the same time, it should stimulate radioiodine
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uptake considerably and cause a more homogeneous distribution of radioiodine
within the thyroid gland. 
Carefully determining the safety of administering rhTSH to patients with nodular
goiter should indeed be a key issue, as injection of rhTSH causes increases in
serum thyroid hormone levels and thyroid volume in subjects with functioning
thyroid tissue. For example, in a recent study (15) administration of 0.9 mg rhTSH
to healthy subjects more than doubled serum FT4 levels and increased thyroid vol-
ume by 35%. Maximal effects were reached 48 hours after rhTSH administration.
The second question to be answered is: which thyroid radiation dose (in µCi per
gram of thyroid tissue) is optimal, both in terms of safety (minimal short-term
radioiodine-induced increases in serum thyroid hormone levels and in thyroid vol-
ume) and in terms of efficacy (long-term thyroid volume reduction).
As mentioned above, hardly any data are available which address the hypothesis
that increasing the thyroid radiation dose to levels above 100-150 µCi/g of thyroid
tissue, whether or not after prestimulation with rhTSH, improves the efficacy of
radioiodine therapy of nodular goiters.
We conclude that more data are needed, before rhTSH can be advised as an
adjunct to improve the efficacy of radioiodine therapy in nodular goiter. Aims of
such phase II and III studies should be to find evidence and definitive proof that
increasing the radiation-absorbed dose in the thyroid by pretreatment with rhTSH
is safe and results in a greater reduction in thyroid volume. Such studies may use
a fixed dose (for example 15 or 30 mCi) or a calculated dose of radioiodine.
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Samenvatting
In deze dissertatie wordt het gebruik van recombinant humaan thyrotropine
(rhTSH) onderzocht als een mogelijk adjuvans bij therapie met radioactief jodi-
um bedoeld om het schildkliervolume bij patiënten met een niet-toxisch, nodu-
lair struma te reduceren.
In hoofdstuk 1 worden de klinische presentatie, de diagnostiek en de huidige
behandelopties (chirurgie, behandeling met L-thyroxine en therapie met radioac-
tief jodium) bij patiënten met een niet-toxisch, nodulair struma bediscussieerd.
Thyreoïdectomie geeft een snelle decompressie van vitale structuren en verschaft
weefsel voor pathologisch-anatomisch onderzoek. De effectiviteit van behande-
ling met L-thyroxine bij patiënten met een niet-toxisch, nodulair struma is hoog-
uit matig en levenslange behandeling met L-thyroxine kan botverlies en cardiale
complicaties veroorzaken. Behandeling met radioactief jodium is effectief bij
meer dan 90% van de patiënten met een niet-toxisch, nodulair struma en resul-
teert in een gemiddelde afname van het schildkliervolume met 40% na 1 jaar en
50 tot 60% na 3 tot 5 jaar. Bij de meeste patiënten verminderen de symptomen ten
gevolge van compressie van vitale structuren in de hals. Vroege bijwerkingen
(bestralingsthyreoïditis en -oesofagitis) zijn gewoonlijk gering en van voorbij-
gaande aard. Verergering van compressiesymptomen na de toediening van radio-
actief jodium is zeldzaam. De belangrijkste late complicatie is het ontstaan van
een auto-immuun hyperthyreoïdie. Hetgeen optreedt bij ongeveer 5% van de
patiënten enkele maanden na de behandeling met radioactief jodium. De preva-
lentie van hypothyreoïdie na de behandeling bedraagt 20 tot 50% na 5 jaar. Voor
iedere individuele patiënt dienen de risico’s van chirurgie en therapie met radio-
actief jodium zorgvuldig tegen elkaar te worden afgewogen. Op dit moment ver-
dient chirurgie de voorkeur bij jongere patiënten, met name wanneer de toe te
dienen dosering radioactief jodium hoog is. Echter bij oudere patiënten, in het bij-
zonder degenen met een cardiopulmonale aandoening, zullen de voordelen van
de behandeling met radioactief jodium tegen het mogelijk risico op lange termijn
van deze behandeling opwegen.
Vervolgens wordt een overzicht gegeven van de huidige kennis van thyrotropine
(TSH), gevolgd door een bespreking van de studies waarin TSH, verkregen uit de
hypofyses van runderen, wordt gebruikt om de opname van radioactief jodium te
verhogen bij patiënten met schildklierkanker.  Aangezien er allergische reacties
optraden en er na meerdere doseringen relatieve ineffectiviteit ontstond ten
gevolge van het ontwikkelen van anti-TSH antilichamen, is het gebruik van run-
der-TSH bij mensen verlaten. Mede daardoor is het onttrekken van behandeling
met schildklierhormoon, hetgeen tot hoge endogene serum spiegels van TSH
leidt, de methode van eerste keus geworden om de opname van radioactief jodi-
um bij schildklierkankerpatiënten te stimuleren.
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Werk in het laboratorium van Weintraub gedurende de late jaren 80 van de vori-
ge eeuw leverde de primaire sequentie op van de β-subunit van humaan TSH
(hTSH). De humane α-glycoproteïne subunit en de humane TSH β-subunit werden
tot co-expressie gebracht in ovariële cellen van de chinese hamster, hetgeen
resulteerde in de productie van recombinant humaan TSH (rhTSH). Het productie-
proces van rhTSH werd gemodificeerd en opgeschaald met assistentie van weten-
schappers van Genzyme (Framingham MA, USA). RhTSH is nu verkrijgbaar als
Thyrogen® (thyrotropin alfa voor injectie, Genzyme; Cambridge MA, USA).
Vervolgens wordt een overzicht gegeven van de in vitro en in vivo studies met
rhTSH (bij dieren en gezonde mensen) en tevens van de literatuur over het
gebruik van rhTSH bij patiënten met een gedifferentieerd schildkliercarcinoom. 
Hoofdstuk 2 tot en met 5 omvatten onze originele studies naar het gebruik van
rhTSH bij patiënten met een niet-toxisch, nodulair struma. In hoofdstuk 2 onder-
zochten we of voorbehandeling met één enkele, lage dosis rhTSH de opname van
radioactief jodium in de schildklier (radioactive iodine uptake; RAIU) bij 15 patiën-
ten (14 vrouwen en 1 man; leeftijd 61 ± 11 jaar) met een niet-toxisch, nodulair stru-
ma verhoogt. Vier patiënten werden tweemaal onderzocht en 1 patiënt driemaal.
De RAIU werd zowel onder basale condities als na voorbehandeling (i.m.) met
rhTSH gemeten. Het rhTSH werd óf 2 uur (0,01 mg; n = 7) of 24 uur [0,01 mg (n =
7) of 0,03 mg (n = 7)] voor de 131I toediening (20–40 µCi) gegeven. Serumspiegels
van TSH, vrij T4 (FT4), en totaal T3 werden 2, 5, 8, 24, 48, 72, 96 en 192 uur na rhTSH
toediening bepaald.
Na toediening van 0,01 mg rhTSH steeg het serum TSH van 0,7 ± 0,5 naar een
maximale waarde van 4,4 ± 1,1 mU/L (P < 0,0001), FT4 steeg van 16,0 ± 2,6 naar 18,5
± 3,7 pmol/L (P < 0,0001), en T3 steeg van 2,10 ± 0,41 naar 2,63 ± 0,66 nmol/L (P <
0,0001). Na toediening van 0,03 mg rhTSH steeg het serum TSH van 0,6 ± 0,4 naar
15,8 ± 2,3 mU/L (P < 0,0001), FT4 steeg van 15,2 ± 1,5 naar 21,7 ± 2,9 pmol/L (P <
0,0001), en T3 steeg van 1,90 ± 0,43 naar 3,19 ± 0,61 nmol/L (P < 0,0001). De maxi-
male TSH-spiegels werden bereikt 5–8 uur en de maximale FT4 en T3 spiegels 8–96
uur na rhTSH toediening.
Injectie van 0,01 mg rhTSH 2 uur vóór de behandeling met 131I deed de 24-uurs
RAIU toenemen van 30 ± 11% tot 42 ± 10% (P < 0,02), 0,01 mg rhTSH 24 uur vóór
de toediening van 131I deed de 24-uurs RAIU toenemen van 29 ± 10% tot 51 ± 10%
(P < 0,0001) en 0,03 mg rhTSH 24 uur vóór de toediening van 131I deed de 24-uurs
RAIU toenemen van 33 ± 11% tot 63 ± 9% (P < 0,0001). Na toediening van 0,01 mg
rhTSH 2 uur vóór de 131I nam de 24-uurs RAIU bij 1 patiënt niet toe, terwijl de toe-
name van de 24-uurs RAIU bij 2 andere patiënten minder was dan 10%. Toediening
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van rhTSH 24 uur vóór de 131I deed de 24-uurs RAIU met meer dan 10% toenemen
bij alle 14 patiënten (met meer dan 20% bij 10 en met meer dan 30% bij 6). 
We concludeerden dat één enkele, lage dosis rhTSH bij patiënten met een niet-
toxisch, nodulair struma de radioactief jodium opname aanzienlijk doet toene-
men. Deze observaties suggereren dat toediening van rhTSH vóór 131I therapie bij
niet-toxisch, nodulair struma, behandeling met lagere doses 131I bij deze patiënten
mogelijk kan maken. 
In de studie, die wordt beschreven in hoofdstuk 3, is onderzocht of voorbehande-
ling met rhTSH veranderingen veroorzaakt in de verdeling van radioactief jodium
binnen de schildklier op schildklierscintigrammen van patiënten met niet-toxisch,
nodulair struma.
Anterieure planaire schildklierscintigrammen met 123I werden uitgevoerd bij 26
patiënten met een nodulair struma (23 vrouwen en 3 mannen; leeftijd 62 ± 9 jaar;
schildkliergewicht, 165 ± 72 g), 24 uur na toediening van een diagnostische dosis
radioactief jodium. Alle patiënten werden tweemaal bestudeerd: eerst zonder
rhTSH voorbehandeling (basale studie) en daarna na een i.m. injectie met 0,01 mg
(n = 10) of 0,03 mg (n = 16) rhTSH 24 uur vóór toediening van het radioactief jodi-
um (rhTSH studie) toegediend. Ter kwantificering van de regionale verschillen in
opname van radioactief jodium werd een methode met “regions of interest”
gebruikt.
Bij visuele beoordeling liet de basale scintigrafie een heterogene opname van
radioactief jodium zien. In het algemeen liet ook de scintigrafie na rhTSH een
heterogene opname van radioactief jodium zien. Bij enkele patiënten was de ver-
deling van het radioactief jodium na rhTSH aanzienlijk homogener dan bij de
basale scintigrafie. Bij een paar patiënten waren aanvankelijk “koude” gebieden
veranderd in “warme” terwijl van origine warme gebieden waren veranderd in
koude. Kwantificering van de regionale opname van radioactief jodium liet zien
dat voorbehandeling met rhTSH een grotere toename van de opname van radio-
actief jodium in relatief koude gebieden en een kleinere toename van de opname
van radioactief jodium in relatief warme gebieden veroorzaakt, vergeleken met de
toename van de opname van radioactief jodium in de gehele schildklier. Bij
patiënten met een basale TSH-spiegel van 0,5 mU/L of lager was de toename van
de opname van radioactief jodium in relatief koude gebieden significant groter
dan bij patiënten met een basale TSH-spiegel in serum hoger dan 0,5 mU/L.
We concludeerden dat één enkele, lage dosis rhTSH een meer homogene distribu-
tie van radioactief jodium in de schildklier van patiënten met een nodulair struma
veroorzaakt doordat de opname van radioactief jodium in relatief koude gebieden
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meer wordt gestimuleerd dan in relatief warme gebieden. Dit was het meest uit-
gesproken bij patiënten met een lage basale TSH-spiegel in serum. Onze data sug-
gereren dat voorbehandeling met rhTSH de effectiviteit van behandeling met
radioactief jodium ter volumereductie van nodulair struma zou kunnen verbete-
ren, in het bijzonder bij patiënten met een lage basale TSH-spiegel.
In hoofdstuk 4 hebben we de veiligheid en de effectiviteit van therapie met een
gereduceerde dosis 131I na voorbehandeling met rhTSH bestudeerd. Vierentwintig
patiënten met nodulair struma werden met 131I behandeld 24 uur na intramuscu-
laire toediening van 0,01 (n=12) of 0,03 (n=10) mg rhTSH. In voorafgaande diagnos-
tische studies waarin tracerdoses 131I werden gebruikt werden de 24-uurs RAIU
zonder en met rhTSH voorbehandeling (0,01 of 0,03 mg) vergeleken. De therapeu-
tische doses met 131I werden aangepast aan de door rhTSH geïnduceerde toename
van de 24-uurs RAIU. Doel was een bestralingsdosis van 100 µCi/g schildklier-
weefsel geretineerd na 24 uur. Voorbehandeling met rhTSH maakte reductie van
de therapeutische dosis 131I  mogelijk met een factor van 1,9 ± 0,5 bij de 0,01 mg
rhTSH groep en met een factor van 2,4 ± 0,4 bij de 0,03 mg rhTSH groep (P < 0,05;
0,01 vs 0,03 mg rhTSH). Vóór en 1 jaar na therapie werden het schildkliervolume
en de kleinste tracheadoorsnede [smallest cross-sectional area of the tracheal
lumen (SCAT)] gemeten met MRI. Gedurende het jaar van follow-up werden
serumspiegels van TSH, FT4, T3 en TSH-receptor-antilichamen met regelmatige
tussenpozen gemeten.
Het schildkliervolume vóór therapie was 143 ± 54 mL in de 0,01 mg rhTSH groep
en 103 ± 44 mL in de 0,03 mg rhTSH groep. Een jaar na behandeling was het schild-
kliervolume afgenomen met 35 ± 14% (0,01 mg rhTSH) en 41 ± 12% (0,03 mg
rhTSH). Bij beide groepen was de SCAT significant toegenomen. In de 0,01 mg
rhTSH groep steeg het serum FT4 na de 131I behandeling van 15,8 ± 2,8 naar 23,2 ±
4,4 pmol/L. In de 0,03 mg rhTSH groep steeg het serum FT4 van 15,5 ± 2,5 naar 23,5
± 5,1 pmol/L. Individuele FT4-piekspiegels werden bereikt tussen 1 en 28 dagen na
de 131I behandeling en waren hoger dan de bovengrens van normaal bij 12 patiën-
ten. De bepaling van antistoffen tegen de TSH receptor was negatief bij alle
patiënten vóór therapie en werd positief na therapie met 131I bij 4 patiënten. Er
ontstond een hyperthyreoïdie bij 3 van deze 4 patiënten tussen de 23 en 25 weken
na therapie. We concludeerden dat bij patiënten met een nodulair struma voorbe-
handeling met één enkele, lage dosis rhTSH zorgt dat de therapeutische dosis
radioactief jodium met 50-60% kan worden verlaagd, zonder dat de effectiviteit
ten aanzien van de volumereductie  wordt verminderd. 
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In hoofdstuk 5 worden de dosimetrische aspecten van therapie met een geredu-
ceerde dosis 131I na voorbehandeling met rhTSH bij patiënten met een niet-
toxisch, nodulair struma bestudeerd. In deze studie werden 36 patiënten behan-
deld met 131I ter volumereductie van de schildklier. Negen patiënten werden voor-
behandeld met eenmalig 0,01 mg rhTSH, en 9 patiënten met eenmalig 0,03 mg
rhTSH. Er waren 2 controlegroepen van 9 patiënten, gematched op schildklierge-
wicht en 24-uurs RAIU, die niet werden voorbehandeld met rhTSH. De therapeu-
tische dosis 131I was gericht op een na 24 uur geretineerde dosis van 100 µCi/g
schildklierweefsel. Metingen van radioactiviteit in de schildklier na de toediening
van 131I werden uitgevoerd na 24, 48 en 72 uur en op dag 7, 10, 14, 21 en 28. Een
model voor de biokinetiek van jodium werd gebruikt om de geabsorbeerde doses
in de organen te bepalen. Eiwit-gebonden 131I activiteit werd gemeten 1, 2, 3, 7 en
10 dagen en 2, 3 en 4 weken na de 131I therapie.
De toegediende activiteit was 1,5 maal lager in de 0,01 mg rhTSH groep en 1,9 maal
lager in de 0,03 mg rhTSH groep vergeleken met die in de respectievelijke contro-
legroepen. De geabsorbeerde dosis in de schildklier was gelijk in de met rhTSH
voorbehandelde groepen en de controlegroepen. In de blaas (waarin anorganisch
jodium wordt uitgescheiden) en in de maag (waarin anorganisch jodium wordt
opgenomen) waren de geabsorbeerde doses 2- tot 3-maal lager in de voorbehan-
delde groepen dan in de controlegroepen. Het effectieve dosis equivalent buiten
de schildklier was aanzienlijk lager bij de met rhTSH voorbehandelde groepen dan
bij hun respectievelijke controlegroepen (1,6 maal bij de 0,01 mg rhTSH groep en
2,3 maal bij de 0,03 mg rhTSH groep). Het tijdsbeloop van de eiwit-gebonden 131I
activiteit in het serum en de cumulatieve eiwit-gebonden 131I activiteit in het
serum verschilden niet significant tussen de met rhTSH voorbehandelde groepen
en de controlegroepen.
Uit deze studie kan worden geconcludeerd dat eenmalige toediening van een lage
dosis rhTSH gevolgd door behandeling met een gereduceerde dosis 131I conform
de rhTSH geïnduceerde toename in 24-uurs RAIU, lagere geabsorbeerde stra-
lingsdoses veroorzaakt in de organen en de weefsels buiten de schildklier, in het
bijzonder de blaas en de maag en geen significante stijging van het vrijkomen van
131I-gelabelde schildklierhormonen uit de schildklier in de circulatie bij patiënten
met een niet-toxisch, nodulair struma.
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Op weg naar grotere volumereductie van nodulair struma met 131I: een rol voor
voorbehandeling met recombinant humaan TSH?
Een nadeel van behandeling met radioactief jodium voor nodulair struma (waar-
bij gestreefd wordt naar een na 24 uur geretineerde dosis van ongeveer 100–150
µCi per gram schildklierweefsel) is dat de gemiddelde volumereductie slechts
ongeveer 40% na 1 jaar is en dat niet alle patiënten reageren op de behandeling.
Eerdere data van Le Moli et al. (1) suggereren dat de volumereductie verbeterd
zou kunnen worden door de geabsorbeerde dosis straling in de schildklier te ver-
groten. Zo’n toename kan worden bereikt door eenvoudig een hogere dosis radio-
actief jodium toe te dienen, maar dit zal de geabsorbeerde dosis straling in de
organen buiten de schildklier ook doen toenemen. Alternatief is om de geabsor-
beerde dosis straling in de schildklier te vermeerderen zonder verhoging van de
toegediende dosis radioactief jodium, door de opname van het radioactief jodium
in de schildklier te stimuleren door middel van voorbehandeling met recombinant
humaan TSH (rhTSH). 
Een eerste studie over dit onderwerp werd recent gepubliceerd (2). Vierendertig
patiënten met een groot, multinodulair struma (80–728 mL), van wie er 22 subkli-
nisch hyperthyreoot en 7 evident hyperthyreoot waren, werden gerandomizeerd
in twee groepen. Patiënten uit groep 1 (n = 17) werden behandeld met enkel radio-
actief jodium, waarbij een eenvoudig doseringsprotocol werd gebruikt (30–50
mCi voor struma <140 g, 58–80 mCi voor struma 150–190 g en 150 mCi voor stru-
ma 200-728 g). Patiënten uit groep 2 (n = 17) kregen vergelijkbare doses radioac-
tief jodium 24 uur na voorbehandeling met 0,45 mg rhTSH. Deze rhTSH dosis is
hoger dan de dosis die gebruikt werd in onze studies. Schildkliervolumemetingen
werden vóór, 6 en 12 maanden na therapie uitgevoerd door middel van CT.
De na 24 uur geretineerde doses radioactief jodium waren 73 ± 12 µCi/g bij de con-
trolepatiënten en 191 ± 75 µCi/g bij de patiënten voorbehandeld met rhTSH. Hogere
maximale FT4-spiegels werden bereikt in groep 2 (59 ± 22 pmol/L, vergeleken met
24 ± 7 pmol/L in groep 1). Het is niet verwonderlijk dat symptomen van thyreoïditis
(pijn in het schildkliergebied bij 52% van de patiënten in groep 2, vergeleken met
23% van de patiënten in groep 1) en oesofagitis (17% versus 11%) meer frequent voor-
kwamen bij de voorbehandelde patiënten. Het is opmerkelijk dat er geen sympto-
men van hyperthyreoïdie of verergering van hartaandoeningen werden gezien.
Het is interessant dat 1 jaar na therapie de reductie van het schildkliervolume 58
± 13% bij de patiënten uit groep 2 was in vergelijking met 40 ± 12% bij de patiën-
ten uit groep 1 (P < 0,05). De bereikte volumereductie na rhTSH toediening was
aanzienlijk groter dan in voorgaande studies zonder rhTSH voorbehandeling
waarin doses radioactief jodium werden gebruikt van 100-150 µCi/g. 
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Hieronder volgt een commentaar op de studie door Silva et al. door onze groep
gepubliceerd in het nummer van maart 2004 van Clinical Endocrinology (3):
In de laatste twee decennia is aangetoond dat radioactief jodium (131I)
een effectieve therapie is ter reductie van het schildkliervolume bij
patiënten met een toxisch en niet-toxisch nodulair struma.  Bij deze
patiënten leidt behandeling met 131I tot een significante afname van de
grootte van het struma. Bij de meerderheid van de patiënten verbete-
ren ook de compressiesymptomen. De afname van de compressiesymp-
tomen gaat gepaard met een significante toename van het lumen van
de trachea en een verbetering van de respiratoire functie (4). 
Behandeling met 131I is in het bijzonder aantrekkelijk bij oudere
patiënten die een hoog operatierisico hebben en/of  een operatie wei-
geren. Bij patiënten met een niet-toxisch, nodulair struma is de opna-
me van radioactief jodium (radioactief jodium uptake; RAIU) echter
meestal laag, met name in gebieden met een hoge jodiuminname.
Dientengevolge zijn er vaak hoge doses 131I nodig voor de schildklier-
verkleining, die een relatief hoge stralingsbelasting voor organen bui-
ten de schildklier veroorzaken (5). Het is daarom belangrijk om stra-
tegieën te ontwikkelen om de opname van radioactief jodium in de
schildklier  bij deze patiënten te verhogen.
In de afgelopen tien jaar is rhTSH ter beschikking gekomen voor de
diagnostiek bij patiënten met een gedifferentiëerd schildkliercarci-
noom. Het is aangetoond dat rhTSH de RAIU in schildklierresten en
schildklierkankerweefsel stimuleert (6,7). Recent hebben we gerap-
porteerd dat rhTSH ook bij patiënten met nodulair struma de RAIU
stimuleert; eenmalige toediening een lage dosis van 0,01 mg of 0,03
mg rhTSH verdubbelt de 24-uurs RAIU bij deze patiënten (8).
Voorbehandeling met rhTSH zorgt ook voor een meer homogene ver-
deling van radioactief jodium op het schildklierscintigram van
patiënten met een nodulair struma, doordat het de opname van
radioactief jodium in de relatief koude gebieden meer stimuleert dan
in de relatief warme gebieden, in het bijzonder bij patiënten met een
lage serumspiegel van TSH (9). Deze observaties suggereren dat toe-
diening van rhTSH vóór therapie met 131I ter volumereductie van een
nodulair struma behandeling met lagere doses 131I mogelijk maakt
zonder de geabsorbeerde dosis straling in de schildklier en de effecti-
viteit van de behandeling te verminderen. Inderdaad zorgde voorbe-
handeling met één enkele, lage dosis van 0,01 mg of 0,03 mg rhTSH
ervoort dat de therapeutische dosis radioactief jodium met 50-60%
“
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verlaagd kon worden zonder dat het resultaat van de volumereductie
werd verminderd (10). Aangezien de stralingsbelasting door radioac-
tief jodium van de organen buiten de schildklier direct is gecorreleerd
met de toegediende dosis 131I (5), zal zo’n dosisverlaging  therapie met
radioactief jodium aantrekkelijker maken voor jonge patiënten en
zullen meer patiënten poliklinisch kunnen worden behandeld.
Een groot nadeel van therapie met radioactief jodium voor een nodu-
lair struma (waarbij gestreefd wordt naar een na 24 uur geretineer-
de dosis van ongeveer 100–150 µCi per gram schildklierweefsel) is dat
het gemiddelde schildkliervolume met niet meer dan ongeveer 40%
afneemt na 1 jaar en met niet meer dan 50-60% na 3-5 jaar (4).
Bovendien reageren niet alle patiënten. Eerdere data van Le Moli (1)
suggereren dat de volumereductie van het struma kan worden ver-
groot door de geabsorbeerde dosis radioactiviteit in de schildklier te
verhogen. Zo’n toename kan worden bereikt door eenvoudig een
hogere dosis radioactief jodium toe te dienen, maar dit zal ook de
geabsorbeerde dosis straling in de organen buiten de schildklier doen
toenemen. Een alternatief is om de geabsorbeerde dosis straling in de
schildklier te vermeerderen zonder verhoging van de toegediende
dosis radioactief jodium door de opname van radioactief jodium in de
schildklier te stimuleren door middel van voorbehandeling met
rhTSH. 
Silva et al. (2) beschreven 34 patiënten met grote, nodulaire struma’s
(22 waren subklinisch hyperthyreoot en 7 evident hyperthyreoot).
Deze patiënten werden gerandomiseerd tussen therapie met alleen
radioactief jodium of therapie met vergelijkbare doses radioactief
jodium in combinatie met voorbehandeling met een relatief hoge
dosis rhTSH (0,45 mg) 24 uur vóór de toediening van het radioactief
jodium gegeven. Bij de patiënten die werden voorbehandeld met
rhTSH was er een significant grotere afname van het schildkliervolu-
me na 1 jaar (58 ± 13%) dan bij de patiënten bij wie radioactief jodi-
um werd gegeven zonder voorbehandeling met rhTSH (40 ± 12%). 
Op basis van de beschikbare data uit tabel 1 en 2 in hun artikel heb-
ben we de na 24 uur in de schildklier geretineerde dosis berekend voor
de individuele patiënten uit beide groepen. Deze was aanzienlijk
hoger bij  de rhTSH voorbehandelde patiënten (191 ± 75 µCi per gram
schildklierweefsel) dan bij de patiënten die niet waren voorbehandeld
met rhTSH (73 ± 22 µCi/g). De grotere afname van het schildkliervo-
lume bij de met rhTSH voorbehandelde groep kan waarschijnlijk wor-
den verklaard door de hogere retentie van radioactief jodium in de
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schildklier. Een alternatieve verklaring is dat voorbehandeling met
rhTSH de reductie van het schildkliervolume verbetert doordat het
een meer homogene verdeling van het radioactief jodium in de
schildklier veroorzaakt, met name door het stimuleren van de opna-
me van radioactief jodium in de relatief koude gebieden (9). 
Het is te verwachten dat  een hogere geretineerde dosis radioactief
jodium in de schildklier gepaard zal gaan met ernstigere vroege bij-
werkingen door thyreoïditis en oesofagitis. Inderdaad hadden de met
rhTSH voorbehandelde patiënten, in vergelijking met de patiënten
die niet waren voorbehandeld met rhTSH, een hogere incidentie van
pijn in het schildkliergebied (52% versus 23%), klachten door oesofa-
gitis (17% versus 11%) en gewichtsverlies (65% versus 52%).
Een acute vergroting van de schildklier met (toename van) compres-
sie van de trachea is een ander gevolg van thyreoïditis. Uit eerdere
studies is gebleken dat één week na therapie met radioactief jodium
een toename van het schildkliervolume tot maximaal 25% kan optre-
den bij doses radioactief jodium waarbij gestreefd wordt naar een na
24 uur geretineerde dosis van ongeveer 100-150  µCi per gram schild-
klierweefsel (9,11,12). Silva et al. hebben de veranderingen van het
schildkliervolume in de eerste periode na de therapie met radioactief
jodium niet gemeten. Daarom is het van belang in toekomstige stu-
dies te onderzoeken of hogere in de schildklier geretineerde doses 131I,
zoals gebruikt door Silva et al., meer toename van het schildkliervo-
lume veroorzaken in de eerste periode na de behandeling met radio-
actief jodium.
In de eerste weken na behandeling met radioactief jodium van een
nodulair struma wordt door straling geïnduceerde thyreoïditis vaak
een geringe stijging van de spiegels van schildklierhormonen in het
serum gezien, waarbij het maximale niveau ongeveer 2 weken na de
therapie wordt bereikt (11). Het is aangetoond dat toediening van
lage doses rhTSH  (0,01 of 0,03 mg) bij patiënten met een nodulair
struma een geringe stijging van schildklierhormoonspiegels in serum
veroorzaakt waarbij de maximale waarden 1 tot 4 dagen na toedie-
ning van rhTSH worden bereikt (8). Het is te verwachten dat voorbe-
handeling met een relatief hoge dosis rhTSH gevolgd door een volle-
dige dosis radioactief jodium, leidend tot een hoge dosis in de schild-
klier geretineerd 131I, meer stijging van de schildklierhormoonspiegels
in het serum zal veroorzaken. De maximale FT4-spiegels bij de met
rhTSH voorbehandelde patiënten bestudeerd door Silva et al. waren
inderdaad veel hoger dan die bij de patiënten behandeld met alleen
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radioactief jodium (59 ± 22 versus 24 ± 7 pmol/L), ondanks een jodi-
um-beperkt diëet voor alle patiënten en voorbehandeling met methi-
mazol bij de 7 evident hyperthyreote patiënten. De hoogste FT4-spie-
gel werd al 1 tot 3 dagen na de therapie met radioactief jodium
bereikt, hetgeen suggereert dat toediening van rhTSH de belangrijk-
ste oorzaak van de stijging was. Gelukkig werden er geen symptomen
van hyperthyreoïdie of verergering van hartaandoeningen gezien. De
auteurs geven 3 mogelijke verklaringen: de stijging van de schildklier-
hormoonspiegels duurde kort, de meeste patiënten gebruikten car-
diale medicatie en alle patiënten moesten gedurende 5 tot 9 dagen na
de therapie met radioactief jodium bedrust houden.
Een late complicatie van behandeling van nodulair stuma met radio-
actief jodium is het ontstaan van hypothyreoïdie. Waarschijnlijk
houdt dit verband met de hoge dosis radioactief jodium die in de
schildklier wordt geretineerd, want Silva et al. vonden dat hypothyre-
oïdie 1 jaar na therapie met radioactief jodium vaker voorkwam bij de
met rhTSH voorbehandelde patiënten dan bij de patiënten die niet
waren voorbehandeld met rhTSH (65% versus 21%).
De studie van Silva et al. is de eerste die laat zien dat de effectiviteit
van therapie met radioactief jodium bij nodulaire struma’s verbeterd
kan worden door voorbehandeling met rhTSH. De conclusies zijn ech-
ter gebaseerd op een klein aantal patiënten waarbij zowel patiënten
met een toxisch (4 van hen hadden amiodarone gebruikt) als patiën-
ten met een niet-toxisch struma werden geïncludeerd. Bovendien is
er geen poging gedaan om de doses radioactief jodium te berekenen
(de doses radioactief jodium werden gebaseerd op een nogal simpel
algoritme met als enige parameter het palpatoir geschatte schild-
kliervolume).
Voordat rhTSH kan worden geadviseerd als adjuvans om de effectivi-
teit van therapie met radioactief jodium bij nodulair struma te ver-
beteren zijn meer studies nodig. Allereerst moet in een formele dosis-
respons studie worden vastgesteld welke dosis rhTSH optimaal is
voor dit doel. Zo’n dosis moet de RAIU aanzienlijk stimuleren maar
mag geen onacceptabele verhoging van de schildklierhormoonspie-
gels in het serum veroorzaken. Daarna moet therapie met radioactief
jodium met en zonder die dosis rhTSH worden onderzocht in geran-
domiseerde studies, waarin zorgvuldig de dosis-respons relaties met
betrekking tot effectiviteit en bijwerkingen bestudeerd moeten wor-
den. Gezien de heterogeniteit van nodulaire struma’s zullen grote
groepen patiënten nodig zijn.
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Recent werden twee studies gepubliceerd waarin de resultaten werden beschre-
ven van poliklinische behandeling van patiënten met een niet-toxisch, nodulair
struma met een dosis van 30 mCi 131I na stimulatie met rhTSH. Duick and Baskin
(13) gaven aan 6 patiënten 0,3 mg rhTSH 72 uur vóór de therapie met radioactief
jodium en aan 10 patiënten 0,9 mg rhTSH 24 uur vóór de therapie met radioactief
jodium. Het schildkliervolume vóór de behandeling bedroeg 81 ± 25 mL. Bij de 6
patiënten die 0,3 mg rhTSH kregen verviervoudigde de 4-uurs radioactief jodium
opname 72 uur na rhTSH (van 4 ± 1% naar 17 ± 8%). De geschatte verkleining van
het schildkliervolume was 30–40% na 3–7 maanden bij 15 van de 16 patiënten. 
Graf en medewerkers (14) gaven aan 26 patiënten 2 injecties met 0,1 mg rhTSH 48
en 24 uur vóór therapie met radioactief jodium. Het basale schildkliervolume was
116 ± 37 ml. De 24-uurs opname van de dosis radioactief jodium, 24 uur na de laat-
ste dosis rhTSH toegediend, verviervoudigde (van 12 naar 54%). De FT4-spiegels
stegen 24 uur na de laatste dosis rhTSH tot maximaal 3,2 ± 1,1 ng/dL. De gemid-
delde afname van het met CT gemeten schildkliervolume bedroeg 39% na 6 maan-
den.
Voordat rhTSH kan worden geadviseerd als adjuvans om de effectiviteit van the-
rapie met radioactief jodium bij nodulair struma te verbeteren, moeten twee
belangrijke vragen worden beantwoord. Om te beginnen weten we de optimale
dosis rhTSH voor deze indicatie op dit moment nog niet. Deze dosis moet geen
onacceptabele stijging van de schildklierhormoonspiegels in het serum en toena-
me van het schildkliervolume veroorzaken maar anderzijds wel de opname van
radioactief jodium substantiëel stimuleren en zorgen voor een meer homogene
verdeling van het radioactief jodium in de schildklier.
Het zorgvuldig vaststellen van de veiligheid van de toediening van rhTSH aan
patiënten met een nodulair struma is een zeer belangrijk punt, aangezien injectie
van rhTSH bij mensen met functionerend schildklierweefsel een stijging van de
schildklierhormoonspiegels en een toename van het schildkliervolume veroor-
zaakt. In een recente studie (15) leidde toediening van 0,9 mg rhTSH aan gezonde
vrijwilligers tot een verdubbeling van de serumspiegels van FT4 en een toename
van het schildkliervolume met 35%. Het maximale effect werd 48 uur na de toe-
diening van rhTSH gezien.
De tweede vraag die beantwoord moet worden is welke dosis straling voor de
schildklier (in geretineerd aantal µCi per gram schildklierweefsel) optimaal is,
zowel wat betreft veiligheid (minimale stijging van de schildklierhormoonspiegels
en toename van het schildkliervolume door het radioactief jodium op korte ter-
mijn) als wat betreft de effectiviteit (verkleining van het schildkliervolume op
lange termijn).
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Zoals boven besproken zijn er vrijwel geen data beschikbaar met betrekking tot
de hypothese dat verhoging van de geretineerde activiteit in de schildklier naar
een niveau boven de 100-150 µCi/g schildklierweefsel na 24 uur, met of zonder sti-
mulatie door rhTSH, de effectiviteit van therapie met radioactief jodium bij nodu-
lair struma verbetert.  
We concluderen daarom dat er meer onderzoek nodig is voordat rhTSH kan wor-
den geadviseerd als adjuvans om de effectiviteit van behandeling met radioactief
jodium ter verkleining van nodulaire struma’s te verbeteren. Het doel van zulke
fase II en III studies zou moeten zijn het vinden van aanwijzingen respectievelijk
definitief bewijs, dat verhoging van de geretineerde activiteit in de schildklier
door voorbehandeling met rhTSH veilig is en resulteert in een grotere volumeaf-
name van de schildklier. In deze studies zou een vaste hoeveelheid (bijvoorbeeld
15 of 30 mCi) of een berekende hoeveelheid radioactief jodium kunnen worden
gebruikt.
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“onze” Ans gaven in Eindhoven altijd weer een duwtje in de rug.  Voor het uitvoe-
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ons. 
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garant. Met name Fred Sweep, Alec Ross  en Tijn Segers hebben mij uit de nood
geholpen wanneer het er echt op aankwam.
Op de afdeling Nucleaire Geneeskunde in het Universitair Medisch Centrum St.
Radboud, kon ik altijd weer terecht voor een deskundig advies. Als “buitenstaan-
der” heb ik dankzij Wim van den Broek, Otto Boerman en Wil Buijs de ingangen
van de Nucleaire Geneeskunde leren kennen. Ook tegen Ernst Postema zeg ik
“grazie”: het tegelijkertijd bezig zijn met promotie-onderzoek gaf altijd stof voor
een goed gesprek.
Bij de uitvoering van de muizenexperimenten heb ik gebruik mogen maken van de
fenomenale handvaardigheden van Gerry Grutters op het Centraal Dieren
Laboratorium en de bepalingen door Jan Smit op de afdeling Endocrinologie van
het Leids Universitair Medisch Centrum (waarvan de uitslagen telkens weer als
“attentie” of  “cadeau” werden gemailed).
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wetenschappelijk onderzoek op de afdeling Endocriene Ziekten in het Universitair
Medisch Centrum St. Radboud te mogen samenwerken met Gerlach Pieters,
Martin den Heijer, Marie-José Pouwels, Sarah Bovenberg, Anita Peeters en
Romana Netea-Maier. Voor hun contacten en collegialiteit ben ik hen zeer erken-
telijk. Mijn kamergenoten op de Afdeling Endocriene Ziekten zorgden voor een
aangename sfeer, hiervoor bedank ik Stan van Uum, Lieke Hoogendoorn en Egidia
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riële ondersteuning van Wil Straten, Lennie Scholte en Mieke van Haaren.
Op dit moment ben ik mijn maten: Fred Apperloo, Marina Grubben, Cees van der
Heul, Job Juttmann, Marjo van Kasteren, Marc van Milligen de Wit, Wiek Rensma,
Anne-Marie van Riel, Wouter Stuifbergen en Saskia van Veen, mijn secretaresse
Drea van Spaendonk, de diabetes-verpleegkundigen José Jacobs, Kim de Jong en
Judith Schaffels en de arts-assistenten Interne Geneeskunde in het Sint Elisabeth
Ziekenhuis, duizend maal dank (“mille grazie”) verschuldigd voor hun support tij-
dens de laatste loodjes ter afronding van “het boekje” en hun bijna wekelijks
terugkerende vraag wanneer “het feest” zou plaatsvinden.
Dankzij de paranimfen Dave van Kraaij en Marika van Leeuwen-Artz kunnen de
festiviteiten dan nu eindelijk beginnen. Wat is het fijn om goede vrienden te heb-
ben! Maar bovenal ben ik mijn familie dankbaar. Hoe kan ik de steun van mijn
ouders omschrijven? Voor alle hulp dank ik hen en de rest van mijn familie.
Tot slot bedank ik in stilte de mensen, die mij in discretie hebben bijgestaan, en
zonder wie geen enkel verhaal wordt geschreven.
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Curriculum Vitae Nederlands
Willy-Anne Nieuwlaat werd op 25 oktober 1969 geboren te Roosendaal. Van 1982
tot 1988 bezocht zij aldaar het Gertrudislyceum en behaalde het diploma
Gymnasium β.
In 1988 begon zij met de studie geneeskunde aan de Radboud Universiteit
Nijmegen. In 1989 werd de Propedeuse en in 1992 het Doctoraalexamen cum laude
afgelegd. Op 28 april 1995 volgde het Artsexamen.
Van mei 1995 tot en met augustus 1999 was zij werkzaam als arts-assistent Interne
Geneeskunde in het Canisius-Wilhelmina Ziekenhuis te Nijmegen, aanvankelijke
als Assistent Geneeskundige Niet In Opleiding. Op 1 augustus 1996 werd in het
CWZ begonnen met de opleiding Interne Geneeskunde (Opleider: Dr. R.W. de
Koning). Deze opleiding werd voortgezet in het Universitair Medisch Centrum St.
Radboud te Nijmegen (Opleider: Prof.dr. J.W.M. van der Meer) en op 1 augustus
2002 vond registratie als Internist plaats.
In het aandachtsgebied Endocrinologie werd zij vanaf maart 2002 tot september
2003 op de afdelingen Endocriene Ziekten en Algemeen Interne Geneeskunde
(Opleiders: Prof.dr. A.R.M.M. Hermus en Prof.dr. J.A. Lutterman) van het
Universitair Medisch Centrum St. Radboud opgeleid.
Sinds oktober 2003 is zij als internist-endocrinoloog werkzaam in het Sint
Elisabeth Ziekenhuis te Tilburg. 
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Curriculum Vitae English
Willy-Anne Nieuwlaat was born on October 25, 1969 in Roosendaal, The
Netherlands. From 1982 until 1988 she visited the Gertrudislyceum there and gra-
duated from Gymnasium β. 
In 1988 she began her study of medicine at the Medical Faculty of the Radboud
University Nijmegen. In 1989 the “Propedeuse” and in 1992 the
“Doctoraalexamen” in medicine were passed with honor. Her medical license
(Artsexamen) was obtained on April 28, 1995.
From May 1995 until August 1999 she worked as a hospital-based physician at the
Department of Internal Medicine of the Canisius-Wilhelmina Hospital in
Nijmegen. On August 1, 1996 she began her residency training in Internal
Medicine. The first portion of the training was undertaken at this same hospital
under the supervision of Dr. R.W. de Koning. The training program continued at
the Radboud University Nijmegen Medical Center under the supervision of
Prof.dr. J.W.M. van der Meer. On August 1, 2002 she was registered as Specialist in
Internal Medicine.
A fellowship in Endocrinology was completed between March 2002 and
September 2003 at the Departments of Endocrinology and General Internal
Medicine of the Radboud University Nijmegen Medical Center under the direc-
tion of Prof.dr. A.R.M.M. Hermus and Prof.dr. J.A. Lutterman.
Since October 2003, she has been working as an internist-endocrinologist at Saint
Elisabeth Hospital in Tilburg.
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